var title_f30_7_30832="Melanonychia hydroxyurea";
var content_f30_7_30832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melanonychia caused by hydroxyurea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30832=[""].join("\n");
var outline_f30_7_30832=null;
var title_f30_7_30833="Brandt Daroff maneuver";
var content_f30_7_30833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Brandt-Daroff maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Brandt-Daroff maneuver is performed in the same manner for right and left-sided posterior canalithiasis. The seated patient begins by rapidly lying on one side (1), and then waits until any provoked vertigo subsides. The patient then sits up again (2), and waits once more for vertigo to subside. The next move is to rapidly lie on the other side (3), wait for any vertigo to subside, and then sit up again (4). The sequence is repeated 10 to 20 times, up to three times a day, until the patient is asymptomatic. The symmetry of this maneuver makes it appropriate for either left or right-sided pathology, and it also makes this maneuver useful when one is uncertain as to the side of the canalithiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Troost BT, Patton JM. Exercise therapy for positional vertigo. Neurology 1992; 42:1441.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30833=[""].join("\n");
var outline_f30_7_30833=null;
var title_f30_7_30834="Lymphomatoid gran CT III";
var content_f30_7_30834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    59-year-old man who presented with abnormal findings on chest radiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image at level of lung apex shows several small thin-walled cysts, 1 to 2 cm in diameter. Histopathology revealed extensive confluent coagulative necrosis, often with presence of pulmonary vessels infiltrated by lymphoma. Areas of necrosis were surrounded by lymphoepithelioid infiltrate with focal formation of poorly formed granulomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: Radiologic features and pathologic correlations. Am J Roentgenol 2000; 175:1335. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30834=[""].join("\n");
var outline_f30_7_30834=null;
var title_f30_7_30835="Foot anatomy lateral view";
var content_f30_7_30835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Foot anatomy lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30835=[""].join("\n");
var outline_f30_7_30835=null;
var title_f30_7_30836="Mucosal changes in Stevens-Johnson syndrome";
var content_f30_7_30836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucosal changes in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes similar to those observed in SJS/TEN can be observed also in erythema multiforme majus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30836=[""].join("\n");
var outline_f30_7_30836=null;
var title_f30_7_30837="Diabetic neuroarthropathy I";
var content_f30_7_30837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64186%7ERHEUM%2F76978%7ERHEUM%2F57519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64186%7ERHEUM%2F76978%7ERHEUM%2F57519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diabetic neuroarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longstanding Charcot's disease of the left ankle characterized by deformity and sclerosis (arrow). The patient had been diabetic for 20 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of LD Hordon, MD and Verna Wright, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diabetic neuroarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 283px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEbAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD51g5dcjFdf4Mt/tPiHSoAP9ZcoMfQ5/pXJW65deD616B8KbRrrxvpCr/BKZfrtH/16APoHxEczlUIyOMe1dt4HgEehRsBje7N+v8A9auG1NXfUHZkITJXg5r0rQITBo1mh6iME/XrTYht78zsMdKy5I/mO38q1L0gM1ZqANKMflQAONtuc8V5V8Rbny7WTnvmvWL4bbUnp1rwv4rXIjtJlzyQRTA8MvHLysxbOct7ZP8An9KpsB7dPWrE5yx+nWqsoJHY9+lSMgYYPY/SkP8Anmh+v1pO2D6UAL16D+VH4dKO+OKUcgcigBAOKKcRznj0pCOucYFADCMg+npUZPT5s+vv/nFSkZHvUZ57HHsf8+lADBn1OM4o6en60dQB3peM9eKAGnrznik/hzxTiPp04/z9aQ9Ccd+9ACbemM57Uq8rjmlPfv8A5/z+dNHbhcfyoAdxnP5808Yyc+tNAOfp146U8E59xzwelACg8AA9O1KBx/Og8BR6EfjTj+tADCOOMfSk/EfnTjj/ADzTTzzyaAGED/Ad6AP/ANdDD5aO+RnNABjnHGacuOOn5U3GDgf54pVBHrQBaiIyAcZ7cVetvTvjNUI+oq9b58zAPSgD2T4Gwky302B99UGPQDP9a9omPQdPpXlXwNgZNGeTHMkrHn24r0+Vsv8AjVIRdgHyYAxWrbqNh4rKhbpnOe9akJxb0gPHvizOZPEKxZyI4lH4nJrjbOPzpoYgAWdwuMe9bPxEuzL4r1E5HysEH4AD+lVPCsfm6zaA4IUGQ59qAO4wHvoolGEjHA/Csz4p3Qg0S3twQDIwz9BzWnp58y/kfqM4zXD/ABfvs6hbwK2PLQtimB5tO+6ZiM/jRVWVvmPucUVIzGtwDIAPp6969b+BESv4tkmYfNb2jOD6Z4/pXktsPmBr2P4Ex7tX1duQRYr1/wB+hAexRF5LkxsBulccjvzgV6dGoS3UDsMfpXm3h+Ez65bcnGQx9gK9JlUrF1psSMbUXKhjnj1qjbcTAOdpYfLuOM/T1q5eqWznmqOnWVrbSO1vBFEWPzFEAz9aAL12AbYqe4r5w+Mku2Z4icZOOvvX0jeL+7x/kV8z/G7amsqvYnv3oA8mkHzEY/Cq7nryM/WrM5HmHGPw71Wfr1/CkMrv/Sk7U5gMjpTeMD6CgAxk/wD16eM+1NGM+/0p4HHBoAMEHkc/WkIIHpS8Y7UnA5NADDjHsPyqJufrUhIqMjGcD8M0AMA4GeR65pccf0pOvPB9KOOQef8AP/6qAAg46fjmkKn35/wpT64696TIxnFAClc9P/rUgBI5HPbil75A7+h4pBnHC/pQA8D5gDn8qVF5O7PHtTRu6Yz+FOCn0H5UAOCn17+lOxQOeoHPtSkH0/SgBGH1ppGT/wDWp5/yajbhuQOtADTnr70g6D0x6e1DE+2foKB1wP6etAARzjk05fp9DikPXqP0oHA6j9P8/wD66ALERyR8p46DFX4cgjrgDris9PvcEVeiyQdpBPQYoA+jvhBCYPC9ozLjcu4jHeu1BJk9q57wLF9n0C3XGMRgc1vRZL54NUI1IeTwa1fuwAGsq2zx0q7qcv2ewkkzwkbN+QoA+d/Es/2nWr6Xd9+dz+taPghR9qu5z92OPYD7n/8AVXOXb+ZcMQeWJb9a6jwmnlaJNISMySYGfQUgOu0UKCT+P+FeR/Ea8+0eI7ts8IAv+f0r12xHk2ruTjamf0rwPxBdfab+6lzy8rUMDFlc4P1oqvO4wRmikMits5GTyK9n+BRCPr0oxxbIo/OvGLYDPFey/BA4tNfbt5ca00B7l4CXzb9puyx46dya7q8bag4rjfhun+jTyY6sAPyrrbw5YDihiM6bHOc1FGqnqMg9j/WpJgMjpzUKP6dKAHXjDacY4GOPSvmn48rs1+2AHDI3v6V9I3DEqea+d/j/AB/8TTT2xwUYH86APHp/vNnOP1qrIcHjn2q1P94n8eKqSY9M84pDIT1yTSdfXNGRxgED3pOMe2KAHDr3HPrTlx17fWmHgdB+VSdfxoAPoD+BpDxnjvSk5pvXPHfrQA2oiOemeMdP8+9SNwpz9ajfknrn0oAZzjJ/PH+falwQMY9xR64yffNBGBnkD/P/ANagBD2zjHNITxyAfpilJ/CkO3GOx7d6ADvzt+tJjjqB9KeevIxz09aYoHQjJ7igBw6Dpmnrz/d/+tTV6/p0/wA/5xTxjHT6YoAdnj37U4gc0gHccZ9utLz9KAA9+p9sUxj05PFPP4VG6nGM0AN3c8k/SjPHf8aGHXLY+tGPoKADPsenrSg4J456UgHzZ7g/lSgHH8sUATRcnHOa19LjM17bRhSS0qgj8aybf7wOMV03hCAzeIbFPR93+fzoA+ldBUw6TEuAMKBWhaHnn9arWY2WSDtVm2OGGM49aoRrWhyy8d6g8c3ItfDOoydCICo/Hj+tWbEZcVznxauRD4VnXOPNkRPrzn+lIDwp3O4nocV3GlxNHpFjCByV3EepP+TXDhQ7qp6sQK9HSMRmJRwVjAx+FMGW9bufsnhy6mOAQjDPSvny7lLEkg88k/rXsnxNufsnhQQqTmQrH1+gNeI3T8t6/WkxlS4kPJ70VBO3vx6+1FIC1b/eGTXsvwQA/s7XyeM+WP0rxm3JDcZ/OvafgpgaNrzEDmWNeOn3aaA98+G2W0USH+J2x+FdFctmVgfwrG8AxmLQbUHuC3T1NaczfvTQIgmIC471UlfAwOBmrMo464qjI2TigBWbcp+leDftAJibS5COpkX+Ve7A5H1rxT9oGLNjp0o6LM65+q//AFqAPCpSck/jVWQE9qtSYOcDHNVZOAOBmkMhbr04pPf0pWOW7UnbtmgBQORinrjABpnGQOOakB4/xNAARknOBTSODmnE9MH24NNoAZio2+9nj8fpUhx361GRk9e/pQAzvwPp1peNv/1qTjoAcj2pcZX2+lACHnJyM5pCMj05pT945HzdeBScY78cdKAD/dA9KQdCBx7UpP16496QY5xn34oAep9+OO3FOX0xxTBwTj+VPAz/AHvyoAf0HFLj60hGOOaXHYA8UAHUfWmNkn1p/wDnmmN1zz1oAjb17UDpgdaU7vejnPc0AJznvTie/PFJz70oHPQ4+lAE8Ayw45967r4Y25n8TRtz8i/zP/1q4WDPavU/g3bGS/uZyMjIAP8An60ID3AfJCgHpViD5cenSqrHdIAO3FW4x8w+gJNUI2dNyXHqBmuB+NNyRYWEAP35WY/gP/r16Bp46kjtXlPxluN+qWUGc7IS35n/AApAcFpkXn6rax44Lg8fnXomA10wX1CD8OtcV4Pj8zW42bOEUmu4sebrjryfzpoDh/jHdAPYWoPABcj8P/r15RO/BIP0rt/ipdm48UumflhjC/TPX+VcBcsNxNJjKshyT7UUjZyenX/PaikBet8ZHJP4V7R8GTt8Pauxx813GMH/AHK8WgI39R9a9q+EA2eF71scPegYP+7imgPpLw7GItMt1A6RinscNyOtSaYNlmo9EA/Sq4O6TGeeTQIbK2Rn0rOuT0x06/Sr8pwrdsCs2ZsrgN1HFACofkGa8r+OdsZvDZYLkxTK+fzH9a9QibIx6cfWvO/jLEZPCt9xkAZwPY0AfNcnQnHv0qq/sOe1WpRj6CqrqBuxnNIZXI6Bc/jR/npQeT1/Gtjw1oM2uXExM0dpp9qvm3l7N/q7ePpk4+8x6Ko5Y8D2AM2K2nlhmnjt5ZIYAGldUJWME4G49skgfU01enP8q6HxJr0EtqmjeHo5bbQYX3hXIEt3J/z2mx1b0Xoo4GSSx53n/JoAcx6jg0xupOeg708kkk9vrSYOM459aAI/UcVGx59KkJ4J5xTGByc9qAI+nOKToMdv/rUowCOPm7cUZzjjvQAhHPUe9IeV56Z9R0pc9/yoJ4OSKAF5HYAj0PFNA4OOvTNLnrgdOtIO+MY9+9ADwckcDjnFOwozyaaOD1OT1zSgjtjIoAkz7DHTrS9B/wDWppzge5p3FABjg/SmN94eufSnnOO+aYc8UARkdO+ePWlXjk4pDg/jRxj3PNAC4yTgc0o9ue/Sm454H5+tLjvmgCzAOcEflXtnwXtdmnNKQfncmvFLb6D6Zr6E+FNqYfD8QOeVz+dNAd0mPMz0Oc1dtxlx196z7c7nLVoWuSyjrTEbln8sLEemK8Q+KU3neLZxniONE/Svb4uLYn14r598bT/aPEupyZyPNKj8OKQE/gSP97ezkcJHjPuf/wBdddp+1ZWbqAM9Pauf8GQ7NBnmbrJLj8BWv5/2bR9RuWONkbYPSmB4d4pu/tetahcZPzTMOT6cf0rm5mz3+taFw5kG587n+Y/U81nzE7hnPWpGV8+/+f8AIope2MHP40UAX4CQwr2z4Rj/AIpm2j7zaiV/KvEoMb1yea9z+DSI2m6KjDLG9lkH4U0B9J2vFs3stUYTlj7cVbthmzdj/c4qmg25NAitey7A57Yx+NZykkEnOB3q7Ou9yG+71xVKc7Tg4x/KmBJF165zXG/FODzfDWoqBn9yeK66A5b6GsbxzAJtFulx96Jv5UAfJE3DHjjPXFVJB9Dj2NX7pSGweD05r6C/ZR8ERXY1PxNqltHLAVaxtUlXcrZH71sHgjBC/i4qRngXhnw7LrT3NxPcJZaTZgNeX0wO2JT0AH8bnnag5PsMmpfE3iJb62h0nSIDY6BasWgtycvK+MGWZh9+QjPso4XA697+0fa6PpXiKy0vwvqNm2kRo7tptm3y2s5PzliOCzcdSSAu3gBRXkHbpQAuDgEfXpUgHr0qPt3/ADp6nj0HtQApGBgfypPfPNKcYwAf0pp5HIzQAw/rUbevJHpmpD1NMPJ6UAR+v+NLjrnv70nr68c0ADHT86AAk9R/nrSEn+H/ANCoI56HntijoAcHj/P+fxoAOmAeMepxSBiRyec+tL7c/lSA45BOPp0oAevsOPrinA+opoABAzg5x0pwOfX1oAcCeOPbpTuBzgUgz0z+lKf88UAJ9BjFNc5PTPtTj0PX8qY1ADGz6H1+tA9h+NA5x398UAjGaAA9c96cBxx9aaPx57U4DpwetAFy1TeVVfvMQBX014PhFtocI6fKK+cdAhM+qWcYHJlH+NfTVkBDpsKD07U0JmhasD16VqWa/Pk9ax7M7lT36/5/CtuyHyk96YGrI3l2hJ6AZr5p1eYy3lxKxJLSMx/M19E6/P8AZ9Du5DxshY/pXzccySRrjJYgfnSA73SQLbw3Zpg/NukPvVbxzcCx8AXWSd0/7vOepY4z+taV+gjt7SBeqxqOPeuU+Mtz5ek6RZA/ffeR7AH/AOtTA8kuSC36VQcknv1qzO3BOQc1UJ5HTHrUjEHtRRRQBdiz5g45r3j4LSIg0dGwOJSM+pNeCxEFga9h8ESGPS9NMZ2yBC27uDnNNAfU0HzWBAOflqkCN6gZx/Kl8PXRvNCgmkG2RowWx0JqdYCGz19SaBGfcjyoyfasaWUNx3HvzWrrEm0LGvFYUjkEgDmmBZgfDEmjXY/OsH91xUcbHYDnINW7hd1jg/T60AfH2vwm31W7hY8xzOOnTk4rS1L4geIbjw3aeHoLw2Oi20IiFrZgxrJ/eMhzlixJJycZPAFX/ibZGz8WXvGFlAkXjj0P8q4mQds5H1qRlFsZ4ApO3SlcYJwfzpPUc0AHGP51IuNvGBj2pmORnPenqMY5NAC/hScYHSl2n1pCM89qAI+Pao2wMZ7VKRjPPP060xh0/ligCMkEds/SkIGDSkYHtnpSe3H40AHH8VJgDvjt9RQcHjP50ntkdfWgB3HXv3NAxwPemY9SCfSlUEDkd+aAHgADlvyOOKeAMkE9aYAeOn405cf/AKqAHnp1+tKRTADjOOh+tP4x7etAAenUfnTDyev4044weQD60w5/uigBjHryc0vY4zSZx/CMd80uCM/LigBM85zyP1py8Yxz9KQH6Ypy/e6Y56UAdZ8Pbc3Hia0H8K5bpX0NJhYgpPQCvEvg7a+brksxH3FABA/GvZ5XBmGMHPaqQi/ZnOD2HWt+yHCgfjXPWBLHA79K6KzwXAFAFH4hTeR4R1AgnPlbR+JrwvSYDcazaRjGPMBP0H+RXsfxYm8vwu6k43ui/rXmXgSDz/EkW4cIC30pAdTfkvrPlqOF+UD6V5v8Zrnf4mt4AeLa3/Lcf/sf1r0uxxNrbMecsW/WvFviNd/a/F+qSZyFkEI+igf1zQwOQmJJ6VFknngVJKTz3/Gmc45I/SkMac4H86KTuM+vWigC2mMgknmvV/CMgTS7T1EeBn615OpwRzz+Nen+G+dJssc4TBx+FNAfU+gYj0e3Ud4k/lWs7hYAW9KydDz/AGZbAH/liv8AKrOozOtlJ9nVHkAwqscAmgRiarKDMcn14rIdgZgckcZOTUl8z5G/DSbRuC9M98fjWdG7m7Ufw96YGuPlHToauffs2HqOtUYXDDHar9qmYSo5IoA8O+Nmm7reC/QDdE2yTj+E/wD18V41LnJ7fU19M+NrBNR0m9tWH+sRkz3Bwf8A61fNEqspZXGHXIYeh6EUmMoSZ3clce1MH4VLLwfrURPvSAXJpwyR0HTtTR605T3wfzoAdz6HP06UnJ//AF0pJ+lB5Hf60ARfn7U1hyKeV/EUwjkZoAjOTjv70hBA/CnbfxPvSEdc4HtQA05ycd+9BGePU0pGOv8An/P+NJwBjAHoRQAduOOaRcZz0GaXHXoM0DHJ7fjmgBRj096eOvFNTqM/l+dLxjnn1oAkGMjHXPSl7cHApg4PXjPcU/scUANb2H501u3rTjjH/wBamE9COnpigBvT09uaUHAGNvFNODxzz7YpwJz0PTjigBSTuxx9KdGckHn1470zI6fy+lSRnvQB698GoClheXDDBZio/lXoTSnemCD61yvw3g+y+EYHZcF8v7Guhif5kBGQAM/X0qkI6HSyC3YfSugsRmQNxXO6cRs4xiuisDl8Z+lAHGfGi48vT7GEfxy9PoK5H4b8XuoTn7sMBPTvzW18apv9P02HPRXfH6VjeAiU0bXpsdXjgGfcAn+dIDoPD/LvIeqpz7189azP9ovbqfOfNnkkyfdya99tpPs+j6hcHICxORz0AFfO9xxHHu67fpzQwRTOTnPP1pMZ7d6Op54/HvSDoR7Uhh296KMen+f89KKALSnB616h4Ufdp9jkdgPr9a8uHrk16f4TXGmWW7jBU/rTQH1T4f502D1CD+VLeSbYmz1xR4bGdNj5/hAH5VV1FyiOr45UkZ9R2oEczfSEXQ28c8jGc8UyQCMMUIyRTVUuZpJMg/dHtULkFOBzjAxTAfYXJV03E4NdPYnPy/3q4hZcMmM5GQSK63RpS8aDqy4oA57XICbu6VRgj5h/n86+b/Gtj/Z/iTUYCMIX8xR7Nz/PNfUviBAl2WP3WHWvCvjPpoi1Oz1BUAS4iMLMP7y8qPy3UmB5VOoznPaq5A9KtS9B0/OqzAdKQxtPXtzTeAe1PUcUAGBjofy6UYGeSOPpTsev8qABjp+FAER64NNPb0qQgAdBjNMPHXmgCI9O3t6Ug6ZHH404jPpnPT0pp+7nkUAJgDrj/OaD93tzQR6Y96B045zQAcAngYzwM0gIAJyPzNGDnA/TtSqDjt09O1ADlIBA4H404H8qauRg8H8KcAQOfxNADsj6c4oJ45xRyAMe3alxx0/SgBrcdzTCff8ASntzkY/SmHOR2ANADecYz/SlB/CkIPf8KUY9v8aAA9akQErtHJJwMUwD/P4Vp+H7U3ms2EGMh5lJ/A5NAHvemQLY+HLSA5CiNRgCpLTBlQHBPT0xTtTby0jjUcKv69qbYr867uD161QjpLQ4G0jA6dOtdHpjZII9K5i0kc4GeB0J/Suk0ls8cDtQB5Z8YZfM8T26Z5jtz+pFR+FDs8FGTGDc3ch477TtH8qo/Fa5A8X3hZuIreP8Ota+nQta+FtBtpBiQQrI/f5jyf50gIvEUht/Aus4bBMLRKR3yMf1rwS5JY4yK9n+Jdx5HglIQQGuZV/HnP8ASvFJmyT1waGMhOcHNHv29aB06kYpcH3zzSATv7UUnJ6CigCwOvUV6l4ZKnTLFFx0Gc15cDwM9K9E8NEz6faYJPyhht65BxTQH1V4Gu1n0e0wQxZAD+HFM1llkkdGH3GwRWD8NrsfYoo1yArkgH0Irb8SukN7uJxuAOM49qYjnr51C4UDaSRgHmswvvAz+Q7VYu5C7uxIIPP6elUQCqsRyD0zQAhX9+ByR1NdJo02HQZwCCK5+TbuyAeUzn2/xrS0pikw7jsfegDf1yITwhvpXD+MPDw1/wAOXVkcLN9+J/7rjofzru5RvhYdsfyNZartDAnr2xQB8fXkMkE8sE67ZoXKOuehFUnzzwa9o+J3hm01C6lurNFt9SY4DA4S5x/C3o3oa8bmRlYrIpV14ZT1B7gipGQHrwO/0p4Ht096THOMCnAeuKAFAxwQQOlB+h4pyrwD/wDWo2EqeRjOaAIzjFRkDPuam2kDqMimODmgCJuvQ0wnvUrDP4VGf8mgBhx7UEDbyTS9Pbik4A6fjigAIz24oAG3GePp/n3p2VwOOfQikXHPHvQAqgHr0+lOUHigY9B+VOB9Ov8AOgAOKPXJ5paDx7/jQAhHHPX2qM/XipGPFRtnJ5oAaR2yKXB9RSHPcjP1pQT2JoAUKc9eegrsvhfZ/a/FkBxkQo0mfT/PNccg+f8AxPevVPgxaAHU75vuqBGM9B3P86EB2eosTeSgknJ/l2q5ZfMGJ6noKyd5kujJyMtkn2rWtdy4BJ+WqEbFicqvHvmum0MlgrdsVy9iwwwPp6cV0+hECMjv3/z+NAHh/wAS1+1eL9ShX70skcH0zx/7NXba4FjvI4FxiFFjHHouK5a9g+3fFJozgr9uDtn+6qA/zxXQ3b/aNdlOeNwP1yc0AcP8YJxHbaZaf3fmP4AD+teUyZzXefFi6Nz4gVByI02j864IjkkYBFSxjQOR1H0oxnk/zowAOR7cUd8k80AIPX/CijjHIxRQBYHPeu18I3G3S1bJ/duyHHvyK4kY7eldJ4Pk3NfWoyS8QlQe6n+uaAPffhxqyCeJGyFTEZYnP0r0LxscJbyAkEqQDXzt4Z1drS5jKPuAYZ7Dsa+hdbmF74bt7kZ4IOQOmRTEcqcrPtY5TB+bHDe+KhWbYmxMKA2D3HWoXmXbliGXODjoMdv51UJxcMN7ZJyrnvzTA2LV1d1Ug9eAeK0oR+/QrjAOOP1rNsNxTzCOT7/rmtC2kzKuQRgn+tAG5G24bm4BBPHaqOQ07I3BHQ1oDCwjaR0FZErtvzt6jmgDk/GenpJDIjhXjckjj7rDkEfjXi/jzThth1IIFkdvIuVH98DKt+I4+or3/U/Ke3aOUffHHHevNfG2k7tL1JdgYSQGSMr3dPm5/DP50MDxgqQTnI/CkAxjoKlcDg846UgXHPU/SpGCjj9KXHB70o4HOaXHrk5NAERXjpTSBnsO3FSkGmuP8+lAFfpwB049KYwGOBUrDocVGw+ntmgBm0jJ+veg9Mt6+tGOOMcijt1H5UAKFPb8eaTBA/8Ar0DIHODj9PalA6kHp1wKAHKDnr9MU4cjrQvbFKoGOp+tABg+1GOvtTiOKTHQUAMP4dqawwT/AIU/86aw+bJNAERHY4FO4B6Ypc8Dj8qB1746frQA6P7/AFr2zwHAbDwHC+QJbly498njn6V4xbRPLMkUfLyMEUD1JxX0Fe24sdO06yi/5YIgwO2BTQmUrRh5zbjznnPetKN8MMYxnI4rJsRmY7zz0zWjCxd1AJwGxTA37I8qejYwc10ui8K2OAAa5i1BLErnrj6V1el4Abb3GaAPJtHXf4+1m7I4iL7SR3bC/wBKuW7/APEzdyR19e4o0aEJc65Oesl4yqfZRzVdG2zlgOWLH8AKAPJfHkxm16Ykng46Z/z1rmyela/id/M1m56HD4rJ7epz/WpGM4zznAoPGfz5pR6ADn1pehHH/wCugBvHvz60UDoMgelFAFj0rT8OXBttaspMkAyeW30YYrLPbvTwSqlgSGXkfhQB2as1nqDxsADG7D8M8V9H+ELpNS8Hw28jDMsWBk98cGvm/WWD3cVwBhZ4VmB6Z4r174fal5ei6dHkIUTd6def5H9KaETW1zJHP5MgGd5RlbkdcYPv/MValUPLGYBhFHR+d30q3rVoy6yJY22x3K5IHdx/XBqhbbisi4BKHJ9dvbFMDoLRd1uGQZHO0VZUEuhVTwecDqKp6VI5tQqtu2t/F15rbtold2PBOMdcjNAEsYZkBckg8nHFVruJVlIGdpxz2zWp5DbHHUYyCBVSW2Z2HBzQBh3kAkjZGzkj8j9ay2tILgNaXHypMCmTzjIIyK62408upYKQwGayNRsWKhwoyvzZz0FAHynqNhPpt9cWN4hS5tpGhkX3B6j2I5HsRVUCvbPif4XGsxtf2xC6rbDY4xxPGDwD/tDsfwI9PGHjKMyuCrAkEHqD6VIyMD17UoA/H6U7A9RS9j3/AK0ARn8Ka3X1qQ89zTT6HpQBXYAjjkdajb9anbtyfzqFup6/iaAIjjPc96ToMdCKc3fr0pDxmgAHUY9qco4BOfpmkUdsH6A05RxgUAKPrTx0zz60KPTNPUEH+KgBp7fzpDUhU9w1I2f9qgCIjqB/Oo2GO/61K2cdD+dMPTqaAGevPGP8KUA5HNJ6dc+9SRL0HOaAOq+G2mf2n4vsImG5IibhvovT9SK9e1xd90Tu+RiMH+WK5j4J6aYLS+1ZhzIwgiz02ryx/PP5V0eqM8uoScqV3Arj0/yaaEUYVLM46FTk571q2sO5jkYwOvrUFogaWQKOpzj2rbt4lWIHGG9zTAu6dAGYYXHOcY9a6GyABIB65HNZumAMRJ1VenP0rVtR8/GehNAHnbxC1ssdGlup5Pw3Y/pWOjbYiSDko/XtzXR+KAsE8UY6Ih69ieTXLTzbRKOp8hsj04oA8X1aTzNRuWOCDI3I571UPT7tPm+aUsTkkkn160wj5e1SMaCAOlLnjBFIOW4xn3ox2JGfSgA9M/Wij8uv9f8A9VFAEw+n1qRB7frTMHjj8aenQYHFAHTXU7Po2hlR963ZTj1VsV23he7eIwRrgoqAD6ACuJgAPhfSXOMx3E0WPqxNdZ4VmSMr5y7t2FHbAz1xTA9jjk/tLRFcgtNbnevHPT+oJ4qncQFNWDAM0co3Kc5HI5GK0vC1vsmZTyjqGz2PPP8ASuoXRkVVVBnByhPOPamIwrGyZbVjgknB57Yres4fnUgYJA7dauRWirFj7x9MVLDbN8uBwDg+lAFm0iRlYZBwQG/n/gaum2gYKAgDHpgdaksbTIPCgtzgDqadfTR2yjHzSjoey0gKc+nAITjHpxWBqVkgwGAGOOe1dPFqkcg2krnvk9BUV9DHcKfLOD0I60AeR+JLJtzzwkq3U44zXiXxB0kw3CXqx7PNGCP7xHWvqDUtCMpbIYL34ryr4r6dp9n4V86QkBZfLiAX5pHPYe3c+wpsDwMDtn8Kdjjqaey4JyMZ7UgUYP5VIyI0xqsEAjAHJ/z/AJ/+vUTjH4DNAEBHuPxqBxirLDtg/wCFQOCOP0zQBEf89Kb1Hb8Kf69c9KQ9O9ACAEMM4+uOtOA9h+NHA+lPTPrzQA4cY/wp4GOuKEPTJp6/doAaR3A5pCOTheaeVHFBzjJoAgf6cVG3uKlcfT8Kjbr0oAYRyMDA+tWLaJ5JESJd0rsEQdMsTgD8yKh25425/CvQPhHoJ1PxEL2Zf9FsBvY9mkP3V/Ac/iKAPW9E0yPRvD1nYxg5hjAY4+8x5Y/Ws+a22kLjI27iSO57CunmjJGHIwWBxk/57GoZIPMUFwN3l9u3pVCMLTrdheONo9AMevetuCBsYIJIOKfYWYOJOjA8k+la0VptyQMkMOfr0oAWwh8uIqO3bH6/rV+2X98gB+9x/QVJDbEYwD3/AM/yqWxixdK2PlUlj+HagDzbxy5OuXUefkRsAfSuOu5CbLVJwc7LZh+uK7Hx0nl65eM3zK2G575FcTqAVPC+sNzyuB7daQHj7fe78GmHpTyBximkcZJNIY0exwMZpc9s9felUcHmkC5ON3egBD+npRQAOOR9M0UATenFPQDv9Kb0xT1A44xzQB0Vmd3hBV/iXUXx7ZQGuq8E2InnhaSVQhbkZHb1J6DjOa5HS8P4dvowR5kV3HJjPZ12/wA1Ndt8OjHbXQa7lSIKxIEnRuOePx60wPfNA/1UJiJOUByRjt1x+VdbbqJEQnkg9q5PTruIBFHzlm+pGe1dhaXsVsVikYK+MEDkimxGguns2DtKg9QanjtoIsh2BJ5O0VUtdSMpeIhmK8h26MPUetWImEjZl3NnoAcD8hSGTF3YGK0QYPDNzx+NOWwhDgzKJnx1I6fQVatwHwMAL2AFW1QKOg/CkBlS2yFceUmD1G0YxWLqSG2kyilR1BWuvZQfrWfqdkJ4iSM+oJoA4y+vVdPMRmYDBZehBrxf43XP25rC1dcLCWmUD1xtyfwJr2PWLQ2gllRG3BSenX2rwzxy73135x+7jaOx/GmI8kuYtkxHoe1QhflI5rW1WDFw3XFZhXqP60hkRX3z+PvTH/8ArVOfXqKjcflQBVYckenGKhkFWHGOKicEjvQBVOR60fh+tOYZ6CmkZ7UAKMg9KkUZ9fbimA5I471JGPY5oAkX1/WngZ9qQfrTx0/xoAQrn29aQrj8aeRwPyprdDxQBC44Jx9agYc9KssPl6D6VERlgB1oAls7eS4mSOCIyzyMEjRersegFfRngfR4tA0e202M7rjO+4kwPmkPX1rgPh1on9kmPU72MfapFPkoRzEvdvqfSvVdNjJjTAw56kjOD6/WmhF9Yi0oOMhflqxDbFjg5GcAYqe3i2qF6+pz7VpwwMAAO+OPw96YGcLTy4/lAwTnHcmtCC3GMEHdgA1OIN+z5eB2FW4oAOnAzzQBCE2gdBjFLbxhY5ZB3O0YqeaImHGMg8UqL+5XPUgk/XNAHmPxHhHnwSKGAcbWI6ce1ef6pEW8LaoinIGD0+tev+NLMXenkIcyqdygdfevOjaGXR9UiAJZ124/WgDwGQDOAeaZ74PXpxU8ylZCMjOcEfjUBBxz19vWpGNBPH/1qDnpg/U4607k96aAM4z3oASijoByRRQBMMZGen1p6fd56d+aaO3XrzTk4AoA2/DkgMt5a4H+kQZX13odwx+Bb8q6m2kUSoVJZQB3ODj361w1nPJa3ENxDkyQuHAxjOOo/EZH413UaLIQ9uwMLgSRnsyNz+dMD1L4canJJut2kySAUODwRxxXqegwFvNllywHRj3NeNeBYm8xH+bAO3A9f8k179p0CC1iXnaQM4piGCMySqUHK8VvWNmxALA4znmpLCGNGGxOT1Y1pgYFSMZHEsY+Wn0UUAIRnrTJFBXBqSkcAj5qAOV1mMvJIgGAuS27uB/kV4D4jtSd5x8pJOPqeP6V714tuC8LRQcK3Ejdz7fSvK9csco5C5AHSmhHiOswbZH3Yz7Vzcww5yOtd14ltCkx44NcZexiOUjqM0DKhzUT5HUcVIQPwqNx6YpAV3+9xzUL8ZqZ/wAKhYc9vxoAhck8Ec/Wo8+35VK/TjGPSosY7jjvQA9ev/16lXgcZ/Oo069AKehx/wDqoAmHqD9KcnXnimICFAPJAHNPXrQA4gEcdaaec048fQ+tNbr/AFoAjbHJre8G6Ut9f+dMm63h5ORkE1hqhdwi8sSAK9O8L2n2azigjHJO5vc+nvQB1Omwec6qoJdiGPsPr/Su80myITleccH0/wDr1j+GdPcruYEsRjLdcV3NlbEjGMKKoQkFrwuVI7VqQ2hxjHQ1YtbVj24rShhYAfLx1HFIDLS1Kt06Hip/s529evWtH7OdvTk96kEIxjuaAMi4iwi8YFQXKbI0AP0rYuoTgADjpVK8iy3I6DigDjtYj3K/GTjNcVewi1vDIv8AqZGAkTHTOc49q9H1a2whJXJxXI3sSy3AULgrwQec5pgfLniW1ez1u+t2yDHO6/8Aj3FZBBzk59sCu4+KNl9n8UXLhSFlw3PHI4P+feuIcdeakYzkY60ZPUE9aXsOnFJkdzQAgyMH9aKX/P8An9aKAJfTuPenL25pnIx+NOHGelAEyEE9s9OK6vwhqCq6afcuFRn/AHMhP3CTypPoTznsSexrk0JzjPtVmI+pGO4oA+k/AWmyWszJPHsYcBDx+P8An/69exxLtiiBIXI4xXzb8MPHl5p6RWuoSG7t0wI/MUOyD+6CecfjXvuham2qJHcsxKsdo46fXHSmI7uxGIkPqKuVTsDujHtxVykMKKKKACg80UUAZWqWSPE52LuPQ4rz/wAQ2H7lhtCkg8elepTLvjIrnNa08XMRGMMAcHrTQHzr4n0w+UzbOhI+leYa5bmNiwH4V9Ga9pePORk9mBrx/wAbaO1tGz7TsBxwOxoYjzhiOajf6c1I4KswPUHn2qJyOOmPpSGV2IJ/nUTEc+n0qVv/ANeeaibnPIoAhPHTNMzweoNPb6fpUf4jFADx171Kp+ufTBqH8BUq96AJl6CnKeRycUxc/wCRTxnFADyc465+lMPXnNObpmmt+lAFvSYBNeIucdhxXtnhXStvk7lPQe+f8814pos4ttSikdcpnDD2/MfzFfV3guxgu9JtJkDHfEpBfqvGD/L1poTNbQ7BfJQIoGecCuusrG3jwSN5/Sq9jbCBSCQXI4AHQVpoRCm5m5oAtwrGg2iIADpUyGBmwjru9B1qhDLJMxPCr7D+tWltlkIJUhx/Gv8AnmkMnaJT0wKiEY3jGD34pVEwk2ttIA6kEUkkcu0lBk+lAELx5k46d6q3MO8h1AOR26VaFvIS+8fK3UDuPTNK6ljzgUAYGrW4W0djzivPZoJEvy3RTyBjvXo+t72TZxtx83auPeBjKzFScnBJPQVSEeEfGm0VNQJb+LDAnr6ZryCUYcjHvX0F8ebEMlm6D52XjHXAAz+prwC5Ta/fjjBpMZW6ce350h7U4ZHTimnp/SkA0egNFKTyc5NFAEgA4447cU5cEimAnP8A9epAcYzwPX1oAkUZPA4zU8fDA1WBzzUsRxjAH50AdT4bciUYOOB0r6P8A3ji1gZHGTjPPX2r5q8OMftIA4zzzX0V8NEBgh3dFy3HemhM9z0yQOgO3BNX6x/DoPlOx/CtikMKKKKACiiigAqpdxAqeOtW6RlDDBoA4nxBYJNE7FQGXqfUe9eWeLtIF1a3MBUFmUlfwr3HU4A0Ui9yMivPdZtAz5I6U0I+StViMN224FSeufbis52OT2Ndx8TtMFhrc4CgRud6n2PP+NcLIRnkCkMhf6Uxj7/jT2Pvjmom5Hb8qAI2IzyeaZn1NOY89RTeKAFB561IpHQtUYbBJyM56ipFYdyPyoAmXqOacOR6Co1IwPWnqenA+lADiQR2zSE89e9GeOfpSE9uKAJrQZlWvo34OXUq6MsSyZEUuMPk8HnH04NfOunfNcL9R2r6J+EKL9mmjI+YlZAPUAEH+dNAe36bIHjDY/xNTzwtI3fjqB61X0tDHEDj7oJ55rYsY96hm/yaAFsrXy4+RzV8KAKRVxTqQDSoY8g5FOwKKKAG7RnpUFxEGG4cH1Bqwcnj9aDwvrQBztzbnB3HnPUmsa5s/nyq5JPJ9K6y4TdnIrMuoucA/WmI8e+MGlNeeQFj3KkeOnQnv/KvmbxJYyWd9LHKuHRsEV9keKzvkK4Qkjq4yMV8/wDxO03TVZ5EV0YHLShtxf65/KgDxojp6djTeT71JIMMQvOCQCajzgcdKQxPUnpn86KFzntRQA709Panr0HWoAScH2qaMA7c96AJFx6mpYwNw5/WoAfmH1FOU80AdP4awbpD3/nX0f8ADhgphUj5WGMH6V81+HGIvEweh/xr6Q+GjFprYE5HmCmhM9y0SHybQDHzEc/4VoLnA3AA9wDmobUfJ+JqekMKKKKACiiigAooooAqXaDbz071xeqWuWfpgHvXdT8oQa5rV1ULJgd6aEz5z+NunlIba52/McoePxFeISnnivo341qP+EfiOORN/wCymvnB/vkdqGMjJ5NRNnBGBg/pT36/59aiPKikAxjkYxzTe1HUnNHY0AOz9cU5SBxj86j7/jSp0oAsIfWng96iHAz3p4PB/CgB5Pv+tJ9c0nX8qQ9R7/40AX9Hx9sQH1HP419K/DaJYtOt3iwsgAYtjnkV8zaSc3sf1FfTnwzJOn2+T0BH8v8AGmhM9a0uVpkCbduRyc10NpjaFHGK5zRlBOD0wa6SzACLSGWqKKKACiiigApGGQaWk7mgDPuJGj4YHFZt7cAIcfePfFbcwBHPPB61k3SqM4UDA9KAOJ8RIWGefmHU/wAq8a8bpHKsiTCMqQQCT0H869t1YB459wB25I9uleK+OwPsr8DJHXv+dUI8D1ICO8ljUgqrFc496qk84xzU+okm8kJOSeT9arnpnv1/nUjDJ4wKKaTgHFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the tibia and fibula in the same patient as the previous pictures. The patient had a spontaneous fracture of the right tibia and fibula three years previously, which had healed with bowing (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of LD Hordon, MD and Verna Wright, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neuropathic disease of foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 322px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFCAO0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5cI68fp9fagj/ADj60Ef5x9aXHPTP+T7UATIuFzxn1AqWMZb6VGv3eg/CpowMHj/H/P8An6gDwMD/AD/n/P56VhAxQKVO5iCMDtVGFN8qjHfnH+f8/wA9+yUtKCfug8Ed6ALlvAgA4JPQ5qXygB93NSw8nO38fSnnk/JgjvnvQBVKAKQO/FVHY+Wx6dq0ZlPl4PJ/P0rNnHyHOMigCtK+RtYYB9KzZpGQFSOvfqO1XzGXYbQeRzVa9gOwdS+fT9KAMuRc89h+lRkYzn/P+f8APvOwAHzDp7f5/wA/rC3JOP8A9VADkT+Lv2qeGEuRtB9P/rf5/wD1tCjgDgdM/wCf8/1tw58nIUZJxkD/AOtQAgQJgD/PT2qGY9B/SrMajZkDJPH+eKhlBAyOfbH0/wA/55AKr9P0+n+f8+8O0Zzjn6f5/wA/rNKCwB64pAh2n1Ptn/P+fxAG7VXrk+tIRj/D0pwTIyfyx/n/AD+pJwMY/H+n+f8A9YAgJjYEc4P+RUjuOGHQ9sfpUB4yfSo2duR25oAbOd0jHH+eaZjjp/nn2pdpJwB+n/1qkEXqfrxQBHjJ4HX/AOvVlF8tSP4j1OOnt/n/APW1UCkkdfX0p4G5hn/9X+f8+4AyUlUzjrkD/P8An/Gv82Ttx+NSTv5jnA4HAqq33j9aAJiOv+H1pQMnGP8APNIR/nH1oI/zj60AWf8AP+f8/wD15YwOCfXFRDkZ/pUkR5x/n/P+fqAXtOTfcqAMnHH19q3oxhwgGM/qfSsLTcC5Ut0BB4roo13sD13dcUAWrfkgnOO+P5VbQb4flXBOD06/SorUZYcDHTj1q6sIUlgSVyAABjNAFO+G2HPynotZdwhO7gZb07+1bl+hkAfseo9+Kz5IsNggHB9KAM9FEaBj16Vn3ihmyBk9vzrVu1wDxjj0rLmG4Y2jP50AULtQyq4GN3HSqhUsMkewH+f8/wBb97xFGO2e34VTAwAP8/5/z9QCSFhnBHBxxj/P+f1vwxEAgjINZhGRx/L/AD/n9drScXFmyMPnj4BPp6UARIm45I4HWq08ZJz2z+dXiCi7eeeSKili9eeM0AZpUDqCOOBREuW6dBSM4ZyFOQPb/P8An9XRjqTx05x0oAYOn+H+f8/zjkXueMDHr/n/AD+NhUORx7dKhmXAPH0zQBBLhRgjPHT/AD/n+tcj2/T6+1TTjK59PaoSOvH+eaAJYhwT3pwHU9fc/wCf8/zjCuOgx/k1Krsoww9uRmgAxyT/AJ/z/n6h4Vvocf5/z/i4jcDtGG9DUQO0FW6jsRQBA2Oc1CTkk+tSyHFRhCRkDNAExH+cfWl5BOP89aQ9/wDD60Ef5x9aALCHI6dqkT7wPTnH/wBaokII9/8AP+f88yx8MMDvigC3anEg+o/mP8/556u2wGDdNwGPeuQTG4ZHt9K6vST5lrEJGzjjJ/lQBoW0ZjcH7wJGf6YrSRJdqqcNkknJqipfy3Y7cZzj15qxBcGMbTnYRkZ65oAtXCllBCBlXcvB6/5P+fXMuEy55PY8VpRbmtIweWDAk46Z6f5/yalzB/rUfIxwD0NAGFeq2SxPHr61nNGe5H41PfPtYgsfzrKuJGkAXJwcD6/pQA26I7NuGeMfhVf/AD/n/P8A9d+0eWPUf/WpqqSQMUAJ/n/P+f8A6+voKkpOe2OnvWUVIxkbf8it3QUIidm6E9fWgBu3JwByaivTstHfvjip85k+UZOeKh1oYsj2/D6UAc8CQeOP8/5/z10IR5iCQLnkAj8qz/8AP+f8/wD19HTBuikXGeef8KAF24A4/wA8e1RSpn5sfp9KtGPdjrwMDjrUN+PKhUdCRxQBnS8kkAcf5/z/AJy0IASe/uOn+f8APu/BPT6YpMf5/wA/5/qAJj/P+f8AP9Qilx9PT/P+f/rn+f8AP+f/AK4BGcxnKduox0qOU7mJA6/59KWYfMeP880wjrx+n1oAZKSc4HA9qaqkjgA1IUznOcU9FUZPT6UANI/zj60Edev+c0Ef5x9aMf5/P2oAkiABPXP0+tWE+9jH6VDEOCePyqaMDdyKAJk4I9q6rQQXsv8Adbr7VyyDLDpXV+F9vkS7sYJH40AaaqQypn5ugFPSLKko2crt6UTxlZQ5OMr8vvTlI8xCnKnGV6UAW7Mfu3cMMBcYx3ApbyMNbtKvfg8VLp8C7pVzweR19OP8/wCS3W28rTmBI4Gfcn/P+fUA4HUpC9yRjgcfrVLbnHHt/L2qZ1G4lieTxgfSowP84+ntQAzYPTJIx/L2pRxgDrx2+lIwbgD8/wAvamlCCDnjr06dPagBucnoAenvn2rodMTyrCP5R83XHeueTBdfl5/z/n/PPVImyxhGByOgoArKmZSccDGOO9Q64m2zGTxnH8qvwKTIOO351X8RJi1AUHqKAOXIO7oMHg1r6JCWhnOfQVl/5/z/AJ/+vuaQhXS5XPAZsfyoAZ5eXG0e31rO1k/6SAOABxW1bpvkFYGq/NfyY+lAEG0j3x07/wCev+e6uuRyentmiEZbaBz6/wCf8/1ldCqg4P4UAQEc5xgdv8/5/wAWuPbn6cfT/P8A+ubaMcfp2qKTluntQBWl+8Rj/PNRt97GPXFPc7mJx/nmmMoOcj/PNADgMnHH4/jUyRd8Bs++MVGqbs+n0+tPEbL90n88UAQkf5x9aOueP0+tBH+cfWgj/OPrQBJEcZB6VZj4/Hj/AD/n/wCvWjGSR271YThuBQBYjGWA4z9M11fhhSbdyMg5/PiuVhIB5GD/AC/z/n363wtxav1yW7fQUAaUxDMuT260sACvtz2AwetEg+QDb75HanQDzHBf2wRQBu2EX3dpB4HP9KzPGB2WMvTDELj8a1dMyxYY68j9f8ayPHORbRrn7z8g9+aAOClUsAR/Lr0qH04/T6e1WiMHHXtUTRgnd1yf8KAIQOnH6fT2pGXcuO//AOr2px5bPX3x9PaniPjqM8UAMt4iZ1CgksQAPxHtXWTIQiqB0HH1rn9JhMl9EMZ79K6a4BJAPsDgUAQwpnryBxVTxJEBb9fStWzhyoY9+mOM1T8TR4hI6456UAcbsO7AB/CutggEOjwqVzu61zcEQeZFC8sQOn0rsNSQqkMSjgKO3WgCjbRbFz1rmL8ZvpWBzzj/AD/n/wCv2CrthJ5PQcVx11/x8yfWgAsoxJdDPQA5xUkybmPqcc/lU2nptid8cngf/WpwTc+fvZ5/lQBRaPHPRQOp/D/P+eaU7dePar2oPh9i8cc8fp/n/wDXnyAFTxn+n+f8+4BDj2/T6+1EiSDJwMfSplTBJxj+lOK9u38qAIVSbH3gPrSiOb+/z7VPgfTHtTWYKeh/PFAFcj/OPrQR/nH1oI/zj60Hvx/nmgCSIfMT/n+VWIx83Q/l0qGLp/nip4zjg+tAEyj5hxn2/wA/5/r1nhwEWjHkZJ/lXKRj51+tdf4f+XTug+bPNAGlG64GQcZznNT2iBmCsCu4fe7VVbkL0zgdK0LJA8igdMdcUAbWnx/J1GT+nFYvj5CY4GHQE5rf05WXBYH64+tUfGkBfT5NnJXB4oA80dTuPGc+lNK9iOv61YpHUHGaAK5APUZz+tGOlPQbm/nT5ASQAOPrQBpeGYPNu3Y87VHati5jCk4JOSab4Rtx5DyMPvcD3xVydMTE4OD0560AJaR8gHtz/wDWqh4lGLWQ+orbtISCck89cdv8/wCffI8VJi3cAcdPXvQByuiQ+dqduuON2en09q6jU2ZrrnkYwKyvCtuG1FpP4UU/StW5UNPkKMcZoAjlG2xYnrnnFcRIC85AByT3ru9QTZppPJyCTXI6dB5t4nyggDPT6UAWjF5cMceRwADiiJBgnHbPSpLhfmxjOetEmUsZnAxxgUAc5cv5kztnOT/n/P8AkxY45FKRj/P+f8/qhoACOD/UU4Dgn06/5/z/AIsXLTIvHJxVlhjO0Dr3oAiC/Ln8KZtBJyufpUj52HpwagdiHIGQBQBCR/nH1oPf/PrQR/nH1pcZPA6//XoAnQYXFSxdT/n/AD/n8YwOOlTRrxn/AD/n/P1AJYhlxwDXa6Og/suAYOSM8d64y3Ulunt/Ku6s0KWMKj+IAdKAJmTIG3kkADtWlY9jknt0/wA+tU4UWSZAM4CAnir1mp7jg8gA/wCf8/qAb+mj5lGD/k/Sk1+HzbeSPH3kwB+FLpo2yA/d45NW9TTcgORjHb/PvQB43IhSQg9RxSVpava+VqUqhSBv6e1VjGNuACf8igCptG7J606rEcYAzjJ6fWpY0DSKCBgkZ96AOw0C2Eekx4xu25OKjuIiz4yeuCK17OHyrIp/sYNQCEsRxkj3/n/n/wCuANt4sKBjA6dOnt/n/wDXheKY/wDQ3+tdUqbBgA4//X7VgeLI/wDQX6Y646cUAZfhCAraXExX7xAHp0q0kfmTMSAN3QVe0i1+y6FEcfNIMn8ajtom8zlegoAq68jLpDZIwV5FcvpEJWB5CPvcCuz8SRf8SyRcdV+Uf5/z/XnVhEVuiKCfl5Hr9KAKEiMz8DrRqa+Xp2z16mrUaZkC9RnGah1shV24PHX9KAOWZMjgDP8An/P+eY2HPH8v8/5/WcjBqKReQAOTx0/z/n9QB9pEDKXI6cClk4O0DPvirMcYRAMdMZ4/+tVZslyen4f5/wA/qARynEZYjjHAqizMTncAffvVq8P3V/T8KpMfmOWI+lAEhH+cfWnKMtjFNI/zj61JEBk8c/8A66AJh16fmP8AP+f1sxIWwB271AgBPORVuFe+KALFrEXdFA7gcfhXeJCRBGqAZCcn6Vy3h+186+jX0+Y/hXaCJZGB/hAxj2x+n+fxAFigJYkYHbjuK0YIW2rlRnnt/n/P6wwoW/1Y4JyeP8/5/XTjiAyy5GM456mgCxDtwMZzg9sd60Jow0EZz9xSDiqca7WbpggD681pYxbrzkA9uf8AP/1/zAPNvF0Ai1NXK/K65wO/PSskJlF4+Uj0612vi+083ypgOBxjFcubfjI7+36UAZ/kj1qS3TbMvGcsMVNLER2Ge4FWNPtTNewIvJLDIoA7VI/Lt/unLD8R3qOOMGYEgAegHWtG5jXd0HH49qSKE8AKQD3xQBEygI2B2xxWTfWv2v8AdFThuK32i4zwCTgenPpUul2QbfIRnggEj8aAMC+iSG2WNFwqgAY/GqVjEWkyADgdMcfl/n/HU1hP3xHcEA4NN0+3yyjb1Pcf5zQBV1SASxBWXI5JPpXK3ifOCBngDAHau/v4CLaR244xx3riLmPeTtBPYDFAFK1iDSrhQQOvFZmvZLOTxyABiuitYjlmIJBFc3r5y2euTQBzzjnPP1p9rGZJl4yF5P8AhSOvHT8cVd06MrCZMfebAoAbKuOf72D/ACqmE3SYUcccj+VXrvBfGM/5FVXASN39Bnn8PagDLu23ysR0HHT0qofmOeM1Mwznjn/9dQEYoAnI/wA4+tTxjC9KhAyeR+n19qtKu5v/AK2f8/5/EAmhXOAc+/HNXYIx6cDtjrVeBdz9MkdK3tGtlkuBlQyrzt9TQBu6BZ/ZIA8ijzZhznjC+lbsCZA7gDqP8/5/nnwI4cbsMxGCQeMVsWiMR0984z/n/P4gFuJP3YO3Bxz+vtV6KBjtBbHzccZ/z1qGCJsLgbu2MdRWlDDIVTYuGPVj2oAjeIrgkAZOMVoQgGMqfX/P+f8AJbJGFUcZ/wA/5/z1bGGVxhSBnBwOn+f8+4BS1m2SSzZZMEAZI/wrlJbdJPmjB5OM/wCf8/17zULV5LdiAPmHBrlfJNu5DgYDYHX3/OgDm7+Fo2CuPxrb8K2YMiSlQcdG649qz9RJubrCgkZ/yK7LQLUx2KKcArz0oAuHGeBj/P8An/PVhTIzt756d/8AP+fW00ZZiSc5Hp0/z/X8wx4QqO54/wA/5/xAGRR7mC7Vz06/T/H/AD31xCkNoAF5wRyKg063Esw+UYA9OM/5/wA+tnVV8tCynP8ADkCgDib9TJPIcZycgdfWrmnINwHP1x3zimNGGlzjByeF6/55rSsIC00aAAlsnjt7f5//AFgDdVi2We0r/Ac159Ov7wBQTn8zzXpmsR7kdCCc8D+lcHJCVuCGwDk4yP8AP+f1AKwTZAQRg4z9eP8AP+evHa7820n+8a72+jKwnKnpx/hXDa0vA4P3qAMDaSQuOvGPy9q1Hi8iCOLByqjJHvUNlbiW7jBGeQTgVcuyWlbjgelAGVKrFuB14PH/ANaq+qNstNgGM1oxo28kg8DrWRrDjzNnXA70AZhHXj/PNQMMdCDU7d+P881EynOApwOOlAFiNSWzgcev4+1W4h1/L3/z/n614hhSe9WrdSWHHfpQBdgUBgMcduPpXR+GSPtRVgMMuPSuegB3e2P8K2tIcJcR/MBgg5oA7K2gVGLN6cZ/z/n+e1Y25YAD7pOB+tUbIbowZVHPA5z+ddPpUe4jK8dCf6UASWUC+VjBLAdcVtx2IMKAgAdio7021tC8jYOR6f5/z/XTVAVBxhfUd/bHrQBjXUG0cjnv2zn/APXVdmCKzlsAf5/z/nN/UQC7FcdRj/CsqVCkuZAcZ+v4f5//AFgEstz5sLb1AA6n0/8Arf5+vOaichgMHP8AEM/lV+5leQmOPjt8orOuEbIJIJ7HFAFXQtN+06g8jDKqeBjNd3BZeXCCwzjpjgVneFrdCHZvvFuPTmt2aRUXCndgdhxQBTnVQCehPTnGf/rVGYi4DR5Yk4+v0/z/APXsFSSAAcscdOvtVmGEs3QsFweO9AEumRCC2ZuGkPXjFUtXRpLR8E8g5I79K0hG21lB98eo/oahmtmKZ9eo9uO1AHLxRfuucYXHPX/P+fx19Hg3SlgOANo496RrUlvmXDE8cc4rXsIBDHwuGP8ALr/X/PcAz9Qt8c45H5VxN7aD7bKABtzkDoMGvS75C0LBTn+tcZqdttuwwGN3y59eaAOb1CMmL0Iz1/H/AD/nnhNaH3Q3OWJx+Vej6shEe04z0/SvNtbOb5lHKpxmgCLSIiqSzEc8KtNnQgYBHHJNacMIj0+EbeWy5/H+tVZFy6cFsnmgCp5YWMADLtzyP5Vy+pfvLqQ89eldneIEhd26hSenWuHm+bezDk5PSgCsR/nH1qEt6Yx9KmI6j+n1qF/vd/xoAvovQAY/CrcC/MuB0qsoywGKtwDknFAFuBflyRwf1rWsYvnDN0HQVR06EzEAdq6fTdOM2CFIAwD6UAdB4fR5bdRyecYxXa6ZG6qExnjkE/54rntFtvIIQbsjHJFdbYMpUgAA9MdulAGrbgiPDZJzjp1+lSHJC8f/AF6WE8hGGd2ATj+VXp7ZXjR8nJ4NAGOsWVYnIOTnd0NYWvXGxgiAkZ/MitjXmKIAgCxZ5I/r/n/6/OPG7FnfkhsqDz/nrQA+0i/dpuG1xknNQ3MGMllG3v7VfhTcwyMjp/n/AD/9d80RcLwCOmTz/n/P4gF7Q44zZkuvfk7utW9qmbADFc4+tM02Jfs+0gbCMcDqa07aFdgJO72x0oAqrbDPzlto5xj9K0LaIRwk4zn26GpoYhK2Gzgc8f5/z/OeVBGuz5skHC460AU1TAGAMDjP/wBf/P8AjWv32xKP4z+Q/wA/597nQADAAH3f8/5/rmuczMoUcDpnvnpQAWEDSu5bp0z3OO1azR4k4XAxnBqxpmnSQ2xZgMs2TTgm+TAVs5IBxjNAFC4UOh9COec4/wA8f568xfQ5fnOe5x09q7SdAEO44U5JUDk1j3dmNrqCC3TBoA8/1mIqu4DAJPHWvNbiHzdQMYG7dJgcdea9U8Sjy0PbAI55/wA/5/HgdFtfOvpJWGRGC2cdz0oAZephto5jUbR9BVGOLO0g9eTWvfRq0igZxntVVYwPlAwStAGPrj+Xp0x5y2E/M1xMwwGGAf8AP+f89e18W/u7CFAD875yPb/9dcXIM7hx6cf5/wA/zAKpH+cfWoGOScdKnYdeP881Dxk5B/OgDRQZcfX/AD/n/JuQd+PSqa5yMA/l/n/P624PvEf57UAbujlh0AyMZFdbpxcxhguEJ64xmuW0Lm4RD/EQDXYGNolCliQvBA9KANmzudm3D/MRk/5/H/Pfc06aTfuxxnOMckdK5SwCkgyAt/k46/5/r1OmthBiPHJGaAN+1ug2PMyp4HA610VnP+7Te5I7f59f8/Xz/TNbjvfFGo6NAVJtIY5CRyWZidw/AFfxNdVayupChTz7c0ASa5F8jlTuJ59eK5Td+82lSMcdP88f5+vY3zmbSH2n5hzk81zGnxI2QTnJ79yP8/57gFy3twYd2MKTgVNBYsEBc55496vwQkgBeRnOasrHvkVRgovGfU0AQmLZGp9e3eriKEUAf5/z/n3jlcx4CjIPT/AVZtAHl4xx6/5/z/MAltY3RWZwFBb/AL6qK+mRFBY5weMVacuw2xkE9OvIrJuoA74clST931oAgN20kvlxYPzYB9/StHR7GOe4QHnJyzEdOelV4raJAu1QT6+v+f8APv2Wi2OyHzNvXkEDkUAXlhhjCoFX+7j/AD/n+tG7sgI/M25IPI/rV2aGRipVgQRg+2ParPkM0GWw3HIoA4q8jIfYd3ByeDVWYlIQzZc9iOp/z/n319SXG8jIIyfesDUrkMjrgjIwOP8APrQBwfjB9wdjjqRn2/KsHTrcWmll2/1k+TjHbtXVarB9ueOLGV3biQP4RWTfrvOAoCqMflQBz1zDlieMH/OP8/8A666RADeN2Dhffn/P+e+pcx7ARjoDyfxqAJgKCe/Ix0OP8/56gHD+NHy8KDOADj8wK5Bh8x/z/n/P49R4wOb4DJ+Uf1rlpcjceMj8qAK0gwxz+v41XqaTHORkVCeTQBqRdTVm3GW/p+VVYxlv8/5/z+dqAc/d9s/lQB1PhSISampJwq8n8K7SSNdzAP8AMTnk/wCf8/ryHhPJmmIxjbXT53xnrk85z/n/AD+oBbtYX3gKBnODkf5/z+u/c3Nvo+jS3twyiK3jLsDxnjp+JwPx/PO04KqqZBluxx0rL+KlneXXhKRbBolt4m8+6LvtJReir2Iyc/XGOtAHN/BfUJ73xprE8rjzrq3eV+OpMik/zr3e0O9SFJIGPmI5xn1rwD4I6dqK+IBqUdu39nPHLbvNwQGwGA9Rzt5/CverdH8pV2D5jjpQBNqBZYUSPJEmM+lVLWL/AEjHzFM/yqXXZ/JgjG3dI2Gz1J6U3S3aVlyQSxAOOooA34kRLclc8nA4/wA9qkhhVXPqeQQe3r70kUZIUAjYD0zV5EQAfN0468kUAU723VQMdDj+VWrW2AHTn+9jv/k1OUj3gEc8YyTWhaIogJYLg89P/rUAUxAseAFxnqPy9qzbqDfOONrDkn2rpEi37iqZI655x7Y/z/jVNlJPcOwU7QcYPH+etAGRZwSOxVkbaxx/j/Suz0qF1twGGCoAAI4x71DaacDtaNPY5Hf0rdt7fA27cLjjNAECxD+JPmxzx+nsKSVQkLE5C9On6frWmICAcYIHJI71Ru4XfATncep/l0oA4vVlUiSNh14BznPNcxNbSXD7MFt3TjjFdV4jCpcQpklgcYFRbY44lIGD1J6/5/z+IBxlzapbRyY+8cnOOfp/OuavYxsYbeBXZana7Fcsd27PT0rnLmEMCCDtbs3agDl7iIoSp78dvxqjKpWMnkZ6cfX/AD/nnevYwHzsGTnAI9qwtTASNQRgZ54oA808TMJdSmYfTP5Vzdx0P07Vu6y5a8mdhklyT+YrEuBxnHbFAFNhkdKgOM8dKmcZB7VCaANOPG8Z4x/nFWocAjjnpVWMfMDzx/n/AD/nNqAZ7Dj9OlAHT+HWKLJt53gKBiuvtUZxHs6cZ9P/ANdcNo74IQ45AwfevSNIizZiTAJB4GOvFAGlAqpIMgEgg4xWJ8T7hrfwLehX+aZ0iJB7FgSPyH+e+sfuspwWJzg1xPxiunTRdOtcgebOztjjO1QB/wChUAd58I7A2ngPTQwGZ987ds7mOM/gBzXcOwUBVIBrB8KWy6d4d02zkVgbe2jR+O+3J/XNasDLcPtG4q3JwcfhQBZuo4bgwmVhuTqPQVVtIGS7by5IyM5A3DP0rUS1GW3EnjGQO3+f8+ue1kIrhiNxyfzzQBt2lx8pMjouecda0IJoeT5inHGKx7PSjKAcOATnjH+e9blhoUbSAO8hXPQ8D+VAEsbIz4DZOBx7ce1XgCVxHyOFGen+f8/WOHTUWQJEhUk5YnORWnaaQm4lizd1zyKAGRiK0jYySAeWuWc8ADGfy61zvwm8S/8ACbaLqmqrLut11S4gtQF2lYVC+WDx1IOTn1rA/aJ1qPwf8NLuKBwuoasfscIxkhSP3p/BMjPq4rJ/Y5mFx8PtXtd6lodSLFccgNEmPzKt+RoA99toBFGNoJBGeO4zVpVwA247PyyfSnwR7U/eKAc8fl0qwVDYGOR60ARqP3YC+mPmH6H/AD/9erPHtZhjAxnNXSvocYNQ3JAQrg5b0oA4fxBbhXE7Ln5uD3rmzet5pPymP3Fdl4oTFuqgbnX5uBmvO9rTyE7R9AM/Xn/P+IBauj5qYQblPPHOOPX/AD/jh6pAoXAH49jxWxcAIn7sliR29/8A9dZlyC0eXA3EYOR14/8Ar0Ac1cINjs3yj7o4/wA/5/Xk9dO5CVBxn8xk11WrnFuQeD057/5/z78hrB/cyDuORQB5nrAzdzdep/nWNMM+3HX/AD/n+u5q4JvJcjPzHoPpWLN0H+f8/wCfxAKMqgZHbNQHrU83BbGBVegDUj++O1XIgNo9vQfSqkYGR1zn06Vci+ZRx7fy9qANCzz8pxngdK9K8JXRksNjHIjHpXm9nj5SAT0xXZ+EZdsskRI+deD6+1AHURIXmOFygGS341xHxStbm/8AEWiWcEEskKgbnVPkDO4By3ToB16V3kX/AB7ARgjPrxitzTYvLQHO4nqDwOf8/wCe4BetYZbkgeZtXjGB1Gf8/wCeuxZ2CB9iqQc8n261FDnIG0YIHAGM+1bdsmAGJ+8OmKAJktVKEgdeMHPNU57IljkHGCcZ/wA/5/XZh2lOckjgcfSoDHI7nI46dMYoAi05JM5B+XOB8vXntWzals4k3+nTn+XvUNrF5ZRuq89v06VpwQ4AckYPTvj/AOvQBchiViBtzlSvXoMf55/yda3jUIu1SMHH1qjZQlRyNxY569vStOGNjgHnP+NAHzX+2ZoF7NZ6V4im1SNdNt3FjBpxhIYSuGdnDdDkJg5xjYOua6T9lHwbrvhnwxqF7qqW/wDZ2sxWl7ZeU4ZyCrE7uOPlZOPesb9tQyy2ngrSoOXubi4Kr0BYCNR7fx19JaPp8GlaRZadagi3tIEt484ztRQozjjoKAIklfzOpOcD1z7f59avjBHT68VUuIG3AJgA8VYhGUGVxgYxQA4uvmBSfm7VUv8Adxs5IHA9aewfzS7AlVJ6D1qVAsyHPI/KgDAuLZ7mUBlypBUn39K5LU9MS2ndI24f1HSvSLi2BQiP5ScdK5nxNY7YxLsJdcAtnt6dKAPPjeKjlFQFFBGc9T7VUupEkUMv3Tngjt9as6hZKLkneRuO7aOODUMqgWyKcnuvGM/5/wA+4ByOuIWiYgZI68VyGsxg2zY5xk5PFdrqY3Pt/hJ/E/SuQ1WIlnTjJGP50AeYa0MXbdTkg1hzLgMPSuk1pP8ASCpxkD061z9yBtyemKAMm4wH4qCprj7x+pqGgDUjyG4+n+f8/wD17luMjpnnGO3aqcf3u/8An/P+e9u3Hoec9PTpQBq2qjI+XPOOPSt+wkaGWORD8w9BWFZctg8/Sty0XLAewFAHoGm3C3KRbAQvoO3NdXYxFhlQDxjHrXF+GIy0O7k/Njj/AArq4p3hII68Agc/n/n/AOuAb9jGwbkcc8/0rZth1GVx6iuatbh5JFwNxGO2Oa1LWV2cHO4D09aANsEBgIwST61PFu4yDn6f/WqvbYkDEAsPbjNadrEpP71ehwcj/wCtQBZt42yMqxBxkVpWsIbgdRzzjg9cUyMDaAuPTjn/AD/n8dG0t2C4Zcgnt/KgCeBcEkAc5AHQk1ftl+bcMYAwciqyBQfmdQe5Pf8ASr9uqbDsOVNAHyv8dJ21/wDae8F6NEvyWb2ayA4By0xkc5/3Nv45r6v715w/wosH+McfxCbUro3qAj7IUXy/9R5I569CT9a9HoARsEEH9aUcUUhyKAEK5NKoxmlo60ANx1IPSs7XoDPpkwXOcZwelcn8XviXpPw28Pm8vts+pTAiysVbDzN6n0Qd2/DqaufC99Xv/hzpd/4mlMurahEb2fsEEhLIir/CFQquPY5yckgHD6qG2hlGOcNtrIudvlqzSt1wCRXUeI7YQyXAU4XPAH8q5CV8xAFeWJGTQBjahuLMRgtyOef8/wCfx4/WHIMhwMgduneuuvHIDBiRxzzz/n/P14vW5Nkb4AOQcdsCgDgddZXvHIxg4GPwrnrrhcZ7f5/z/k7WoNvuGYc5NYd6eHPt3oAyJfv9MVHTpMbzim0Aaa53DHX/AD/n/PNyDuP0/wA/5/rTUfMPr/n/AD/k27cZbAHp2oA17JcMvce1b9lHwDjPsKxLJM4ORXU6HbG4njXGdx9KAO58PQeVYxkg7vT3NbcabiFToB/n/P8AkpZwE2gCgAAheOv1/wA//ruQW20DHI+6BjGaALNrH8obkHpjua1bRQURQRz3/wA/5/rmxIxYn09Bz1xWrZxbApY9fmAHU0AbFum3HH5gn9a0LRTxgZPXkcdP8/5659qBjGDnPXtVlJCECKv44PP6e/8AnuAbqXMcOTgMwAHqB7CpluJXZS3AHBDH+grLt2KsgGMKf4j69c+/+fro2wBKkhuOx6/T/P8A+sA0reMMQWYkk9Mdfatm2jVF3AY3YNZtmMtjIC5/E81roAFAAwBQAtFFFABTCDkZHHvTzSY9e/FAB3rlfiV4zs/APhK713ULe4uViwkUEKkmSQ52gtjCjjljwB6nAPV14J+1p4+fw/4Ti8MaXI39q62pWTyz80dvnDcf7ZynuN9AHzFPqGs/F/4qWR1WZftmq3UduAnCW8WcbVHZVXJ7k8k5JOf0NWOO3tYreABI4lCKhPRQMY/KvEPg/wDAfTvB7+H/ABHqUl23iS2hd7i3Lq0KSyKRgADqisR1IJ59K9fncrk56e3tQBwXi2XyruXzDlZCRz/SuM1Bl8o7CfQGun8eSlZUDhcEnkdDwPauMuZ9yYLAk9SP8/5/mAZGoElHx1HeuI8TShVIIySc4HFddrN0sKtGBuJGSSPauB1x2kclskn/AA6CgDk5+Wz69qxr77jg8HHJPf8Az/n32rtcPxyaxL4EKc9cd/pQBkP94/Wm058bjj1ptAGjj/Jq9adgQTyPrVL/AD/n/P8A9fQslyQOuO35UAbdgOnTnHFdn4XXN1EAuSQSPrXI6cmR056V2vhkhL+AnGNwoA9F0oYR1IB3YwO2a0DEfL25z3Hv7VWgKq2F7Hv3q7C5L5CkZ6cdfbFAFizhUoDg7jwc9DWiitHtySo9j3981FaP8wBHJxksKuSYdwWz8vA44xigCaBi3CMOmckZqaHJKk/wnBwPpUKkxADI3Mec9vSrUEYIHK4HPPGf0oA0LZfPYfL8vr6f5z/nvuW8cYJwQzc49KzbQRqAEYHgCteEKVwvPYAc9ulAGhbRgMuCT/I1pAYFZ9mp3hlORg5OODWjQAUUUUAFBoooAoa/q1poOiX+rai+yzsoHnlYddqgk49TxgDua+XPgbpN98Wfi9qfxE8RRs2m6fPm0jdfk80f6qMcY/drhj33FTzk19R67pGn69pNzpms2kN5YXK7ZYJVyrDOR9CCAQRyCARzVbwl4Z0jwjocOkeHrNbOwiLMsYYsSScklmJJPuT6DoBQBqyDAOPTqaxrvKD5iAhGcY68dK2yM1nX9oX3vvVcg9fxoA8r+IYJFsSM5DdBj0rzu/lKDgYx3IzXqXjeHNsyyMp2fd/PpXl95HnII59f8/5/qAc1qOW3Fs9+a5jUgHBIBPNdffwkZK44JzxXK6lGcNQByV0nzMMVg6mOGxj8q6W7+9nvnrXM6qMK3THrQBjk5OTSUtJQBpf5/wA/5/8Ar6Gn8uo549RWf/n/AD/n/wCvoad94HB+hoA6fT15AAya67R4wkkZJ4BB/wA/5/8Ar8xpKFthxnp0/lXYWUQCjHQDP+f8/wD1wDutPYyIB1LcgY61qxKoYYHzVzOm3TRYVl3AD9K2YtRDgnyyCOhoA3LZ3DFmXnrz/KrcUmZFMnI5J4rn/t8rOuw8kZOav2TvIjs5ODx7GgC+krPKdxwP4cc1o2gYv/IfjVGzjLynjP4ZFb+nQ7pFPAA9V60AW7S2JQE8oOCPT26Vt2dupG7OeODioLa33AEgADtjGe/5f5+upAvGQDk8e5oAntMjBIPTGP0q+rBhkHI9aq2qZy34CrSLjtgUAOooooAKKKKACkcsB8oBPucUtFAFGX7c4PlhEPbkHNZFzpOrXP37xB7ByPw6V0tFAHA6p4Ku7pcm8RuOQQT/AJ/z+PHal4JaENuvI1bkn/8AVXtzHiuK8UWYnmJiBGQTu9BQB4Xr2mLZq6Bt+0n5unNcRqlsw3FRxz1r0DxZIGvJYh91DtJ9T3+tcjep8uCMe5/z/n+YB59fxlSc9vbrXKaqflbOMZr0DVbQkEgA/wBRXAa0m0uMdG60AYtFFFAGl/n/AD/n/wCvpaaCSOCMf/WrN/z/AJ/z/wDX2tHj3BMLnnGPWgDrNCA8xR2xjNdlZr8wPTn0+tcvo0WHU+ntXX2MZGBg+mO/WgDStV4Jx3xmtCCPACnqT+X+f8+9e2jHAx0/H/P+fx07ZMk8Zbt+P+f89wCSGHB2j5iTxmtuzBECAEHg9f8A6/8An+tCJOQSMk8dOfp0rYtoyFU9l/WgC/YxkNyoLeoHv9K6ayiURr8oAzgfnxWPp0ZyCNvHUkf/AFq6C3iACgA4zjGM9eev+f8AEA0oI28scA8bfqa0LeLcoLFWz19ap2/QktlR2NaVr83JBJ6Z9aAJwu37o4xTqB1PSigAooooAKKKKACiiigAooooAjnGYm69DWHdOpfaVBDDGSDj0xW5Ou+JgKx9RhJLMB0wAfpx/WgD5+8RQg6jcDOfnPzD61yl4hJJP19eK9C8VWu3VZyI9qlj8orjtQgJ4xg/p0oA5S+gypI/LvivPfGdoYdswHyvkE4716dcwnJHXHT3rjfGsIGjndgndxxQB5nRSkYJHpSUAaajO36VuaH91Pw/lRRQB6BpYHmjgfdH8q6yyA3RjHGaKKANmIAImB2H9K1IgPMHFFFAFzoSRwdo6fhWzYgGKUkc4HP5UUUAbulqPMj4Hb+ldDKAHiwMckfqKKKANVQAXwAOB/Sr0IAk4H8P9TRRQBNRRRQAUUUUAFFFFABRRRQAUUUUAFV74AwMCBg4/mKKKAPFfGYA1+6UABQ3QVwuo9E/z2oooAwLwAXGABjbXE+OR/xKf+2gFFFAHl8v+sNMoooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the foot demonstrating features typical of neuropathic joint disease involving the tarsometatarsal joint spaces (arrows); there is destruction of the joints and adjacent bones, infralateral subluxation of the metatarsal bones with respect to the tarsal bones, and proliferative new bone formation, including extensive intertarsal degenerative change.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30837=[""].join("\n");
var outline_f30_7_30837=null;
var title_f30_7_30838="Inv perineur panc adenoCA";
var content_f30_7_30838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histologic appearance of pancreatic ductal adenocarcinoma with perineural invasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 238px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADuAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1zUNRtdOjBuXw3RUzyT7CvOde8WNPrsdl5U6lCJjLINsZT0Q9zVTxB4M16WP7TdTyTlBuk8ps/UisjUtMe4sFFpeXdtjb5c8RyR6q6nryOo/KvSoUYxkpN3d9una/y38xwwtPkbpu6aab8/TzWivp16I9d0LxFprwCIXSF1GT844Fbw1O0WDzfPTAB5JrxPwz8PbXV9TaVJ5vJXDTN90Z7gAV6xY+DtFgCmS2kuWHeaQkY+nSqxNCjC156vey/wA7Hme0oqfLBNpd7L9X+BV1fxXP/Z9wdJ02e7nCEK8UZkG7sDjnGcV5Itt4h1qzWHxH4V1e4maXzPPhi+z+X7KBz0/Ovom1tYbaPbawpEg7JxVkE4A3nHbnpWVDEUsPJyjC701b2trpY3eLrRjyUrQ3732tupLp5Wv30PmbWZtLTU7e3uLMy6jbAKFvpWglix0yGxuH0NdT4a1bxjNqgmutRsjphP8Ax7IgO4Y4Ctj9Qa9surW2vYil9bw3Ea8ASxh8D2zXAeMtPsdFlhNrbxrDPlZIEyAh7MMdM9K6ljYTioOOuu+qV+3RfcdVKo8TL2cI2bS1VrtLpdq6+/oZkupObgrdu6HJKx/xE+lTWt/hytvuA4JLnj8qwNI8MaVdaoLixgLXAbgi4eXyz+J4NenaH4TtbNFe9C3E55IPQVnUjSglZ/hb9Wd2KxccPHknH3u39f8ADnF6xHpOq2F2lrd/Zp7hNskyW7MVPrnFO8L6fo2l2qxRzvcvxulIOZSOhY9z9a9YSNI1CIojT+6Bis+40exmlaUwrDMerRfKW+o71j9Y91xjdL+vI4aGOp3/ANoi3a9rPZvrZrfpff7zno9UuLdB9hkldeyt8yj8DVLUPEHiZoJY7TTkkyhw+0o59gDxXY2+mQwyhxuJ7A1oD/VgcnA6DisXKGzVyZ4yDknTpr5nzJ8NE8QTeM5YfENncWVldOxmMzncDzgKp7V9KWlvHa26RwqERQAuO4rI1/w9b6pOl78y3kSFVBb5SfX2b3pkGo3Flbr9rbfFGvJYAYHvW1arGpGKgrJK1iavNi5Oq5Xk3tt939fgbwUnIxgH8qSaKKaIxTxpJEeCrLkGq2k6hbanZxXFlKk0EmSrKwwfpVXXPEGkaBEkmr6jb2vmErEjuNzn0A71zP3XZ6M5adGpOXJCLbMPUFXwpqaX0aEaTL8siov+rY4xn0Hoa6iyvLe/i32pDJ3xzXkfxN8Zy3MunadYadfTSSsJIIvIYxysGwPMIPA6kCk8GXuoaHrcNtZX1jJoixN9pt45fMkW5ZixBPtnH9K6vq85U1Ulpvv5f1b1PWng4zpcr/ire2unRO17P1toeyljjpx7UE7SQACBzXNXnjjRLO5t7W7naG6uc+VFtJZ8DnGB096qWXxG8O6hC81jLPcW6MytLGnyKV6gnPauZQk+h5/1DE2vynZAgZ2/eH6V5r8Tr231bUl0C6dRYwRfaLwBSzPuyoQY6Hr71XHiPxd4sknTw1Zvp1kAyLdTrtJz0ZR0PHOabofw41SxsDE+rusxczPIzeY0shGMuSOR7ds11UqHs5KdVpeXX7un9aG0HSwc3GU7z201S76rr0Vr2et00Z1jrS2l8umfY5kRYFKNHjy3bosK9846noKxfF1/NBaJPFpEt/c+cnmQtHlo1PoO+Oma6rUvBer6fpU8tldfabtMyRu44GOi4HOB2zWT9iN3qEV3cXMMFiFUtAUYP75Y8cH1FdMYQlLmT283/kexh8yhStKm1Z6bbdFpf7zF0uW61l72DWbQaSl0rJb2r4SbZjBbHU8nOelZ0/hK80yzsdFs7e21fRZd63cVzIUMZ/hKbfmVSxzkZPWuq1LT9N+2vq99G0TpFvNyz/PEv19MdulZfijVhpa3etaV4isW0t1DW1jcWfmRE8AqZV+YrnccjnNaQqK9oLTtr02V1r+SfXQdaVStSUp3d+y06dNf173GPpPiuwsNIs/D8NgSlkBe3m/IQx5xCF6tgADd3z2xXqnw31+z1jRIIbea3mIXMDxHCyr6Af3lOQRXmGpm+v8ATbHX9G8TQJaykTNEVL26EJhlJX5wpI5zlhXn+p6+lj4Vh/sq2u9D1O4ddQuRaEPEUeVkyh9QVUhePlPtWdWm6sXfe/S7+/tp28zh9hTlDlqO1/JKzV79r383pdaH1+cDjbg+/WlYAqAcYIIIIrwfw58QfEtvq+qWGoappl8tjbedhoJEKhVBJZyACvfrnn2ret/Het634cS5S2toI7h8RSWjGQSRY5YMQNuTkYxkVxSwlWO6MKWVyrTUKc07+q/QxPGzaWPF2naZpUC3uqSyvO1r5xSIRKDvZ8HrjOFPX9DzGs69q9xZXSNdS+EdPtbiNdNRrRfsyBCwCkplyHycggrxXp/gf4cadYX95rMsbI+oP5zQhi2CeSNx5255xXdPoGkNnfpdo4I/jjB/nXSq9OC5J+9/X9a7+Zvi8XCMlT1fLpvqrdnr+VtjxLS9HeB7mSXUU18TWEV1HYpaqXeQKCZMkYw5GRu9vSl0vTbTR4WSCG8llnK3dy1/IF3SuQNvmkhd454Fet3XhKzKOdNklsZCNo8s5UA9Rj0rzvxp4EtHF+dfvJ7m1lC3Umy5bMJhU4MS4O3gnPBzmtI14VLpaf1/WzM6eJbdqc313XTV7ppff1Oc8U683hnxJZ6mdUnu9Aucwz2sU0cphmw2xPLHzKcrnd36VseC9Q8b6nbzXlhpVulqznyFnRopNhJ++pPDYx9aa+jLpum32q+HLS0k1C8CXMMcqfLxhlweo/Tk13Xw48X6bqMf9i3M8dt4iizJPZyHGWYbjsY8Pjpx6Uq0oxjzxjzJadvvS18rs6JPE0aLd03/AOBP77W08vn3M2TTvGdxG5voLScAfLGjYJPuTXAyeC9SsgZ9b0+7vdSgm86C4nufLhkfIwNikgbfXv6V9FYBY8cD1qrqVlDqNlLbTkbWUkOT933rnp4zl05Vb5/5nBTzCopJytbslb/gX9TyXwF4V0jxQt5rIv5RdFzDMbScuMrjO1jxjpyBXYQ/DrR7cXAhudSjknTy2kFwdw+nofcVy3wl1qzgsbZbK3WDS5pZIkk2kbiGbkexPI9q9bRhKPk/ecZ4pVsRVhNpOyNc0jL2mknytaWbS+5WPP3+HBtNPW30fXL2ORGyZrn9679TtZvTn9K83k1LVfCd/p2ieIXujIzSh7q8yBckk+XskHygnpzg4719DgFcgjr61leKrOwn0O6/tg2qW6LvEt0QqIw6HnjrRSxKfu1En52s191jipYivTneMnJPdNt39L317aNfmvFPCOvalqkWtDW9Ei06SxkQZZRsYt92Fe+cZOefetrTNa03WUl/s4C6htHWKaaHhInJ+4M43dDnFOvbi7Q215ZRW85PySxfKqygkDzQ5B27efrXPX0Gt3eoW9lp+n3WkJvkk2Wk0cwuApGJW3KF56Ada61QU9Y6ddWu2q7+mj8z2J5hOKtJvpt5W17arpf5bnQo95K922nPEi/d3R8hWweQD1x19KuW1taWmm2xZobq6VcveXDnMrc/NsHf2H51zGqeJbWz1HUIL++0y2trK281Ht5PPuVk3BW3RplQAx6dsVzumarBHodzeafrWs+IdRvi8VnFLbAKJl5ZuOAADnHtSinKShC12/07pPbqm0Z1JxrvnxEpciS1XzSunbfvZ301N/4i+df+H2snuVsbe7mjglkitydwY/cAbkZPetzw1cefEtjNp0ul6BbGKO2WVhE1xs6sU6qh468n9KwPh7rM+qSppjai+pXcAEl/fRwILSzJHygsT83TGR3rY3T3uqzW9tol6iYIGrybJISQPvtHncF9MZNTKMpx5WrNfhr6f5j58JhptW93dPvZK2rkrdbJb9maHh6GOTx3fzReXeT3N2H+Zi/lxKBg47AYwO3416u54J3Enrk15v4f0W00nX2m07UTLq2oJho5pN6IseCcqv3evTPp3r0jlf7xAHORya48VrO6d9F/X6Hn4mtCpyqmmlFWs99Lf5X766iHG4ArgHHemvgFSQRntinkYzgAn+fvTV6kc4xjGOMGuc5nYxwMgLjg81w/i7Q3tvNu7OMhWBL7BkL9V9K7lCNi/Kal2qV2sfkIxg+mKuM3TfMh4bEOjPTZ7nOeBJoRpUcKvETjJbf94118YO3Ljaep9CK8Z1e1vtMuLubS4YZQZPlO7h1P+xwRUdh8RtS8P3ATxRLp9pavnyUj3MWI7kn+VdVSi6q9onv3/I0lhvfapa6vTr1/Bd2e4L90Hdx2AqvqGpQWAUTlix+4iDLN+FeeQ+PLjUgw0to9oXeZNu5FHXOc1u/Dstq9q2s6hK0927FdrLgIAe1YvCzgnOeiQnGnTV6ju9Eku7V9Xta2umu3c2VudZvubW2hsoDzuuRvcg+iiq8nhG1vZJJdWuZ72Vhg/NsUfQDpXS4Oc46ClB6qveslO3wqxPtpxfuvl9NPx3fzbOD0jwBD4W1Ka/8AB0vlfaT/AKRa3RLo/psb+Hv1rqLPWFNwLbUbZrK5YYAcgqx9jWsuAAMgdxgVT1exjv7F4nJ3Yyr91OOKudaVS3PqXCcakv3vXr19X3+Zczxhjk0je2PxrnPB2rpfRTWMtzDJeWLeXKgf5l9CR710QJxjI69qhqzM8RSdCpKnLdD+cc89qQmjJzjHvzSnHOeCD1pGY1hyD/ETnFcZ8UzfR+HVk0yKBpzdJFKJBlTC2Q+fwrsZJEijkkd1VF5ZmOAB7mvMPE3iC61nULVtK8oaLCzCUsp82ckYyg7D61dKDlNJdP6/E7sBSnKftIrRf5bev/Dnn3/Caa3ZzwXmlaXcWXhnTYys0UsYRQoIBdUGGJ5GB07msXUfFWqeJtUTUR4bub7StxXT7sW26aBj1fuOMZ54yKS98V+G9BsdV06yg1bVZZ5Hz9py6+YRgqehwB6DsKg8Oa3eSWukfaItbuvsjPcw29jAltbyoF/1ZPGQCDyQTyeK9WjTU/3qjJqKWuqve7etry62skvS6PUrKWGXKuVSd7L3dEvh05rK/W7v2W56Hp0uraF4RuZ/Fha7kidgJLZj5kwPCBU47dc1HoFnLHOi2GjQ2+izoHWNl8qZJzjO4HO4H65rzx9c0bWknv8AXYrq1vrOZJ3t0Z7sSW5IUpgkKjkkck8Y4rtb29vo7ZbWe+ll1K4kZYRDJE81r3RSijCnA5DHPXmmopq8d5dOlrdO73vrpbUIVF7T2cnblvdtWaa3dm9Fbqls1axgxajb6euuy+FtPuL77BeCKaG8u90ew7txhY7TjI5TJPTqK3/DKa4NEFqH0U6fMqm3SOz2BO7RyAAc9OQT05q7FZavqS/ZdatdFvrBIxJA7yFnku8eh4AySOQfWrMFsb/RrSw1ZZtNupyWmWzulk+ylWzlHxtBIHPBxnFZq0E7u70W+mnZL/LRebNYydefJKnzNO+zutL6uX+au9FZLXqtC8fQwX50HUbJlu7SJXka1kR1VSMgsmQwyCOmRXWW/ibRbhwkWoRecVz5L5WQe+081400dhJqEsunfazdxgW/n38CFwwGQA4XJU8EVR1TxRYpLa6dfWtpeam7pHHDdRiOMo/V1kcY+XoVXHtWUsPCbVr3fZfozmxGUz5faxSjfo3qvuut77XPbr3xBCSYdNzLcsQu5oyFTPfB68V5JqttqGr+IdSj0XWQdMnnR1NkmXkZMbgccAbgfYiqFjN4lm0Zimh2dlIH8lW/tLlLd8h9pGcHGMfWvTvhdZ6bomlnTdPh8iJW3RMxyzKfU+tOEVhk52v9z/zt/wAOccY+xi+XVr1S/FXfyaPN9X0vxNJot5a31zDDdJcedZXFxEY1kT+K1mA/hPZh3HOK0PCFrr6fbIILOCXRprcLBp7WqkWTH72GwA/U89+te4MgcYkUMM/xAEUp9Fb5SMHjis/rmjXLuZvGrk5XBP11WvZf8E820PwRfRWYtpoLOzi+8fKULuJ68LwKwvFHwyljuG1Cxmu4xgK/2CYxsBkfMV6NjnivZc/vMMR6cU5Www6g4x06VKxtVScu5m8ZUk76Jdkrflr+J84ajL4lsdS0y10+5GraHIm26aWNfM+8QcgY5A4xjFddb6fqY1aSfT11E6cYwqWP2YLHGcgZVuCMjt0q341urHSviHpNklrI0+pum6SIYSEDJMjH1JH6V6u7E5A6dc9c1rVxCSTUd/69PusejUxfsacZwW67/na1/nv6Hgdn468Z6Jrq6Tqx0trxpWaGzljeF7iMgbBE5G0v1yM+ld/4a+Jmlaxq9/pXkXKXViqtJLszE+cA7GHXBODXT+JNCsPEmmvZ6nAkoB3xSMuWhcdHU9QR6ivnbxt4b/4Q+0tYLLUptHFreM5jhLzNeE8kID1OOQDxy2ahRpV17q5X2/4Lv+VyMPUp4r3a0dV1W9vTTyvq+573feLLCCKTyTJLNjgKK4DUfE8dvfWpuphBPezi2h4y5Y9s9q47VhqMugWV/b3eo/aprlbT+zZBHauFOWeUs2eANo/HPSui0y6ns724h1C3tEtfMX7BPJexvJcryA5BHBOB09a0WFjT3ev3fml+Fz0aDoYa8MPByfd7fero1PtF3HY3JtLGSW958uF3Cs/OCfpWRaXEOoKq6jp81jeW/wA6meEgxn1jl9M9q05L+5hvoYZtMjeF1YzzpMVe3PYKerfpirSCO7djZ3d0kqMFzNzk49ehHtVxcYxenzuZVqmJVRSasn92no7/AIMpt8SLnQXhtr68W4jfAjmkgZlPoN68Vuaj4i1bUYvs8lvHDE/DpE2N/sWPQfSs5Wa2YtcW6W+M5e0Xarf7yH5efTFYkmkTNrE2ofbLmG2kxn7MSu5hwMqcoB9AKn2VGWsdH5/8D/glK/tH7egn5x2/PX8PQZe6TqesXskdnrcmmxJcpPEhtlHlRqhV41x9/dwecYqOefWRpltpWqz6ldvdzyDdpEh/cInzIZHGGUkD6Vtzfb1t1k0vTxc3EeTsW6UTE4wRggA96o64NUt7eC9tfD80yt80myQQSD2xnBNXFSlbRfh/X3ozUsOpyi6jjf7Mldf5623UjMX4wapb+FdQvY7CWK3s2it7WTUlaNrgnIOTycggg0zxbqi3/hrUNS8UeHpr+DTDbyxrLfbYbhnA3FR/DtLbcHOcitWZrrUNE/tG90nUHSJgXsWnSZxjHzbOhxj61TI8KeL7u2muoZ5ZLTLtZTl4onOflMkZ4bB5/nnpTVJU3zxTVr6rW3ldfh+bOerBVYONPlctLpWXz3u/PVryuYVlrd9F4r1Wz05FvbJ1gE0cm0W1iQMyHzc7WMfChB945wOOdDRtTLW2jPDHBY2niGaWWf8AtB9ksrKML5SgnBbHsORj1p6+BLFbyBoLj7FZC5a6ntoQXS5kKMqj/pmoDt09T7Yj0/ST4T01fN00XsNjZ/8AIVuv3iqULMsYjGWXBYAbckjk4qklJ2pu9/xey009XZ79zLEqUH/tCttultu1fVeSuvudkWrPwYi6BIXgi0zWruPF5c2BGMhjgfNnjGM+pFR3Wl6mvhddDfW2j8xzE19arHC8gPVAMgZPcjk1oWeuQX+hWGt60tpbPcJsy8+ItxJ2j5sYzjv0pVtI9U0TT59TsbN7pLlrlIbO6EiwlTwwkU8k45A44xUurNyXO9m/N3+/VaG6w+HpU7y95uya2Su+nRPW9tPPQ5fQ9E0fS/Hljpmm3dyt/awDzFuFMiTER5KxKpwGbuWBFdhpdrdXMUl9qW7SEkjU+SswLxtk7g5+7zwRjseeaXRY9L1u8m1yysPI1OF5LZpJ42iZ+PmA9frUmohZ7uMfYxPZGRAEiIY5Y8MwB+6Dx0pVGpS0Vmkt7br8/Ly0McPW5Wo+0cU97O6d29V5NPbWz10V77OlTQ/8JrZR27+SlpbtHNHAPlkMmCpkPoP1r0HAJOBjHXnmsPwvp72wuJp7GK2mdvnIHzOR3PoB2rdwM5PIxXmVpc0vTQ4qyp3SpbdfNvVjSxbJ5Yn0o/h4z0p2ePlJ5ppXByD26AVkZIyVHHJOfXPSsLxPfpHC1p56x7xmVyfur3qD+273U3Mfh60M0HT7bcNsjHuB1NPsfCUTSmfV7q4vJWJZgr4jB+neumNOz5qmi/H7v8xRcaDtL4uy6er2uvm77o818XawzMkOlXRs9MC7bqdY8ySL6R56VBaXFprenrDLYSS2EXyx27wq7n1bB559a9zi0qw2qosrbI6bowSBUF74Z0q8Ls1nFHMRgTRfK34kVvTxNOmrK+9/n/Wy2XY7sNi6VNpeyWit3tfd201el5auysrI8y8E6BpMOts9oixW04AkjUkDjopU8j6V7VBHGke2NVROOAMYryfVtN1Pw7eGWKQlSPkkEed49/8AGun8P+NI5ZBbaqFjmIBDH5elGJlKulKLuKrlkrutRXMrdDtQPm9umc05en3Tx70yCSKeMNDKjqeQUbIpt1cRWsJluW2KB1Pf6Y61w7HDyNuyRYHJ54z2qhqmqWulx5uDumOdkMY3SOfTHb8a4TX/ABbqN9qP2HR4bu0t0O6SdlKM4x1UkYArlfF2nyf2CEne91C/fEkttp8/+kSLnqe5H+yDXRDCydnPRO3r9x2U8NC6UnzPql066vZdOvXc0dNB07xZc+JYbYC9nBWaIv8AwE+g4zXpdjqGp3iLKmmwwRvyDNNk/XAFePjVLrSxaeVps04bYJIY1AkRTjrzxt7169oOrW10nkxyDK8D1/Gt8RT5YrS6Wi+XzOjF06tWCrez1klJvXa1l+VtVe1i8BqWBn7Ex6kjcp/rTSNRkJ2tZw8HkKX5q9nHLHH/AOqkxgDGB3riueXzW1RhXPhxb+UNrN9c3qZ/498COL/vkdfxrL8ZeHNNg8Kag1gP7NlRCUnhGWye2O+eldLqmp2ulWzXF9MIkXsTyfavOPEXi19aiCJGbSz3fL5jYL47n0Fa0/aT0jt+B6WChXqzhN3stv8AgI4TwbbWlrr+oOk9w0lsVie6urbBlkYHowJ24HcetanibS9N1FLYatrdsIbd/Pij8zaVcd88frWpb21tcOIpo5DtXOSpXjsBSy6LZySYTSIHJAIkmhD7vbnNenKtzTUpvVW6L/hl92h6jpRhGSteT395LS3dpv11u/wM97XRdRtLuF/7Pa0uXE08cJVFdgc7ztxznrinpFY2H2+90xIYDdybriWMBfObvn0HX86sX0OrWUIXS7LTBIq4W3uF+Qj0G3pmmyQ3kuih49De5lkA862WVFAJPzKrEc4/DNJpy2lo9N1/XReQYdxpTjOcI912/FfjuQaxqEtpoV7dzWjCO1jE4VcDzCPTHPQ/lS6LbPdWds09yHlZBIXiQqgVuQAvXoeT9aZouria6+xnTdSsbq3wgivITlV6fe7iqd7eX+oS3OkanossNtyY7q3ulZXA7kqcj6fmKl0pK8eXz+XzPTp4no6i17Pq/v2t176j9L8HxSNi5urq/e3n3R5naGONc5wAD8wJP8RJ9K1Nc06LUb66n1DVZp4pgsQ015h5MJyNrIm35DkHkHPPvS6JZW+mRRwWgcIQdsceXwfx54qA/wBkaJc31xC+lW15cyGVoZJy0lxKWy25eSufYcE9KFOcp6PbbT+rHPiVCD9pKLl999PPXr6Ibcz6NDf2tj5ps7iV5FtrcSOBuA2sWI4BOflLEAmsKeXxr4FgSaG8l8UQyXSBV8lvOjUqdxcjOBuwOc/hXVuI4Hup7ySPbJKvlosILwjHCvt5bGfvEDrV/wC0XFmArCJ1VSA4UlgD/tccexzUytLWSv8A1fT+mcXM4q1F28mr39e/lsdN4W8dWGs2ETXpitLzywZEEgdVPU/MOCB611VlcQX1us1pcRXELYKvG4YEdjkV4Fb6Xdy6etvLfXTTwq8Ucmnotukat0eWPbhivTjtT7PR7rQownhu+1Nrm8fyhLY4hjtmVd3mOj8KrEYPbqOOKmWDpyb5JW7b/mcOMwMKfvPR/K3+aXa/4n0AQATjGe1VtQv7TT7X7ReuUjyEAUZZ2PRVHcmvCZ/iJ45ghuo76fSrCSK2VlnnikIMgxuJ2hgQQDjHqK0NB8X22v6zD9o12zuLiJf9VJ5jOhP3sZACj3GazWX1UuaW3lqcUsK4XvrbpZ/5DfHWoarf+I9ISys7iW9upitw2B5VjbqR1I+6wDZBzyWIr07wxqqvG9rdSgbWxCzHG5Pf3rxPxLB4iuZpb6yvfs9hpYE1nYQSqI7lgcYbceWYngnOMHHUVt/adcvLSC80u/tJ54SiajYytGIXBAyUdN3zqcj8OnatZYbnSjdf18v66s7KulBRq7eS2v59fu22XU9q1K+i0+xmu5CXWJCwROWY9gB614NqmqJ470K6uLppdHnhukure+uVDJA0b8SIehbgqV7ZrR1qW4+zyw3MsggeMgMkuPJYONpGDliRnis6DwprU2qWUWnSFNCHmNJD5S+VOR1D89WyByPpzToYaNNXm9SsKqNKlKUnv12+78DXun0vxbaeR5NvqccYZN5ba0aSKQGVgcjnqOuK4qzFxp114T8JjTLXTddjgl33cym5SNVZpB5bEZO7DHaD8u6ukt/DPidfFPkmy1PS9DhtJAXtJYoYbglT+8Zxzv5AGR2HTmue1weKw2nSG6vZUtZDH5OnQrLLIh53M7EEt2OOOmK6Ywt8Mr9tddfw16r9S6fJWmpUbJLfrbzunuvNfodld2xu9dgt9PsxBaSwl2cT58hh2MfVgf74zyadY3l9BbzStZ3VjHDMyh7t0jR1XpICf4T6Vxmk+HPEOoBriefXre4vZGEN2YRHdwLu3tEUzho2Iz1GPfOK6XVPCWnTRa2b7RdUkTV9j3ZeXEqlTkMpYkKM84H8qzqQivd/z/r+trmqxtZR9ipKS6ax797/AC1/I17az1C6kmuxqFnevCRtS3kEik5+6yjAX8ai1XxLo2iQxy6yLuxeeYxZtiJlMuOhAztPI6iue03wj4dsNUmu7LUvF+lJdSq8nlOgXf6ttzuHsfU1Pc+C7K2kuB4c8THTFlAmuVOmear3AJ/fbmYsvXoOBWbgr2b/AAf6ompi6s1yzpO62dkreXuPb8dtzbXVNOub5LWLU0+3Ebo4ZTgSKOvzheGHPFRibTtLs73V7/U3ktLU4nYtLMwbOMKmOgPH61jz+H3uZHk1XxPd6hM0IhItVFvARjjIPf1x1rYgttNdgPtbrdBAPsccsYjkOzbgrnoV6ggg1TjBe7fT+vJGslW9h7ak3e21uu3V822uxLqmlx69Z6fd6Xq0+nvKgntrm3fyxIrDjduGP+AnBFSfYdVjtYbe5v8AN2pyJQqb369jlW+lccNBGheIYXsbO00nTrt1tvtdteSGSQt/dtzlc4zgcYJ61c8Mza2JJzNrOryaQCwEGvaWscjHOB5b7sH68fSnyThFapr0/XX7r7nFGv7Z8lm/J9/K1n87a+RLBBrw1e5+zaupj27ooJLIop4wQvOBzzgGrOq69DHcrYWOrWEl3BF5t2s1vMCiBcsVCA7j6AE1pDWJjp9/KPD+sZjEUREdvGJ33ghmiIbJC9x71S+2aDo6WWnX+p/a7qXiMybopipPViVByPTPOKvSTvKP3L8dFb+r6hHFyusPF8tttn+Etf6a0M//AISzw34i+yaSk7ak16pHlNZsBEy9pVbOD34/Okv9OsdNn+1G/Phm9s0SFbm2TZBfADcsax/xKGIzgZzWzqBuLK3kuPDWnzXTOy+ZPcwbEaPnLGQDcQMVSudUku/EHh5tO0xtY08AyS3iOA1scEdf4R75/Ws0uVWs3G22n5efp5l16irJOMlz3s3s1fzW3W19H8LLumu2maDcy+IdduNVnaKW4kvxD5UqKQMrHGOcLzjjv2xVL4S6X4V1HxVZ6x4fs9VgSGz8q1lupNnnKOGfbnL4zgk4AyMD01dY0/UNXjvYNQvZdK0UCIxjRU3XQiA/epK5HAY4Ocn0xWj4b0C18N+NbW6t7pv7LnszY2EUzEsuW3tyckkmuao17GUYvV626Pb8tzhg5c6lZ9k9eilva3ey0+dmemc8cjA6Z4zQO5b8vUU3oDxxwcdKdnPAOPwrzjnTGtxwMqe/HNNIwgDZP4dBS/eYEgjPGR2p3XALZI60xp3MS1iSCNUhjREUAALwB6Yq0AdpHcenFRRnjJ2naeMVYB5HOAwyfb61cnd6nPFcqsh0Rz8zEemMVKgGM9v8801eCCD8wHX1FZOueIbXSYXMjFp/4UUZOaizeiOqhQnWkoQV2N8a3CRaBKrbWYso2n6159MgnvPPljWSIJtAI61Drd3fajKvkamtu8h8zPk+a0Y9MZxUMUOoW0tu1tLEsZG2SKU7GIzywPTn0ruo0eVavVn1WEgsDSstZWf47rv09Df0uOyWFkUmB8ZIQ7SPxqvdRzTXLLFePHGeNykqFx6nNcx4i8PT3dzb32gXsVpMAfMEql0cf3hzwR044q14ftrm2V2vLqS5kBwWlYhD9F9K3ULx529V0f8AWxKoe2cqtJ3T362+/wA/U0ZrVGKW8esXyRpkzES5MjeiljwOtNtNL0hHLm7lWYsdrRJ0btuIPX3p0MRlmcTG2lUZJjTKtn2z2p7ybVAEaf3SGZsL7A4p88noKFGOHk5U5uPf+ntfyRHOk+5lCgsOrkglh744zVSC5vbeWObTZoEmZwZFuA2HUHkAj7prUWR4VQTxOjNwoimLDHcnPArLkna9nuBZG0lEeWbEyM2enAHSpW/oehSrudPlWsZaX28utzqZPF+oW8HlRlXYY4yM/nVOfxl4k8n9yttx1D5yB/jXMqs8d6jXN1ZQwPw32ghQh9A2f0q7cwXsFvLKYoGZTuQuSYyD0yRz+VCpQXRM5amBw9OXLKGvn19DJ1jWrS1uIZPEl+zalNl0haB33Ln26YrWgu4dUhN2iRGwClYx5e0cD5uG5qNNS05Bbm7fTRMSQDuz83sTyK0VuLNFze3FsFIyWeZVCj8a2fuxtbX8PkZ1KSU4zktunX/hind6rc2T20llptzfW8q5drf/AFtt6fKeGGOmKlvtSEEUVzeajLZwyLvUOhd/pgdDWL4j+JFhZaza6XFFNcxy4w0EuwDcMLggfN7mpF8ZaTbXkunapFe6ZMG2bp/38DfiAGH1xxU06bqxvGN9X66dCrum+bkS0vbeye34eVjWtRG+ZlaaKPcMyTpjf747H2plgNVj1O4SNdSntN/CXYAUockvHKv3l7bCMjsT0qv4Zi1ie+uotV1my1G0XL2TQfNMB6OAMYx0q5bT3McUyaveWtqgfbAsRkOEB5LDoPwNKyTei1X9fP0LbxNbST1TWyvdW6Wtp5vQkvWnm1C3lk1i+hhtshYUYMh46yZzux6cVm6ZHaWNsxvLp7xpn3S3RhxJNz3Ve3QVmeOta8NLYoLyAXM02UXyGdQ5XoCVYDH1qtqWpeIrnRI0tlXS3nUeWyS729iSO1aU4ScLrbbovxFLCpqLtZ+vbraP6nW+T9utlItC8BBIcEx7cfxLzx0rkde1Cx8MyfatAt9FS8C7ZYJ1cykHoySepOcj9a5/w14Y8Tazqw0/Udeu5IZgVYQzmYlvYHhR9a0dW8GeG47iG2u/Gem+daApMHulkdSCchz0BB4ArSKVNpTla/S/+RnGVJScJv1Vvzvc6601a3u4dPmTUYbSSZD51jcRoHLgfMockH8al1HVbW30KfUIrVr5YkMjWyXAQnBHG4/nmsPU/hNeayIPsNy3lCNYyI5FUj1YhuoPXiud+InhK18N3ZurW/uZYolWLUBEd29cAEqfXgcVLjTnJKMv68xUatJvljJuT1f+W518HizTtS/sqfTtAVLi6hZ3to70ebEVYjDL1IJHD9Oe1X9R1vSz4OuNS1TSNRt7OF1S5UoTIFJGCGGDjNeSfDTU5L3Xdlt5Md7FAyxl4wCyZ+7u425zg/U13vhfXdalW9tZpLFYrdWgTTNmXklPGGDnlFBJ6jOMU3TjKHNS9b38zOthpraV1Frdt/f/AJm7oetaRObHULKWKdL5WghtlkLqu0nLlCowxA5J4JGBRFbalFBqgh0mwv5HkXyZriVVkuIpD+8VjjKBegUVyVlb63F4uh1F47PSlt7NrPUNTsbIPDDsLbdiNhfn+Qe2T6Yq14R8XaxqE2rw6pZ2thcxyr9lxCXjZm7h8ndgc8Eg5NS4yUvd/X81p+P6HPKipwtFJvvv1vbVdPI0rVtN8USXVl9ihksLdxDJbukkcscgb5crgKVOOCDkd60Y7PQdDdreTS4tP2KZmWCNuffjr6ZqG78ReIotPAt4Ev8AV5ZZZobIbgEtE+9vftIcZC+nuMVW8J33iOfVtS1DWRKNMmWNdPs/tAWAMT82FxvGMZ565PtTkprbSPr/AF18iY1eaNpJSt63/TT1L17qWmppU2pabaXF9cooIt7UESLk4yynk9c9M1c0XVNVn0yJntdRsRcHDWUihXcDuAe/pWJc+K7GHxBft4gay0kRyhLS6t5nke5P8Ssv8LDjPIHPGayLv4k6Y2rxWNnodxdybvlvXunHmMOhxkjH5Vk43VrNv+v6ud1OHtHG8Lp7prr5O60/E6qy1C11C71KJ7TVppYiA5u0fG70yeO3YYqfTLPVdQ1DytQn0y0s3z5JcSvLgepwFH0zmuH0X4q+IJNcZLnSDHHCQJFizuh9HweoHWush8deH5dSWO+1SzluWU7SjNtcE8Lnp164qpRcVdxdn3/4ZHJUpY1fwWl6f8G5qxT30MjS2k93eQA7NttyRjpwRnbTHsb68aGKC01WSMyYIaBkSNRngZ7c/T0qpJHpGoRyTfaJJpInBH2eUGNMfw/IxYe4NU9auPE1jMh8MeI7jT3kGDHer5sD56MjYY5HYYoUU9Fo/PQKSrwkqiSlNdbP8k9bF7Wd+kWck17pd7pEEI3SXrhZIlBOBvG4dSR+eKydIvpJ73U7XXLqym06V4xbRR2Do4BP3pC2AQeDwx56cVtavppmsrnTvEj3eoLMsb3Nzesf9IVOThRhQoJyAOR7nmq3ifS9Ou9Ol0yN7iKzVI44pbGOTfb7OY1yCQAPfgj0PNXBRta33fn/AMA82WOqVnau+b+vPbyLCz6k13q9nNZLbQ2sgFrc28kbNNBj7/lclccD05qtNDFJepHJY3F1ftG72bpDEocqP+ejL8v4ms3TfDNpoKXOq6dDqtndKzNe3s9p9qZ4z1BTspIDfLk44zUd7qCQWFpDBreuavq2oIzxSo0ERaRl/wCWcbkFFGOFA4zjmnGk7tx2/rrb9djoeL9nH2UZ3fk/8n/TuaOmtrz3lvAfD2sWcksRd5/tUEsURBOQSuMjGOR69KuWiatHcau17bahcfIsdlOscbhWOcyopY5IJH3iKW1ElnZW2j6nqlxcX0cRvLu5uirMvy7jGGHDHsMVS8JeNhqN5JpE3n2Wqw7pTaGIAmIgEZYcBsHIArB+6uZRVtP+B95pGrisTDkdXV38rrrre+muztpfYp+G4bbSdY1GxfxjrN1dWC7b46iqlEc87gckgY9yK2oPFcuo6rJpNlFJd3MYSWK+ghEqTxj/AJaJJzwM4x9ag0drq28qxvILfUr6dWifUb2BVkeEnKoyjqF9STmjwZqVnJ4zXwxqVpDYXenp5qWEAG29yA26I8bQDklR1H0qZ8kVKXb0X9Xf59BN1KaprEQUlbS75r23a6q3a766PdbtvrevWeGuo5plXK7JBuwPXA4/A1zvi6z8P+LtDGkqb/QPKk81oLKIFLh85xtyMtnkV7Xay28ke22ChEOCgXBQ+hHaqWs6PZalA/nxIksYLpMi4dCOhBrlp11CWmn9dUc1XFYav71ajZrrF2ffb5bXSZ4pqvg3w4mtjVNU1m/uJDd26rHLLsyygLFGUXJZvUn36da6GLUX8OeLpkuIbm7jhCvc3FySEgZ24ETE4xgn5QO3WtiyvJpbS1N3FHe3T7n+3bAjxY6buODjv71N4EuI/E8l9/aulXkEumzhVW6XdFNuHyyI+PnGB+FaTnGEW5R300S+Wy8mtfL5xzKFRQlqo3dm276JO19tfLb7zvflYZUsf7vbI7Ug6ls5A4x6U7vycZPX0pMZTj7vqO9eejjSQhATA3Yx3A7U1QxjLANgdW/xpy5PI7HOPWqFzpNpcana6jcK7XFuCI/3rBBn1UcE/WmrdQfQrQFGQOkiMvqGyMUXN5DaQtJNKNg6AHivHUa4sirWrtHCzYYIzBVP9BVm5ecQh7i5nKtztWTcvTjIrrlQ13PVw+TqfLJyun+h2l744Qb47W3bCg5mfhVH071w9zqN5f3bP5dtMjN1cncB6j/CiCO6uWCm6cof4I0UZHuatXUJtYRDDbEknO88r+Nawpxg7rc9qjh8NQXLbfz/AF0YwWlvCqmQfY3JIAjckt6jbUxkt1BMMF6xGM7W/wDZsYz7CrVi0scYkluo5ZmXIAVtqj2PrVS41a3a2uFW7ysQIcrklifU/wBBV31tuzSk6lVyhdqC66/8OY0t3rz3Q3eH3eAsds4uNvA6HB4JrQjvZVYmdUju8YaJcSY9iRwKW0mkv4ZBp0jvbghfmPU+2a1baOJY47ZYeYZA0owPnNdFScLWlGzX9a30Of2NSjVfsXeHl09b3fl2HaeWkiZr0JEyrkRxj5nH9KZFHaSThLq9kjkbhYQ+/GR37CnXGtaVDcxO17bI4OzDEfe9jXH+LPFscOoC3i00raSkn7SFKiV8ZIDdqwjCpUkopWudVKEFepJtJrXa/bS/9eZ2lzbokSrM5lkX5TLJjsK5GG88I6HBJPo4tLa8LmOVY/medj/DuJ6egHeuLi8RHUbx/s80hVRg28wzszxkMvXn19au+G/h/cXKzTiCaezuSY54NoJU5+VlIOQwPIb0yOma6Fh5R95vRrv17eaf3GM3HD6yd2mrX0tvffqv+Gte5sr4s8O6lGLaRXZpY2DQSpuVvb61QuNX0ex8NXWkaPBeqkgNzEDIQJOzeW/bHp7VYufhtcNerbXckkbwkAOpAk9m3d+OtRyaRp2jrc28ck4trklGhk+dIph0kU9s9D65rRQpaqMr32+W19DseK9u4vlTtZ+l73t8v6vYPhXoln4lnmhvmV7c/eklXDIQOr/h3rI1DQJNHttQTXHZYrKVvs8j/M0sT8bffBwR+Nei+FLN4fDP2bSPIjnnuFt7ye4cKsdvjL7AeSx6cZ61l/E3xZp01qfDOmwNdXVvtRZLhUMec7mJZjwQB0+tOriJyxFo9dLelru39aXPNpTlOq/5U7+iSa321va2+lyjaeH3sfD9hrEAgvikTTQtJCA5A/VcHtXceEbmz8baU4WKO21mJNhjk5ST25GQa4jTPifb3+lPp2rWVrYWES+TbSREjc3cAkfe6dOORWdZ+JNU0YEW3hm+tHZyIpXBG79ACaqpCpX5k1rfR+v9bGcaPPBc1ozvvf8Aq/b1J9f8E6paX8jQRvp9yzkmPaVV1IwRkEYH0rkZ5dR0YWWj6fbySykvJM+0yguScIB2wAPzr1bR/ipdrp9xB4mFil5agMUY7pQp4yQMjPI4rnb/AMW6rrmvw+XDFDptzjybywGCF7s6N1weq4HGcVVP2qkoTXzXl0vrpobKvVacqq2/rbfY6/wjpVm9jZS+JLeG1d1DzBkyu4Doueh+nSunbxB4T0qRxDp7yvEhd3lTIRAMk5PbivEb7Q/F2v30s/iC6S0tbYg+dMyopC9DGeODWjHp9rPrdncTa1cXlwzCK3tLdPMH3cF2PQpk8k8dqxnR9rrKVvJfh/TsY1MNTld1JNpdtv8AgnbXnxwsktvM0HRyxeVowxAVcgA549RWJL4+s7+2ubzSfAGk3d63ztObRRvlzw3K5Yg85p+l+CrvTLZrfTp7cs45nki3eV6ssZG0n3JxWrofh/V4knTWNWWdioCSNbIBEPZV+8cetSoUIRfLv6tf18zJ08ui7SjdL5/nYwLjxf8AEybTFufKs4LyRjGkIdFCoc5LA9Ow4Oai0ye9hs7nT77w59ofySPNS6TyTIRg5U/MEz+NddonhOz0y7aee/vtTkICK8owU556nofpWhPYWizs/wBu1SNMEeSdhjOe+AKlzpx92FvxD67hoy5Y03b5L8LfqeReELjX9FaO2h8Hi3iebzbuZgsrzJ2j3P8AdTvxz0rpJtE1PxA0U91Ha6VNgqRESdyE5ALHv9K7fSrGzsbdYLOweePov2hvu565PXFZvi3WrfwzpkeoXumyPE0iwhbGESOCcndgnAHHf1p+3k5d33e/9fIX16lCTdOnd920v6+857XdFsDHa2uqprupKZFjRrUmNFOMkfLxsyTy3vXXxwJb2tnHpypaNahRbY2gg92bHsTUWp65baLa2txfpcw2dwglBitJJNgIziTAOxuelZGq6nqBhiuvC+kx67pkpBaRbklgc8gJxgj1PftU8tSpa/8Akv0IWNUlbkt53b/N2/AsLqniWO21NpbSzaeEq+n/AGO42NcHn5pGP4cfWuVY+PY7W6uJI4I7oQsxMk8bAszYCR98hSSTz25r1GGFpIlDRPEsiBzHKQGBI5UnuBWdqWg2cqhppprfacLcQSmN429Aw6dutKFWKbTS1/ruZU8ZCnpb8F/wDynwzrlvGjjx1ptnPGrbWS7tt27jGUcHHH+TXTS6X8KdXtoRb6zqFhas28QQZ8tT3AJUkD6muwLXlno4Gpajb3axIfOk1C3DB065PGM44J71hR+G/C3ifTpJrBdOFk/7uR9Nj4UnqG2kfqPpXR7VWvdpbd1+X6DliKc5+0aa84u34WN3Srz4aWzxwQ6uk8xRUAln5YDj6H6VBq3wj8Ha863mh3UdvPHJ5gjRg0Rf3HavOvEfwj0uzs7m80zfcmL7hS4ITI7PwWTv8xGB6ip7aLxFpsLSeD5LW61GIxu9vDKku1QvI4OWbpg49a51Cb5nGd196+aasbRhCcXUhWcZLu/6/Ib4w8Bav4L1K/1zSIZluBiRXhPyHn5iD7+hrT8MazrOueFb25uJk0m6d8H7KP3rhcEsQTgFhkZ+tJ/wufXNH1qA+KbVYrSWDZLZR2zud+77zMeAcdhmtXXNW8IX0c7aLo14mqXMO6KGzjf9/n+Er0BJPbmtEql0px18krfO5vGU5K1aKkl1VtPU2/D19ZX9nfa4k88+n6UARazSbgWb1A+XaOxHPrXnus/GnxjYXzjTbbRxYnlbUQdPTcM56V0fgtv+EE8Pvp3ib7NBeam4kuY3bcIYywCQ7VBAYse5z+tZ93p2maxfRLqHhKfT54gxZpbtY4wM/KrImXY9+oHvUqlCfMprTo9DB+wjUclFyi3ps/X8TK8I/FrxVd3hluxZ21tcP5FnFFAVQzHkjGc7AOWPRRj1APSeBfE2p+Mbu71PxRoGlx2Wnbmi1a4LCMEE/IpPDe2On5VBLLpulahBarpYvLeRNjWNjpDSyMO5MhO7kjovHHPFWprC5vrLUIPE9xpSWUDNFpzR/wCjm0hfloTGMBn+6BtyeDzSWHVOKV3r169f6/zMMROEnZUkrbd15+vYln1vQr9LJBaedrcis09ra3TQRk4zuj+0KN3GMgHP1q5NfabpEUt5Z6dq0fnx+Us0rRmCY/3A/wDA2eBuwKw4IrVmxe6jd31vbn544bYzMCQAq5A+RvYHt3qjN8Q5/CV/fWmh6HqOsxOyhjcoyoVx86um0nI+76VtKFl7qbS33/y/Qxlh5JcsG/K97emlrb63/wCAegaXer4hsLSaSzuoZZxsRJo9kluFyPmAOfx5B6ik1HSb2Hy5NXZ9igrBdJGjypwSMMBkH0HXmuIS+1vVjaavonw10dkb5ph5ssU6Lk8KcqFPvg/Suv8ADfjuy1G4l8PLbzjUYADJpV/MrM3+xFPxuYdg3Xsa45RcbSjt8lv0309HYv8A2ijeCgtNWtJW81dXXXVX8ypo/iO/+wXGoXerMYVcWkL3FqUljnPRD/E3upHvmt7w9qXjn/TIvEJ018oJLCe1XdHcA9VKEhsjn0rm9cTS73XDotvotzZ3bzfa1WSKSOO6Z1BeQydN6gc5xnoK6Dw5JNJ47uooPst7biCCIxeYYjZIin94AV/eEk8BTgdzRVjHkbS89Uu6tr+ff1Mqs41Iqokk5Xula22r+/tZJaPY3vD2nXVtrEyXquI/s6gtgbJ+cg+oK+g4rrACSBxsHAA4pCTt57EcmlJ9MH3HBrzZT5nc4pSc3eW//DikAYLcn1ppHJ44J6mg5xkA89zSklfmwADgVBImDt55ph3DlTz6HsKeTg5xxjnFBOOD+fX86APDbWNp4Vjt/NmmfqoI8sr7g1JHpC2kis8oSRgQ2AWVz6Adj71g6FJq6acRDajJTi3Mu1i2ejcZFFx/bYsJ7jU44Eu8bYbWEn5M9yeua9qVKcG3daf1ZHtfWKNaoqdGPKpPv+L7Jf07nRmeGyiVJpobOIjBhXEkh9zg8VnWOoRSahInmzFYkLbpQASp6D0rA8N+GTaBbi6hkt7iTLlFYYC46n0P1roNXu4RocpcTyyQH5Rb4aSRQe2eMVU1CDte/fy/zOmlQafe7VvO77eeur8jV0/zA5QY2t8ylzxj05p97AgZrdLeAITuZ14OfYDv71neHpv7T063ntLjzrcDG90Kup/usOmRUeqapb26bizSyRnDMuAyn6elYSjOE3FrVHpRjRrtVYS36DokvW1RDbTJHbRDMikqEZfw5z71zvjzXf7N+yPYSebHgmWJyfmOehPGRXN23iny7htt28qmQiUsh3Mh7LWdcxrqcd3a2cn9pLu3RFkZXHtjuRXX7GXKpx1srrz9fv3NIwjTquM9U9Oy6xv+HraxJr0C3N5/bdi8kmlXfzKseGMDj70LjgjB6HuORXS+GIWYFI9R1GK2kUK1lqFqJEHfKyfdI69lNVvA3hu9TRbiDbLbzzMuEmXarY7nHOa7jRPAGt3OtROUkiiUjzJ/MIDL6DPWuqVSNGPspPb+redtl/mebJqMOavO3L172207v+7u/wC7or9n4CtJbyL7M2nJdSR/NGuRlD+nNdzZeH4dAs4rdLw+aZfMl2rgP6A454//AF0/XZLPw7GLmG3Ml+sAiiQDsOcZ9a8e8VfEqZXR7a6hivnwFsnUsYmzyXI/lXkxnVxUlFPS9jijSq42HPJ2jbrbe3X9PQ92vb3TwHSWMeaxHJGCCO9cT4iutJ1LTryW6hto5EbYjxR5LY65xxyOleZ654gv/Fkdm2n3sQvII/8ASQm4KrHgEeo7YqC01H/hE/C0ltqCy3lzOzBIkbgN1zntjNaRwTpxu373Rf5G+FwSp8ji3zaX7rvczNcm1OaKSfQdSjn0uc7fKQMW3r1jYEZRiv59s1uafo+kXen2Gq3Om31zc3KCKWOZVWXcPlO7+8DitbR7Gz0zwx/aqWN3cXN0qStAsZMkr5yBj2J6119gl3JZRSXCRxX8q5cg58jPT2LD8q6qlX2aaj0dvw1X9eRGIxUfdlfTW3mtLNry09WcrB4NtJWtmOhokVsuLYMvMZJznaTjPfmrFroFzFLdSLp0Rmn4nkklDRyL7qxO3seK0/CmkS+HftRl13Ub9rlg7vc4IbHp6fn2pZ/GOjC4MQubmaaJtoEdnK3PttXH41nz1JNqn73pfrucrxM5NpR08/w/4YpWvhSC3nSeLSLZ5duBIqdB6ZIq7Fozo5LbI8H7nTb7jFadtdQ3kQmkeYq/OJVKkfUHpUsckKxkBjyMqFUDIrCdab0e5sqtdLRL5I5C70XwlHfJaandwnU5uI4prlmOCewJwM10FhZaRpUUVtbWdtaY+X5c5I64z1681auLS2lkE8tpaTypjEzRKzp6YOKdG8JcNKmW28lH/XnrROq5xSu/Pt8jJynJvmd101K2vazp2iW6Xmr30lvZ9AwRpBn32gmmeHtc0vX1aTQ7/wC2Rx9T5LKF/wC+gK1I7kBi8Rl/Lr+lIsrSlnO5T0Gcr+PTvWaa5bNO/wDXS36kyjGOtrFS5hnbWLW6h1KZLKFWW5sfIQifPQhuqkVceQB8bjHH/Csp6+orEvdegu7mTSDY+I42LGI3kFkY0X/aWUnp74pdL0C8sJSYPE2s3sAPK3kiTqfzXI/A1bp+6ud27abr5fqRComubU2ZYEljZZLeN43GNxyQQaqwQ3kepxy22orbaVCu37HFaKPM46tKTn6YxVtFdHJjLRhuMYKq2e2apaq+pNarFov2LzVON12rlenYpz+NZwbvb8ynHm2f4mvDcurEJMQWOTnjJ9zTFAaVy0sWRyWU4H4etcxo+najZhEvr6OSaWQtKklwzqc9k3cgd8fWuiiidN0OUBPRmG7Hpj/69FSmouydzOFRwWhFrcepvZtJpEVhPdKcgXjMquPQMvINQ6Pql3dxywarolzpd4q4ZHkWeGVT1KSLwRx0IBFR2LavDM8Op2umtb87bm1mbdnsDGRnn1BNXlnRcb2wc8545+npQ/cXK0n5/wBfrqWoxrK6d/IikgK5HyiN+qtllI9CDxWZp+iWGl3895pdotrNKhik8j93uTOcEDhuenGa3lkj+bzAxBwPk5FVNXvYNOt2kuGlW3c7cxpuI9+OaI1J/CnuUqSty8pAyTtIr28TROuFZw2xsY6EgYOahuNP0iW/S9uNPtHulZWWaS0COp/66pj9aq2MGr2upLI11HqOkTqCGlHl3Nuex4AEifXDCtW5vbm0tZ3sLNr6ZQMW0UyxNJyMjL8Dir5nF2i9+2n9fMmpRla+9hHspIrcS2pmtIieWY+fFj3yCB9alk0S/CrPZ3Vnb3Dj9zdQoWLfV1JHI45FV9Dku7eae/aSa1iuSpjtAg3Im3/loB/ECSD2wPercMzwzxvbW0ESggMY4tmc9+Dx60pSktLnM3PmtF/1/X/DHL3NpeWr3cV/pyyR3kZhmurGUtLwSQQM4U984zmmDwq+p31l/Y3jWRPs8Swtp93IyGYDJy4JJYnJyfSte2tfF9pebLjxJbazpu0gWl9ZopY5yrPMvzZHQeverGrX+kbFOqeHLqEo4BaAedsHcjHUe3WtlOV7Qs/TX8HqW8RK0ea6a6r/ACehxGs/DvxZaCT7N9rkibJY204kDe23g4rjtO+GXj6zunn0vQraaMORCt4R+7Gc7lVzwa94tFkthG/h3WHjSM7jbTkquPQo3TrxisHxRJrSyXWoXV9qNraRciOMPJtUdcBapYidT3Hb8Uzshjq7VlUVu7Wpyfh60+ID3Vvp2o6BZ211Ezyi8urZ1jjlPAfemUYgYwWBI7VuaB8L/EVt4qsdc1/V7VIrCMxIqy7g6sxJJOBnJJJJ69KyJta1q6srS9sNK8QaxYsA0dzL5uw+pMAOWI7Z4Na58Bu93Lrs8kWjXNzARJcX941xJIG5KGMnag9hnGKdVNQ5ZNJP57fP9DOWLqOTlzRXmku29nrr5EHhvw74o0/4o6rPfXtzbaRGyut1dsq29wHbiOLnGSOMdsfSmePfhbpfikXfiPw/qqgXFwFmNlGbgZQ4Owr+GfTBq/ceH9Fl0XSNN1CV9cGns+x4gUjiEn3sbjjpxxyO2KWeay8O6GlxeW8Js9PBjijSWdUjQnCgRqSCAOpwTnmo1lK8Xdy0tZar/g/h0OeeKqxanGWsNE7WutN/y7HL2WqeNvCl4b7/AISVdV09QIzZajI2zyyMAtuxg5GOufWu+bxxZwSxazBoNzeapeRLaxw21xGyxKvOCQflXOSTjtWbFf2PiC2Ma23h3U7aaMgIrCYOD0DksGUj3GaPDel6fodrBp2iaVHb3bSq7NpuoeagfPQ7gSM9ME1MqcOsdeutv1DE4lVLRnH3l1S1819zfn0OT8Q/GvxdHby3thokFvpkExje4jiMoPTJy3XHrgda1LDxp40uRa3+j6wmq2twocRS2UYQ/wCxheQR7Gt/xdpWva7pEtob28tTy/mRspJIBHlNGV2nOcdQDXNjQjP4VttOv/DGtIZY44rkRLDAqLu5fYp+Ug4JAFVy0nJOMVyvRrR/O+jFh8VTUJc8FdWt53Wt/K6+Xpqdx4G+JVtrKLY+IIX0vV1m+zlpI2W3kl5wqsfut/sn9a9EkLKcbcYrxfVtNMen3NncqqWKwBEeYkLuAwHyeuMck8+lP8Ca54v0rUv7L8TCK8aJVfzov332iE8KyEc4HeuOvh1b2lNadv6+4JQpVZONOVn9yfpvZ6N27Xtsz2RehG07h6mmkghe3fmnAq6hlPBweDxjrSc5yVHcn61wnOzwq3mXTkWXVbr7JFjCkheSfb1q+ltbzQLdrORG/wA3nO24t+HasrVdBa/v7a5vwHtBxFDjKsf9pe1Xo9Pa0uEkiWNwq7WixiIjoDjsa9ZyTirvX+tPU+j5G5ynTauraKyv069nvfcsw3tmYsRzlyxJLsemPY0lq0DqVCwKu4/PGoBHsMdas2VjaYEZghjmXgkRjrTbt1tUkdhH5SDBGMAD/GspTjsjso0JJuU3dvv2/IoX18dNtiCsccDqeeBtb3FeVzST3moXcttqAiuxmTypv3eFHpITtJ9u/vXQarqceuTTiFb67shnfawBFZsdwzdOnvXHkaa8c17HFqLxxEJ/ZlwPPTOOG85duQPTANdtCDhK8t7fcunrr6+dtyqtT2aapL3rq+l1fez7aX7eTb0Egv4dSubNdRiisYd2157eMruI6luAPyNdRoVhfQXk99qNzb2unqNttIpVFYZ4Ixyf51kWI0zV7+ztLvTZxqhQNLJbbYom4GA8ZHHGMsD+B61peLf7HubnTtL1g3G6JcIliDtTnucfr7V3Tm4uMY2vJtb6Pu1vro9OhhTkq+rukkm79Oq17O6u+unU9h8F6YmoPG3npPIAG3L92QHoa1/FGt6jbwvZ6R8kkfyM4YIob3Y8VN8MdJj0fRYIklBV4wIEcgsEFcP8SdIOrRT6fqVxc2kBmMolRMr+IHXjuK8Sraddwjql30PNpTVevJ1NeW3n01stL6/5mFF4f8WC/uNQl8SW0880bBYjM5wT0PTGB7U3wr4VGkai13K1m+u4IeZGJ6+gPGTnrimy6fMLO2sPDer2Vt5HyLvndpXU9j8pBPtxitey0/UGa3bWNU06OaIlC6sGZx6BeOa9OV0tGl0Wlnb/AIPU39pFxaqPV6tefZpW0006FjStFtrazvJIzBaNMxeSeNNoznnAPX8K3NO0+xmSF40S52klZZmV8H1HpXN+O9a/s62NtaW+5pI9guZzk/UL0xW34Me6fwzaNdNmfZ2UICueDiueSm6ftb9bHPiJTjBTl9pvf0N2P9yCCCHJxvOGP4elV5pFVjGrk5PzfN1/3jUYjHmlmYuQSzbzhVqPVYLq60+WLT9ROnuSCXihWRm9ue9YJLqzybOc/P5l1ExtBDmT0HA/E/4Ui+UhLET4AOcy4/Dp0rjY7PWNQZLXULvxVaiM5+1RfZ4Q49MKScfh3rq44oQkcUUd3cFQBmWTDHHdj61VSnyfaT9DsVOMdGm362Q95JZmUxK8SKfuKgfI+pGTUatKWAAglHI+ceW9SuJ97Nuk2f3VcE/jVLUIZXjA0+Wa3nbgtNAJQo9sEVC3tcUOWStKK/P/AIJN5jhSY28hlzuAwVx/Wnh5Agb7XK7EYA4wfwpbZfLt1jubiZ2H3i9ttBb1+U0y7FxBCJNPtPt0v/PFZRFu9wW4/Ci72JdOMnorepIsV67b2kk8xsBWeRQcegFU7jUtXsNTaG+sZrewJwL6a8h2Hjuuciqdrqc11M9rdeHfEGmuxI+0SwJ5QPtIpI/SqPiHwve6na29tFrlukKZdpL7TobyQn2LcD8q1jGMZWqW1/q+h0On7SFtPuOsXZPHGVuovm6EZfPvxwadHp8hJaKaNos8x78SH3x0H0rko/D8P2e10+TXtcjurdMC5s1W0VwT0wi7ePSlfwbpVxM91f32o3l4MAT/AGlo5OO+UwCfcipdOkt5fh/wwU4VuXl5rHWyxyohUh/LyQA/I/8A100q0SxgjavQr6gemOlZ1jAtpCI4nu5RnCPdSGXbx/eNXRG+CsSbCOXcDv6Y9awkknpsaRUkkpPUZNb201xHc3NvGfL+VZWhGQfTcan2BASqqyg4I6H86ckrZKW1zIJGUZUtuLfUHt+FZN9Pq9ld/wChaNbajG2NwN4baSMnuQwKkfTFOKc3a/36Cacd1p5F2RB5Z8kOHYH52jD7fp7VQ+36npk4e++wy6cTtM0KujxZ/vDBBGcelXreZ5ubi3lspd23bOQyk+gYcfjUkdxhizxywKrYDPjY3upBPH5VSk43TVzN0qcrdH2f+Y0NAJWeUbATzh8Y/wDrVIVikYKGUq38akBiPXjgiid4rtA0iLuwQWAyfxxXn2sT33g/V5NT1XWBH4blkH7mLG4Z/hERzke64PWnSgql03ZlyoTteF1+KPQUUxHdHI5H951z0qa5Z5IWMdmHl4J9APU4yaoWV3Fd2lveWrma1kAmjZTgFSOODg9PWrcdwjRhQGDE89j9ahrl3RyWnOVnuSRfI7ZI3yLyE5I+lTP5ccz24z5igNIewz6f4VEs91HE81nGspxlTLyAfT2z61FaSzXluZZFFtcAZkj3htrdwah7XLVFqV57E5zNDN5Kl1DbdvTepHUGq2l2UthaMsd5Pex7twjuW3yQ5/h3Y5X602/sHvNIurRrqVftC7N0J2tC3ZwfUUzQ47+wtbSLUb6K5v41MclwqeWJB0Bdc8NjGSODT+xo+uxolFtqPy8yzFcQJKpltbVgQYwskQJ/xxSTWMRuJGWa5S3dgzx29w0UeQPvEZ7+g61oWsa3V4RLCA4/iU9ffI4qlcJBcQXUcERjnV97LnPnAf1pKbT0MZ06cnfl/Uraikn2YyW4utSnjBMNqb1o3diMbdxPTHrxWLpdxZz65b6adD1O01Hyt7u8Akt4Dg/K0wJGfoK3tZXVLa2tJ/D1rYyXTAB49RkMaY6HDLyD3Bq3cTTxwQxySCK6ZRh0/eIWzymep9ia1U2oW7+f6ExjCMtNbf8ABKyWjR3Ecc1kSVOQM8H3B71jf2ldnxjLpMmh3NtCsRlivyzSROR2bAAT25rY/tCCcyLHdRSTRkiQJcKWU+6g8Gmac95BqNihJls/nM0k0xLjjhQO+TxUp8qd1rY0jGUmm0rK/Xe5Ho9pZ3Go3C3ljBBeSr8lxbhRuUdA3HWq95CPMW185Hs3ZkkO8pJFKMYUgdVPrUmmyai/jZ55JojpcsGWiKKPJdTktuHOCDz2qLUtRhsdMmlu1BtwGmiuEj3l48npjlvwqryc7J3vYnkUWm10u18/6ZmW2mahp/jO5g3z3ekXFqZ1DPkW8qj7qc8hhzz0NS2/iG1i0B9ab7dFbwqfNSWApMig4OAOtbVterdWlldR5VHh2iTaVYg+oPTj1oiESXU1vulmHccMGX3pe0UneS7f5FTp/Ze6T++7d38ippurWmvaFGbK/lureVzIBOSAy91568VynifxPdeELzRrzS4kk85TbQvMSUh3/KCT1K5UV1VzYwW3mQw4VAw2+UoUID1wOgNcH4zU6t4XNtECraTcrESqHBRmDKS3cgZ5Fb0Iqbcejvv5p2/GxlUpQdSNSlflvG/ps/uTZ77pE9zPpVtJfCAXjIPPEBLRhxwwUnnGelW5MnH3sk9OlYnh60uNMtbaH5ri3lJcvv8A9UCARweTmtth90byOOcCvGTdrk4iEY1JKDurnjdtMLpLZWQgpJkFmOTxU9/GYWknk8yeGMgsqc9uvv8ASqukqbi9WTyPKjUYJ5yx+p7Vds3gg1Ix2zN9kcMCrHdtbPXNei4uO59DVxFOpVaw6sktfXd2ev8ATI0lila3kgljS5Kh/JZxvxnuKdqr/btHlRSI7naUI25wfWue1i20nQdUGqXzbbiVvkkYsXGTjO30966CO2e5hJhYq7D7/POaqdONlOO35PsXh8XyxUJu9rOL6vvp2vc8j1GSVbi2sLy2N1JnCi1JVt5/3fXpzTJ/D7Qbry20+6SYEpJBFcK6wHPBHO4/0qx4ztbuz1iS5tZzZtzHuBK+Z7fXmsrSdKZdTjggt7S9OPMkeBm/cY5JkfAAHrjj3r1cPJVUpS0avr69PS27N8TH2EVOLSiktNde/Xo7Wtu777G9Z+G3AWXUdTubqZmDeVGdzA/3WJ5rutIMEf2f7W8EHO1AwBcAdgOprj9Fv9Ft72QWYBaQfPcb9kZb0UPg4/WsvTtNntPFUWoazqEcs28tFBES59gRjC49OtOfNOapu9rN307bf103MHrGTv73bq7/AJJfgfRtrrccV+jRWaSwiAATxsOB6exrWup7XU7OL7ZakxzMQjMM7frXEeHoYZLV5LKAxzyAM+5juc/Suq8M3d9dtLDe6c9vCgKeZJhdw9BXhVKaV7dDxsVSjR9+npay3120dvxPO/G/g7VdNhubmzup4YgcxPZZDj2NcloPiHVLnZpXivT/AO0rSUFd92v75Mdy+M/zr3yKSQM2nzPKu8ERTId5I968T+I/w+n/ALXhuotT8hwTvd1Y7xnqMd67MJitfZVtU+vbz/4Y78PVji4uNVJVI6p/10/M19NGj2mmrY3qSXQiYhWvBgqCeAGPQdK6O18u6jR7VgV/uE7g3bAxXjesR6tqWmTwasz2YjdRCZQzGRFHPQHHHOe9O0bxhFpktn5Nw40+G38kRv8AfeUDhxjoCx/KuqWHdW7Tu/8AgX/4BVbBWty7638tVp2/4CPUby01MM1zPqs9vbxvv+y2lqGMij+A7uSTWtA3nwedFkLIu4BxhlHoR6iuBs/iUJbWe0eCwn1e3bLQ31yYEb1CS9N3scZra0LxhoeqWSSzNLptw52tC1wrqGz03YxmsZUKrjtdLqrfpv66nl1aThLVWa7bf8Dv5nQZjztlDM46YcgGlUxlNqbSp4Kh8t+P/wBeobbUreSRxFqNq4XtJuBUe7AEVQuPCHhvXdSfVZtOt31V1P8ApVpqMkW49OgcDP4VgoWfvp2IdWUL3f8AXz/4Ja1C1v5LN/7Lv7C3uMcLcozj9OQPpXPX899pn2aXUNc1Z7kLlrTTbEzwvjqANpP5mtGz0M6PDbaRpS2cx8wvM1/rwabB9FXr9OBWnFD4hM+1PCeoxW+cebb6tAAR/ewWziuiFo/C1bz5V+ZEsU7Wkk/u/Qxh4ys2ZBJZa7bI4+V5dOfaO2DjofbFa0t7ax2bXczlbRUMskwH3U7sR1qzHcJHIILmy1Ezgc7nUhgPQqSPrVe6MDlJbq3WBlfCyY/1eRz1/l3rKcYP4Vb5m9LEOybi7Mg0vX9Jv1H9kaxa3UYGTtk5/FTyPyrTids7wxVCcAfw1ixWNoLwzWMVtI3RnhVQA3uMZGfY4qtNY3767Fqz61qf9mwrsNhawAR7sclmIyw/D8aHTjf3br1IqV4y0uvyudO2VBURLk84zuXPrUDAOSqtG0xGSQyoQPp6fhWLoGo6nqV7c2k2iPpyRoJIftVwryTrnGSgwU6ZBPBrNuvEGmXDi4g0TU9YhjlaE3dnZLNCCv3v3mRhR6555oVCXNyv9Bxq8m0btddX+R1s9u9zbNbxyyxArkSQHlT7HBArmLrwvqlxeQSnxHdNFGCAQmyZf+BKdrfipq03hfQUm+0xFoAxW4Y2t5Lbt6/dB2nnPaugRUmiJ09ZGOd20jcRnnt/WhTdLWm9+6X/AATSNaDfvRKVzoNjq1ukeq2gvZgm0zl/Ll9zuTBHbpU9np1tYQxxW4uXEY2oZ5GkYe24nJH1zVS/ttI1ub7DezwzXNswcxCcLPEw7jYQQaitbG70dYmOvzzaVHkzJqKiV9vZllUAjB9QeOtQ+ZxtKTXlrb5f8MdFOVOT9x6os+ItLnvYFubTUtQ065RSVktZFaM+0sb/ACtz9K5618RaxbTxQ3djpl9cHIaGzY212+OrLE52S8dVQ5HbNaGn6g9vquoaTrU5Vpy01ksuGS4hIydjDh8Z+6eQDxxV7+ydPjjgktrOBPIAaJWXdGrdjg8q3uOa0hKNNctRXXT/AIcJ03ez/D/LqaVlci7tY53tSFkUj98hikT2K+oqpcaPpl46G+sLa7uI/nVrmIShfdc1euPPaAGKUBVGPMfnnv7/AEqGFTJD99FxzyeXHtWHPZ3WhyKhPXldl/X3EMsa/I8extvQHgHFSwsjkpAh3A/PtYY6Z4qRoy/3lQoB/ABx6A+lUNSW/ispW0uO1muhg+XOSsZI/hJHIPo3ShO7sEsOkuaMtTObRLU6g19pl9f6ZfqfmNtNmNs9Q8RyMH8K2pLq8tr6FbuCYyOmWuo1BRh6OvXOOhFUPD+tQ63fTWV5aLpPiG3UEwXI2lgRwVccSofXqKvuL+NJFWZbC/Qsqlv3ixuOhI6lT6dcVpU5r2m9v636omNWal7OUdf6/Mvo8N1gPI8XQJNjIXP8LD+6f0qveQSyw3EHyi6GVic8gPjIxVXS7y9uFuF1myWz1GNQLpYH3wTHP+uj77T6HkdPemeLINVl0Cf+wLlLfVIwk8JfHlyFWGUJPTI4zWPLafK3/kaO6W1jY0mW5XS4Zgiw38kZdoJMAq2MYPPr6VnabqcF9cCE21xHdW+S8To0ZLnODyORnPINTa/p2oa9olhdaLqp0a/ba8pNuk3OPmRlbHGe4pumRavHaGPWry0vLkHCtbxtGqj0IJNCUeVyvr21uvw/Um95u+60+4nNpfmRGsltWkVt0wlkaRgvcDGMGrbLPDbJci2Yc7TkdADng0w4hIMYWGNOHIBLOfwrD8LaXb6Rqeq3VvNcbdQfd5ckrbB34VicHPfj0paOLbFZvzX9afMmGl+H4tRfUR4dsjfMwYTpEEYsT1JHX3rQgvUuri+hUWxaMhWhjlDGInkbh1GetQ6yl/GsTaTeadCSQz/aEaRig6hVX+L6+tZ2t6jHoX26/SylijkKyk20Aea6kb5QCo5yOMEnFVZztd3YWhJWirL1NAw6ZcaTe28qEzXMZtpYYiSWTnPTkA9fpWaljeW2kix0o2tpDbQbbeOVN6xEdMew64PX1q5dbbmF/s0VwiqFeaSIhdzfeKkj7wHcDjrVfRbOQ2ly93qct3m5klXeAPs6sMKi+qjt9aE7Rvf5DUXDmcttP679W/vLxiLQW0srwzzlB50sKcM4HJCdBk1Q1PXbPRoIbjXLyO2Fyxjh6nOPQKOpqnqvhtdTuILjVdSnls7NGkfTLNzHJNJj5cupBA+tVLq7v9Whtr258Dn7bYg/ZIprtGcN0AHYeuWzWsKcXZt3XXZa9Fr+LtYiUuZtR766bLrbpfstzQv11F7+3lSeCKxQDzo5ISzzZHCr2X3JyaxPEU4NrfhGlCmIoQ69D6DsR79q1tXudYu4NNWOOytslZNQaf8AeGIYy0UeOCf9rgVia3ZS+IbjT9PMjhLm9iQrE/zBF5YZ+g6inTaUlKXRX+41jCTi49G7b30bS/r0dvP2fSWC6RYAj5jBGMdCCFq62CThgPbPSomRgAFXKrhUHsBjGakAAXadxIGcHn868eOiVzjnJTlKS6u541pGtaddX0kVrdxyzRfK8Sclf8fwqd5RD5kUc8ihTuKxoV3H8eRWLpfhaztbiTUYLBop3yTIbgkKD/s8CtQXActbyModx98dQPxr2JKLStvbX1628jvpx5K8lDWN1Z6X+e6uvIj07SA2uT6lcOktvNCFAky5A7gbuFFT3NvObmB7S4gisw2ZUkzux/sn/GoZdV0+GG0h1XUfKaZ9kW84Ln0wB1+taOoGOC3KrdzW/mMNsnByfTpxSjNvl7bL+u504iiqVSbjP947O1ulrJ/hv5GNrWmQ3qSvcJFNCwz8/QgdDmvMdUurKWGbTtM0+bTo3bMi2pYG5YdMszE4HYfpmvamDOFS5QuwGfMDDaw9xWDqOkfYzNqOkRILpRjfGoaVVPXYT90++KulUjB2lt/X9a/cd1Or7SK517ys1/L/AF269rHBadpo0aSzl8U2jS3agGx0tnLOCTnzZiPuqOu3OT3wK6rwpDpUSySWUFobiZyzmGTzCrfU1x73EWibr27ivpIZ9yyC9m3tz3C8ZPuateDTa3l68mnay8FrvBNs0PlSSei7gSCvrivUcPaRk7+bt+TS79+vokc817Jc03q2t9nvt0STez7u92zuLvWLnS2lmtn8iIHLySAYOOuKXw5411O8MlzK8zRgFxA+eU/vfSualNjp+p3T6ytsBefJEis0jMo+8SOij0rO/wCEev8AXLdn8J6iYLJmaPyVVoiwHB3NyWBrm9nBQbavtr08/wCvU2qU4VJWklv16ry/H7j2PQPHmn6/ejTrO6gN0F/5ZLyMdiR2rdms4NbhaKFy88L4cLIMEj0Ncx8KPAVv4PsmvtWFpDcyqA0jNgnvxnp9O9dPf2+h3UjSW2oCykPJMXygn1OK82uqcalqfTqtVfy8jx5TjCq/Y+6ltpf7xNR8JTXbKYpIrcIuOE3uT7muV8QfCaC5HnxIjToo/fD5ZOOflPQflTvFVz4iM1sPDvjmxtLdQPOW4s2HA6sGAOfpx9ayl0e+13VbOO08Y39zrMLFnkhPkqFPUsgyOnTuaqhCdlLnsk+z08/T5m8MTiqUfelolfrb023OD8V+F4NEQxm5slurh/3aTWxk3L3Pu2T1qC1+HVxNBF516zwJ+9VoF2AMe2D2wBX0YNC0yaX/AE6e3ur6PCiV9pZCB6dia1I7CzjLNMlq4GMcAADHer+vyUbbv+rW/M2ecwVmk721v3Pmyy+HnjbZI2j3LFhIXdcgK393BJ7D8K3Y/hb4/vo/9M1ayVXG4wMNgB7cpzivcdR1rSdKti8txEFAPyQ4Zj+ArgNa+I6PF5i3Cada4bYX4347b+mfanSxeJn/AA1t1epDxVfEXl7NJPvf/P8AQ89v/DninwpEzah4K8P6mQw8ua1B35HOSep/GkXxxqNhZtP4k0RLCJOV3OCgB7HgnPsK9H8B69deI70R28009i5Ild+2OvWtjVfAul6tcSKZInt8A7AqyEn0wf51dTFTi3Guk3+RMZ4eMuWurPyba+57HmOg61oHjrS/JfSIbi2tptyQzRFER8dQysDzjnse9Xx4o0bwsMXCQWNrF+78uOFnTBJO08k++f1rsx8L9MfR5bCO4m02GcESJCFRgDwQCPWqDfCDwva6PHp9xfvJbRklTdMGbntkEEVDxVOSaXlpra/V9SP9ib96V079NUU9R1qPxDd6RPYXWkJZTHzWLJl54xn5IxkBW7Enp17Ve8OzWTQiTxDaW76i7f6vT5HEMCn+AszZcjrkAc1xeqfBWzuLj7f4U1lbiOFShtoyN3flWJxn2qTSfg5p2l+GvP8AEN7dW94z7xsmIdR2zg4zVRlQ5eVtr8/zTKlhqM1F06t+ml7v5anZXkmgzXl9BN4T1HyWjVvtLyqpukzjAy2Tj0Paqd3rXhaO3g0a7sr3SbC0k8yNI3CxbyPl3Y4OM8A8VxvhjxNcapfaloMN152nRfPbTMyyMhBxj1wRnOKXTJr7Udafwz4z+wXtvDAbuymK7lYKSMMh4J7Y7dq09iou0u193d+fa5lLCVaakpys187eZu32u2kOs2en6Hfl7qSTy511S2ktkMWMs0cmCu4f7Xyn61sXcOpyX0T6BqFtqMccYYrC2HJz1HOCPw/Gs3U0k1S4tYI4LLUbZstPKZ8RQooDR4UHexLcEdBjnirYS5kExuNTS6DuCytEUKKByC5wET/d5qLKyt+Ov6f13InCXxc6flbf52tYp6V4cgh8RX2sX1jcW+rz/PKkQBWJsY3ICNxJzzgkZ+tNnvtY1G5Np4TuZYtRsS0k9nqumukd4mQCol7MPQdc1jeIfiHY2d5pNjZ6jpFzFbznzkSxkk2qcfcfIww5785yelW7zxd4T17xAtsLnUbO7thuU3cjGJQOcq6tlR7nitPZT0c1/wAC3k/y7D/eTfM4uy66tfhr+Q7XNGfSdN1OeG2Oo6HBE9/a2SylJ7K6A+ZYXxxGQSdvbHSt7wtf/wBs+GdO1HDq1zCrFSckDpye/TrVyHUxqMrtbS29zcmNJStvIvmMrD5WKtgMCO9UZ9StdKDPPCbEnhkPyY7cA4H5VzT9o1ySWv4nTRnzu99fU24om80ktjA4CcZ+prE1A+I4btBp6aZe2BJLx3LNDKPZWGR+Jq5a6jFeWwl05obksuY1VgCT3Bx0qjDrOth1hu/DpMeQPNiugcD3DKPWohCavovmW5wu9S/qFnZ3dvH/AGpHEI4mEihicIw77hjJ+tQpbapFrckq3ccumToMQMu14H/vRuOCh/un8DWomx3eF49jY+6wyCKo2Wnf2Zd3DQ3Lf2fIA62j8pE3cxt/Cp/u9M9KiM7Kz/r/ACCabXusXUreeaFTa+VFqESk208yeZHnIyCOoB6HFOSZb6zmJikgmjJVoid3lsBlirfxL3BrRcLtJTcvcAdD7VXuopUfzrb5WHzK2Pvc/MpFClpY8+ScnZ/8MRpM8iJcq25vuhlHVex9wakt5EljkiWFgOQoY5/AHuKqraeUyLbOGhbLhCcGPudo9PalguigZGUhg+PYn0Pp60muxrGSqK32kadoZYHDXDB4cZ37hx2A9Rj0qB1uJJmdwEKtngHlf8KjkuZ4br9zaTtbsOZWdRsyeeOpond7dMr5ruy4Clzk8+nejlsYtzk721EuL2KMSSz3sVh5YAW5lnWNQxPA54xVafW70+KjpGvaQfJuIw1nqNuAyuQMssmPu+x71alsIZ7Vo73T45FJDGThznqNyHIIz7cVT1C41DbbfYrm0jtopN88M8Jfcp42q2Rt9faqhyvT+vIpxUX3t8vx/EXUrdb2W3mmuru0Nq6sIrUhDOAeEc4ztz2GKkuZ5jMgCEoqlmAbHX1x9QMUryyX1tEYHgmQNtYxMoR/x/nio7Zjc3jIjFBA22SQHK4HX8M0notehdN99P63/IdFq1vaGS0utjlAC0UWS+R0AQcnipjLGAJ1tnjAOUQj5snnkeoqpquv6LpV1bR6lchZrh/KhVU3Oc+pAJxWj9s0qQLp5WXau5BKvJibrk89qcotJPlepild87Tt5eW/3HPX/hjTZb241C4SWHULja73UUrRylR0GQcAe2K0JD5MAdCxlY5eQ9vRQOtXJLK+neFopElgDKCJv3RZR0PP61l22ja/HqF3dXetWHlzSBre3ACNCmeQGHLD61Tm5r3pbF88NI8yt/VlbfX/AIco3OoGbVLmwWG4e4SNWed8CMK3RVJ4LDqah+GVv9o8cSWyFpbPQLcgTPJueSWU5yffGasa4iKiwwauv2xmAVkh+QAcsqk8bsA884xXQfBuygh8PXV9HbLFJfXLStJ1aUDgMT374p15clB2+1Zf5v5q6+YudSUpJW5V97eit5JP79TvM9ySSeSadj5chjyOmMfSmjuScnPelX7xbOT/ACry2caPGtRniinREu3a5dPlgAyAPX/ZrMjnDXSrdmJoWGBLE/zBh2wKjt9N1G0ujLBqE17BIcu86ZCr/sIOFz79qtzG5hYvBOqxd4t21QPdTXtQUdGne56KhVheKXbql+u6tqmvnfbTghsUuR59vDNME8wecqFgB/EM9PrUEEmqNqzzTz2kunuOFaPLJ6Y/xplpPHcwYw0kAUcr91vY96i1KC11iykgE11YJuBby32ZI7ZPao0g7W3/AF6+p04fDVKl+Z6pLXt5Xvda/LXqbyIJcAu8cw7/AI9RVa3faJJHYiaMkZQcOPWqds+oNewrGytYRgAoyruHvuHJ/lWrPOd5jniaLPIPY+4rGcXBp3uerhantlKi422drp/d381/w5Bf2UGrDZv8uWVNq3EQGc46cjg15Df2S2V6Ekvp7ZvO8mGJtxuJH7ljjCp05z9B3r2LYro5Vi/vu2/l2zVPVbG11MRvfw5liIeK52glMevtXVha7pSutv62PPqqdHmpyWvR28vyel+q17nmF20GmXjtrM+n6v4hXZELWENIljH6sygKXPTAzjnPNepab4z0rSNMtLeB7Ky8xRt3j5uOPw5riPEHw9s9LkuPEEXn6msjectvCcLvP98jnaOuOp6Vy17pmqapHbX8qQJNIGRVuIxHtXpnaOg64rphy4ilFVN09VtbyX6+t7lqjCtaXNeL6932tfSy07fPU9Z1HxCL6Nrx7iOZfuRzSNwT32noMe1ZU/im3t4Ht5Z4muUQzeUsgDEfh2rh77T7bQmtNQuri01GSzVILaxWXoxGWduwGe3U5ptuFvNTl1NY7cX9urG6siPlI+709MHBFH1eml7qulfyt2+T0b00uXRuoLporLo328n0T2udHqHiex1CyuoNPvlluigATJAB44ViK0fhzfWng6TU/tV3FLqkpENzKW+VZevloT94rkZPrXmdvaW+y7t4IViuHQSRor7WBHO3J4xitLxJosuk6jopsLdplls0k85VLl5iCXLH13E9O2K1lSgoqEtObT9d/VW23sFSi6r9jzXjq9rbWtf1vdfM6eDxNZ3WpSJZzSss8zb55JCmMdW+npmtq91pUsm3yHCYDyeYDtHv7fSuLPhp7nw75P2WK11GRVP7xyXIH3sk+vH0xT9O8A3RlYGVXiEQUNBC7nPXPPU5pShRT5W7W/E2coy/eN29d+n6P8Dc1fxlauHsxLCsLp5S3MUgPzEc8jpWZoWjQa9ZQW2oXQuZLO4aMmCcy5zyDg/KMDt1NW38A3g0IWduty8huFnkmnt/K3ccqCfr61ctvAklpfw3mmziP9+WeIuB+7YFSoxwSATjmp56ME1DT+lb82YTq2SdOequ/wA1a99L6aM39N8UWOjiXStLJs7KGAZm6NISehbrknPArC8TeI0m0uKLRdSNjcST+XFcQAPhwOjc9D1z7Vl23w51I6dHY3V7HBbw3JlJR8iRe/JxycfhmpLPwtoNhdXVjeaoL26lxMLS125Vc/KxfnB5xwKiMaMnzat/n/WoKFODai0/xv0/4OvcreDfGtxEuprfXV5qH2WN5pLyTKlivAUJ/CCeBk55zVg+LrbUNHij8QQLJFc3Ii2RSEqBxht3sTjPsa3pofDekRutzPLpktx8sipA90CMfxsBgCsO88D6FrlzbXNjrljPZxDbJb6aSJZCOgO7hPyOOuKvmi17SUO2uqWnnrYUXRhLlTcX077f1sWtPv8AWdK1gNaa1p32OWTbaQ267BFGM5PA+Y+vJ6GvUrTW7PxPp/2bVTJbyRkeTeADDH+9j0/nXjNr4P1eLxZH/ovl6VMN8zwzBmjhXJW1jwSyg4ALYy2TnvVnT7DxfpttqeoX8a2t3eAOsk4ItrJVJ45yAMYA+lc9WNKslG+qW/z/AMvUHSVSXMtH3Xn9/wBxp6x8L9T8PXf9p+G/7Pm8tXkWSVD5T56qSG+Qnp6c1Yu5UuNWsYL2CO31G3gjlureIhjblyuF3dxk9O/0qfw19sbRYI31iHVZi5kZ4ZleEHOQCQeQPfFFnpMFpJq+rw3q3VxcKqXJaZRGir2BHA6fWq96m+WTuo6LSxDrc8ueclzWtp1+V7fcHiCC10m7TVGtTd6iyG3tbYMEiQH1H8X+etUbTwrqfxJkAu7BrLT4lURuSwjVu7AZ+fHOMisny/D1zq7eKru9Fw8O0pA5JitsH5cDPJOOB6nmtlPiYZtHe4sb2WC6kR9kDNhowv04xjoe9a+yq8toL3l36fIUJcluRJyel3ey/TTzPRvC/wAKPDvh8hlRr2dfmBuMEBv7xGOtct4j+DiXr/vb22NiX3FVjKO7c4U46rWZp3je7svC1pGl5JNq+pTeShjG+RmzyvtjvXSaFr+oaBp95datKzzMocCV/liXnJ+p4rgnSrwbblfp/SGvrkeaftE+lu/ppY8t1rwL4p0rWZL/AE2C6t7lpUkAB3ARqANmR94cD5asReOvF48Qro0+mWd1YJJiQXEO4NHnkkt90j0r1rSfiIuoaZb3E9nujuCVWPlScdx/jXQx6roiwb2t0llY5dpIVLsf9o9yPWidatD3ZL8n+d7fImpXdSMZV6HzTa27niOjfEDRY9Zng/4RaPS3WQiSeCEBGVepKngcehrvmmt/EejOfCt7pMNwT+6mjO91IPPykgN6Yz3rZ1nw94R8TafI8kCwBGMki2YCGQDkqyjhs/nXl+veBr/7LZ6n8OFni0zzjJOxG2VFXgjZ/EPoKtVac9ZJxa+a8tzL2dCukotxl/e/z0Og8PX2pJr9/oXiDUYLzWYNs8dlFFjy4iMl0bqVOR8pzj1Oaj0ybUdG1K9j1Qb9LuN0zLGpkSOUn5njz8wQgAsh+6RkcGuY1LxTfR6VBp/jBYpYGiWKZLgm3vNwfcojkX5lI+Vufl9a9HSOGTTLW/juXuNPGwP9oObizbG3LsOoz1PvzV1oOHvSStLtt8vP+rkRU8PL2VRLfR9Plv8A5mnFLugRopFZMBldDlT7j607c+N4AC5xgdjjvXK6kNS0jXIdTiLz6bNstL62jBYKOdlwgHTHRvUGup8/zjghSQMqa4ZRtZrYucE1dIztauJrKBLu1t3uUjIaaOJf3wXu6f3iO69xnHNJhZ5PPtmLQSbXV0HykHv7c1oygoVkXJAORjjBoghBhkDoVjyWKr8oJqub3bHHb2b5kVZF3xl0MkuwZbyV37SO/wDjirJuCkKSoQ7SnCZOFIx60kjCGEeSmGQ9uoz9KiSOBN8kggRD1DPyjeqjoQfT1paMHJ25p7GfLcaRrWkZttcvrET3Jt2u7clXtbhf+WcnHy5AP3hgin61e6ZBoxj1jUtNOnSHymM84RZcg5BPbNO1Lw/JLNd3uizS6Xe6jCiT3cAXcVU8ZB4JGMZ61W1qwF9YJZb1XylQyXr2kdxLK38W0P8AKp68469K1jyNrWy/L8P68ibt35NXpp6d/JevUtWlnZT6TbQ6F9iXTmiMSPbS5iRDkEqR16/nWVNrXh/wjZ2vhvT7WVIgo8qJPmZiSSZJGPqc9/wrb0WZdPsLe1s7drm3hQJvu3Bmfn7zbQAM9MCptb0Tw9rLW15dJBI6uJI08vLRScDj0P1zUxnFStNNrX7+7LlKXN+8Vl/Xz72PM7XSJfH0LXK2d5piQuVt76Q7ZmGfmCJ0UcfeYk+leg6Lo+keFNLitba3S4vIVDMsZLqgJ6sx6knrU95IY5E0+3dhbxkYX+J+Op9BXMR2lzfWV9pmr3dtJKtwJIZdKuWgmCA7h5pOQvTvwR+daSk63xOyXT+tx1KspR5Yu0X6Xe1/S+9kunzN2Q3d7PdXd0wLkbVji4jjHrj196zb2aCzguLu4kto3jXO6dwCD23En5RnjOK0tyiRngkVwAN8icomfpwT9K52eXRLlr6e3l0e5uZIwLhH/eSypnAzjIxxxilTTk/e20IjywXLTsr7d9vx+d/mclrD6n42h8Py+FdGuZHW5/0l2/eJbZOCW24BUgHB6EV9LRKkcSRwoqRRqFRFGFA9AB0rjfhVHCNEuLi3gkjSSfYhZdu6NRgbR6DpXa4OMAj3PtXDiZynVtfSOiXzb+/WxOJfLL2av0evey6CHkHIG7Hrz1pWwSSBgHvmkLZwxIx7DNEi89vl5wD1rE5j5/YXOuXllNpmrxjR7dm+aKZ1Esg7ns316VVj0SS+ubmHxFqtve2UzbkhycAeqsvP4VT1K9lWzIS6tbrw0yiLy44djbB2VkBrR0fUtDg0aS30h0sFiRitw+X2k9zxz64r2nTai5JNpdPV3d1ZWadrb+R7EKikk52u2lzJduqkm3fVqStd+mhu6dpsdvB9m0uKC3ih+UAnKhfXkk1DdxXEzyabqemy3NrJgrPHGWgI9C2QQayFj13UNMAvdGstQg2ZTUDdiFZx2+UEEGtTSbEWlsFmuNQVWwStxIJfKP8AdV+Mim00nKbu/wA/Pe6fqvuHTUa8o+xfL6a2tbZxurP/AIZ6O0sNqmjWyW+mQbUi4VHmPy59W5xVi106G5vJb1ri8Fyw/fItzmMH/cPH5VTvbDU7q6Uwa29pZAfNbx2SOZPXDHkE9M1Y0eKK2vTHb3Nv5sZxIJDuJHYH0qVPni5p+9rfe/z/AKZtVg8OuSaslbX8f+BaxrWyvbO6wyM0bH5gQNqnHU+9TqquAtzGQD90tzn8qrvKTKd0vzAYwBj3HNLGzBWJkDHqWJHH41hyXHUxkpaz1/NfM53UPD32KeW702+n0onlmUeZGx/3e2at6bNeNarLrCWl865InEHGO2c81rXC3ILRsgaTGUkwVVuP8iubbT/Ft6vk3j6TDZvIGzEz7goPUk/e+ldVOcqkeWclp3/R7mUp0pPnS133tfz6X+d2T3mi2Gs/Jc28gWRxIUUFQT65pbDw9a2N3dzRuFlnOG3DhEznaBj17nrTo7/7PcppUN2txqBy7BnCySD/AGQeNua0leUwlXTzyjbZI8h2Q9wdpzUyc4LTZ/1+ljqpOFa0OZKXRN/NL9bfMwNa8N6PdslzeTG3kiXAmKgADPp1NXLXUtLRUWPWbUtGdsYJIYA8HqOarS+H/DgkaQ2+rWd2WGVjuz5R9RtYHj8at2el6WvNpp4RoWJjlcb9p7/MffvWqnTcLNt/cv8AMmtRxEHacfm10/r1Hi0jiI8ucq6ksrGMEDPOeetVp7G9uEMmoarq0kf/ADzWd0Qj02x7QPzrUtNK1S8vvPbUJ5znCwrhIo+OjH7x/OuVtb/WR4gfSv7Rjur/AH7ry6jiDQWqA4CQKRksf77Djt60U222oy1S/roZVVzt3in9z/MmhTULaOSey8N6qWD7Uyu4uvqN7c/Tn3rUuE1JtBEkNsttr9022KK4IkFomeZXC8M+OidB39K0jCjXmYY55Zed87S528fxZ5P0Fcnq7eLr2bTdJtC2nXt3OUkmiVTA0XUSF87+Ofl71Mmqqt19Xe33v+uyIhWlGX8kVvZW01fRJ/0ky7YeHLO2kE161zd6m/DXl426X3OM7UX0A6DuanNjqUOqLIY7Gw0mKDzXuZVLTM38K8HAXocf41QuvEOm2eoweHLPU7vWLuNhHcSNHhC4PLufT2BPHU1Pb6mdRstRuPAWlPNfQuEa7vHaKyJHUruOGb2GOuT6HSbfxyd109Ntnstexy+3rRX7u6bfml83p2e5rrpV8Uibdd3l8wDvMixwBgemVJxtHvmuYn1a5lvrWxivBpOpyMY44b6y/dXJHpIh/LHWuhmPiCHRI52srfU7p3AkSKUIoDDkAt8pOfwq1arqUk0bXWl2k6wlWVDtZ4vVVbpkf7NZq6aldW/r+trHTHFTownHmUn0afn12v8AenbYowweM1KI/wDZ1zG+RK1i5iEZHTe7EdazrHW9es7qTS77R9btbubcpeCQTwxqRw+5iUc4J+UcdM+lQy+F9c1HXJrPXbm9+wYku7Q20xRD8wxG6+w7Dnk81pJBd3Mp0uy1eSwhjgIktra3K3Eq42713gbMH+IZ+tVeM0pabaq1l+H3bW/MdSvy6T5Wuj3d/mn/AJle30u/0m2msz/wj1xZXXySxNYC0aXsQzxcA++K6C2sreSG5sLvSRYW00HkiGNhJE4PRo2HQj3xWHpngdtJ1V7m3v757VgFeyuHEglUDC/MTlcEk+9by2k0cDQ73w2fLzIZI0borMARuwe1TUqRlGyf4W/BaGcY03L3XaS7NtPba+z9EkeP+J/CGpaHqaaVZRreWcgXdc3AwcKOFI/hA/M1l3Nva3c8tzJp9z9nASFYCpie6kAwEc5xFHxnaMsRgdeR73Dm4s/7N1O6NxOFAF40AGW6b9o4UE9B24ryrxB4X1qPUWvbrUhC1uWS1gWIbIlLdVHQE9S5yxPPWro1VP3Kjv8A16f8HU7lKpOKS007/pr/AMAo+G76Sz8VQT3E8TaoLQwqIYvLisWIwsaerYHJ7A8knONfU9VN74WIjnj1C7WdY5ZImHkuWP8Aq1B6tjP9K56/lm1fVriCyW/jMVv5KXTN80rZG/aPfJwSc464zVe28M6ro179otYZb7UIz5NnbW8LPHCxGPNkONvy5z3y3sK2nUjB3av56f1/WzLVPSMlv26/8N+PVtGzpnij7IfN1JjNFZRhCFIBLH7oHqAAB/wH3rqB46s5bucu3+jW/kxIQvJkYE4HqcA8+1cvP8PDbwLp8N55t1OVMkbhWkYD+EKMnJIzzgAe9aMHw1htIHOs6q1pNLIZYgITM6ErtyVU9QOmSMGoqThJqTj/AF8v+GKlOjLRStbZK79bLch0nxsfDekyqszy6pPcyy74j+73Z+6pPYdz69K9P8O/EO8eOD7XGZrowrO8YxvjQjgEV5daeBNIt5XWPVruS5yFglFmU+zx9W2gkgsQMZ9yeuKjfwPOLeQabrV0l3PIXluHiZXmixwm7J28j8fwFZz9nUXvw/z282l/V7mdaFCum2tfNNfpdHrPjHwd4d+KFvFILj7JrUDAs4+YsB1Rh/WuLt/Ek/gvx9b+G9Yjhltrm32yBG+QLgjBPcnBrldOt/F3he1juLCLzJY3UyCGQPJJzhY/y5Le9d5rPiXwv4mttOtvG9rHonitog9vdMu9UbPGWHUHHOen4ViqDj/C95O3qv68r2OepCWH/dzd6Xpqv6+fex0sNlNp+qX1u9/9rt5dk1hE4ClIdv3c/wAWf0xWjA0U8SPE4+bBOOO1efeO573TfDvg7WrdhHcaVd/Ybm4YErErHKFz/dYblJ/2h7V20Msc486NhhzuRozgBj/Q1jVheKlf+lp+O5z0pOLcX3t/wfmaUMkgk2Afe5K9m9x6GmFmacTAbrUYDKvO33x/SooLkSzN5bqt5bkNMiHlFP3X9gcGpJFhkjlnRZlYECYAkbvesNtGTOCTva5S0jVjca9rNlJE9vdWEnlTxyAESxt/q5UPdWGeex4NZdt4gxq7aRr9hcWbRysbe/jTzLd06qd/8JxwQe9X9Y0iLV3tLuOZbfWrECSwvh/y1TPMMn95T0wa0Zbhx9n3Qtb3TfIVkPyPzyo/+vWqcF03/Axttfpp/wAEyILlpb+8/sPXNOv9OkCyBYZQ80DYwxKg8Z7e9aen6okkEscMEEyxOYzzuJI6g47+tQQ2emW15cT2ug20F3glpLdQGIP8LnqBnn0qzLLKkRaIpax7duIflyfUmlNxexCbdlJdPT9WOM1jOPJltmsXAyJ/MOAe2VPaqwETFmFxCSBnIzyKw9X13xDdRzWsOj3aTIQItTheCWN1H8TRuQT7r1q3pcmuzMw12W0lsgm5JIYjE8jd8oPlC/jV+x5VdyXpe7/X8Wg9pNXlFNJd/wDg6l1Zl+2i6mbY8mcKRyFA5JPauYtrvS/EFpr8Xh2wjvLu7IW6kuImhiul+6DuHVRgg7cc1o3dxo+ql9N1Ge1uGkQzSWgkzIVBHBC8jt1rRuJXhsQTGLayjUBIQNiBewx2pxfIttfw/wCCVyRlpF6Wt/T/AEKNpBFBoVhpU6W00caGGWOBCsL5/gXd/CBxk8muat9LsL7XjZ+EtKhe/wBnlS3MKbIIoweUY9OPb9an8VeIDZpDZW/zXs5WKIqGYqSepVecV6j4D8JxeFNNkja7nvL25YPcTSHK57qg7Ln8airL2UNd3ql033f6Hcq8MPF1Zay1Xq/8kt+utrm7pdlHp2nW1nAqokSBcL0z3I+pq2DjqRkHGaB85weO1L94ryT1znpXmo8WU3NuT3Y05ByTge9IcEZ3D2J5xTnIEhOMA+ppAwyMZPOcY70C9T5g1Lw9PfSf2hqcd7oNvIvlyfYblTEg9HYHH1xXSaJ4b0eHQ47SxV3tJF/eTqMGY/mc1iaNaW/iW5u5NUtonxmNYYpGkt4QOgDZ2knrxmq8ulW/h/WLVLjWLiX58wQNvEca9WyV6Djivci4xboVLx5tVu11dtXfz7b9tfRdKtKPtqbu6fyd0krp23VrNu/Rp9tnxRp+gQWunaVfCby3P7gICrRqO5fOF/U9MVQ8NS3FvqTpJdxagXby1tr2Uwm3i/vKj/e/Cn61400e7SNY7ZtR0gTBZ5p0KwRydgAeSfp9avaJDJqs8+qaxELl4JP9DWW0Mewdgp7jHTPrToOceaU9U73106W01118rrW62Mayc4RgnyytZO1mn7y0atpde8vsySbUtjo7zZpl2jQTo8cjYWOQgtu9gO1ZfiE2NuyatHZXT3wYIUsId0pHct2IFaMn9jzapHe3WmQDUo0yryYBUfyq8k8pbzEuJo2bnjCjHoMCudS5Gpdevmr/AOR7sVXxMPZ1ddEr3V9utrrzTZhXs15aazaTR/2hfWlwohOn29hhoWOP3ksnY8+/4YrR1KzujC0OmeSuoxneqSMWVh/dJ/qKcWurWG4l1TUIjEwLBkUoQn909cmuW8RWc8+jQjRLrWJITJvEFlON0wPclvugemP8a2i00k9rrX1fW/b8vQ8mFKrhqt4S961mr720vouqsumuu5t6PHqNtdSi/wBLFqZjvYi4M8TNj+EN9z6Vtx2VwWAzBDDngySbRj1AUZJrlrHWk/faLb6k5v4gENxeqIzu/wBn+/jpVi60O403yL6YXGu6jAd11d3F8LW2hTHCnkKT+la1Ic0/edk9rdez1e3zJw2LjZxaXMt03rH77PXpfc07jK6uqHS7Qrnal4kyM6jHJZeq/TJNNg0lNIu7y+0XTZpdWuRiRLXO6QnpuycL15NN0seJtWW1lb7Hpdlu3Ktu4mYrnjDYC4x35rQ03VrHVBc2Gk6kLmKCXy7g20b7XfvmRsF/qOKxnF09Fa6Wtr7efT7inWhOyeqdt9Vpqtl81+DOY0LVta1S8uor+5guJbZ9j/ZrMzRWz/3TKzhWfHUDIre1vRY9d0Z9Ou7ibfnc0+VjRSO5APIFaNpHa6fZLZ6dDHHbx52rGgC5J5xg9c/jVKQB0ZXUZHVWG/PtjoTSq1oze3Lbt3O3D4Svd1aMr9r9jmfDd7oz282g6Q19f2doStzqBlKR3E2eVXuw4OT0471q6JFNY311G1pptjpca7YUs3PnMx/ikI4xj15rO/tZ9OvYTLJqmnR3DsIdOSxjlU44LFoxkA5zzzVeLxDrEWo3J8Rtb6dpMILRzJbAAAcfOxyfp1Oa1cnO3PNNtO+7u+vez+4zjSqw5vZwdo2ers19/LpdWej07o7ARL5ioscxJIbbtyfz96j1e2trlrc3Qw8UivCFJUoQf4SOe341jWsOn+JbGDVLLXtShtFkIQ28nlee4wDk9wP61Jr/AIkg8Pxo2q3riOVsIShlwQOmR0BrJ0uWSV7SvttqbPFV6kdIqUUtXv69LW9GX47C3fUJr2GKO181ju2oAzjpj9O9Wf8AXoqXTJHEpPlQrICqoCckg9T05x3rzS28Q6x4s1uHS9CgvLGyT99LexRN56rzwQTtwemDj8a7PWrS5kllB1R4rUESRNHH5ckJUZYlxwRgHggg4qvZxcV73fvpZ2MpV6lGv78bWS13f37bfNa6d6Xi3S7q/WOZNc2zROA1rbTKkQXupbO7PTjAHtUs6+IrOxtBpkNtdOBlmnuhHsXupJ6+x7VBpFpoGvaRIU0uW5triVt1xAwLSN0MzFTtU98EZ7VLb6RHpfhy4FnBqNxcNuEdnNN8rlTgYJHyg9cZ471tKThHlk9n5W/O/wCAqdejOFoq/NdO8eny3truR3mBe2WseKUdNTiZhZjS5XkCIQMrIf4mJ/Ct3TdSN9Z3N/ZjURIv7tmniEUjhOQgbbllyfXFcN4GQ3DaoZdOhtdQjxkQXx6E4xu34JHOeK6eDUrbSfEJ05NYeeZIFmltp2LMkRGchjkYxnocCnWglGyTvv5d9jOlBc7pwlG66O/3arz097XoUtAn1nW9Hlm1e4exudQ3KoTEQtIwxX933BOOpye9b72rW9lDDaOyNDhWe5/fBiON27I5P1qjqeuaSJ9OFjONTDSeTb28BD5OckMw4AGcknoKsjUVOqaVpaXGmGabdNI3nEybBzmNAOhwfmJAwK5/3kn/AF0Xb0O6osNhqcXOKUnd+e+1/wCvvLUnnG2RJ2t1JGC4yobHp3z7VTu9Y03SrGKXUr6CC0DiJWliYgMeBnrz7mtvToNX1NZjb6VKli0hKSmQATKOjc+tZmpwXtoNLsr8aU8ctwTepdWTuZefkWEElcjuzH3ArNWbtp/XomYVMT7Om4QWvS1tPW7/AMvUtSXIsokWOGAsdxJghAbjqen061HNe+aYY3nvXLjL+dKVQj02JgGsvQ7GG31jXdQttVnvr2e58u4Ei7PJZBjA6Arg44HOK3reCM3/AJl/N5jHIWKKQFeudxGM5pv3JWQpKlOnzzs3qrf8A56GS5s4pJorK2t4RKwkt7eNVeZAcK3r74rPsJtUnsNWGmxWRu7edTp885/1iN98uE5BXjb0685rs/EOk2lv5bhpTFKAsbLjJJOdvtgDqBWHrMo0uO3N1dDTzdTKiTSR4AOeAzDuffritIVPaaJasiT5qPOtF81f/Pz7GYtisktpc6pd2k9zbMTFDzAkJcEOykEsC3bPfmrZtLqO1VLSKJbOILs3yGbK45Ukndn3qvrRmjjhfSp9MuYhgeYsoWWVs8BWzhyDkY571SsYYLrVft9v50HiC2tcPpk8hR5V53FAeG79BW6i5Lmv/XppZefQHUlFXdnHRX1a11Wqel+lwli06adYDGlndfea5juWjiK57Zycj0zzWle+AdH1WJIfEGqyXlkx3JPaRfvI2HpIcgD145qlqHiLRbBZJNe0a+027P3I7m3cRtzwflzn86uW/iXR7e+tbGK/jtLmWITrbS7kjRcZJbjPbheKzrRqyjytO33lU1DR05NPz9Ol7/kdLoenLGbm3fXIJNGG2KVbuzUxzw9DGwJySFABY9Sc+lVtSv8AR/D8SXNleRt4eC/u+SWgXJC577OwJ9KzFGs6vpd7P4c0B7+Tc073E4aNbpsYCxkn5unXjtXoGkeC9PXwtc6VqyG8j1GLdd+aAHQtzsUjoEPTHeuKpVjF3nr5K3+W5lWg8N706mr3Vr3873WvqrmJ9n099UtdRjBF9FCUZ4mx50bc4YfxD+IA9D0q4bg2MztG4liccAj76/3T6GsePw7caD4et9Cn0g3djp8bRxX0LlpChYkMe+eeV6ccUyz1C3ggEEV3BeRqvK5O9B6HPOaGudXWpnBNfFqv62/4JQ8QPB4f1CTVYJNRPh68Gb2EwtMlvIeN4K/NEfcAq3sai0+w1G3xe2niB9a0S5IMtperukjTHyuj4BD+xGD35qxcTXOp6gf+Eb8UtY6jZcyxxEOWTjKyRH+YrYvLsyWq6gqyyz+WWliiX95JgcAL3zjFdEpyjFR6vf8ATdfjcySp3u7abd1+H/BKF4G1/R7ebTPEc9kpDI1xDbpIZF6bWz9119jVjQLN9Mtmtri/vtWBIcSXYA5/2fQe1YfhzX7K7u76fRLa90+QuJblJLfydzkYJdDkZ960Jdb1e41tYYtJ+1WhGDfNdoNuev7vGaUlLWlslrrb8+v9aBVpTiuZLf7/AMtEarOgkRmcRQkliFXLE9MVz0V94mbUUe7utCiscss1tvkLyJ2II43Y9eKuXssRSWKeSeN/MwWjZWLLjrjBI+lZaXGrX+pra+G7DTPs8ZAlkdGLITjG52+Vevbn2pwhaLenqzmjNVJL3XJ+W3q9V/XQ2bOCwNxPfadZpHfSFRLMFH73n1PPTseK43xBa614n8aW2l6HdPJIgJubmOXMdshPOB0L4zya7jQvCl94l08TarrWoRQGR45bdbY20u5Thh838PoccjpXdeG/DuleHbL7Lo9pHao2dxX5mc9cljya554mNJS9lK8npft9+/lpYtVEpqVXVJaR1f3vSy66Xb8lvT8F+ENP8I2c9vp7z3HnSGR57khpTwON3XHtXQkYkAzjPUChgOg47nFKR82QetcEm5PmbuznlJz1kC5L9f60DlBz93j0o65xux1ppzv5JwaQl5DjjGCoGOgJppI7YUE9+wpGB64we+SM0p5x1wMjcRk0DR4BKmueG7Py7nR7d7BG2wx2UwUoCedxYYFQzeK7USbtKu7ZYIgBfNeIRtH91cDDk+2a9U8Q+HbbVNOlt3ywA3cnIrzj+w0vQIrxfsmm2mVSCVtw6cyEnp7Cu+lVjNS9pFNr8rW13v8ALXXse88b9Yipp2WqaS030tpdPtrbTZ7GnpcdnqVjayQWOnGyD+ZCsdqmAx/j6YH1xmtTUbETxupleRW5wTwcetYvhe+0mLSpIbDUbeWytGIyittQDP3ieD36cVNH4jsLme2is7ozG5jaRDErMAB1boAB71tUoyU2qasv+B+dkc+HxUVHmkldN9NNHrvdrXftfUwfEfhqbWWMSX7WCOgjmGNwMYIO0Dtz6Vcu9dubTUYNPktobbSIU2tPdn/XnssbZ+97datw+IdOnu3tLn5bgIZCJRkIo6szD5R9M1Skbw54iuYLWea0vn2mWHYzb1X1HHHStaSqRSjOLlHfvv1Xpa66F4qeHnLn5uSaVlurbbbP+Vd7Ws9jYni1Szs5ZbO3F3ald0dvGwMje+TxjH41Rln1afyJ10yOO1K/MhcidG9CoGP/ANVUNZ0u+09ry/immvEuSsSfZt5ltY+5UA49Oev51aMljrdtNo9trUwu1TyZpQ/lzHjkFTge1C5eTmp699NVpr16XWumvUzdatKqlimo366pPa3Te99NbreOqY3w1baQ1zc3Tmxn8QMrGWUxFWVc9gx2j3IqTWF0WHTLK48QTx30dvIZIowxnV5D0JRflyBwB05qtqXhm5XQl0XR9Tt4Y5I/KnlubUSM6/UDv7Ypuk+ED4bhu5LFru5LxZNsxEEbY6BXOQg7knniiU4JyVNtW200+7S179L67lTpVabjOa0b111s7K3M29td0lyrRoet1aeI8anb6pf6e8JAnZ5QsVuPRwTtU/nU9teXmrpBHpd3Zf8ACOMDFItwjxTzgH5mQjBIPtgGsXVPB0d9awy29lbQ6spW5mib/SYYhz/Bny3PvzTLzS9MuvEVhp+oQavrWqSRby0YEH2Vew2Jwg7jJ44rpThJ2106aPpd2vuu2q+8458qu4axave1nvpzctmnqu/o07GhZeKUGtfY5dGtrHRYHa2huJJ9xQoM5fGFH0/U1v2viLS7vWY9JtNRE1+6GQpbQlgi4yMsRhcj8a5+7sdTi0jULrULK723R8uLTbW4hDWq95XnxgcDuM88kVV1DV5rDw3ZxQav9mgyGl1PTgJIoh0VJJCN00p9FGO/Ss+SnOMe6snru2r39fwfS7NZYicJuNNtJ3aTu7W3t1t0aSvdX2dzt57iBC/ktLbt90+f0bPb6e9YYbRGuXQHShLcuwZmlVlnKn5sg8EKeM4wKqPrMWkSiy8ceI7K9heIOkahvtb7vuh+Pkz2GKi8XxaXpV5oFudO0gCSYxCK6R5JXDYBRQnLH5sndxz+NQsPFNRd2paaXs/vXfc6oZu+X3knKKb6PpdWakvlfU6Oy1TSrjU7LS7a9tL27dGaO1tGDIgUc/cyB+OKyNV8Q+G555LLWhBpt5EwXyLxiRJ3BBKipbfQIvDup3SW94miaPchjNDAyWrBUXcW38u3fqcAZx2qDSdU1q7t18rRLPXfD8kjJYShRJ+7z1YzfNt68nBYg4AFJUac0tN7bu3Xva1+11rvciWZYpVfcktP5f1i2r762d15rU2V1pZn+yx3MTeYAxit1aSV17EqvOOnXFLqSahdW8Mmh6hHaTwncyzRYWT/AGZFxkfhWN4jttJs/Eloi+HWPiDVEaNZ7CVoikfAaR3ztXABwcZ/SugAyXimVVC/JbNHIfNZdm0kseh5/rWTlHkUob+qf9ejX3nRS56lZqrCPK10Vv666qWnZEcGjWjT2EiyRWMkTM8sNqrLDK7Y3HAxuOR1OaTxPBcPLHBZaz/Zl6xK74oVlcjGcHdwvb61zOh6La65p8Et5p+pRQxyPEH1KZzNKF6ODkcdhgV0F1YroenWlro+mWzGYhd13MzeUp5Zj1eRj0CjueeBV3SajGXpta33vTysKth6XOqlr73S1d9d7pXfXXXY5qPwck8V1D4lfTnYFTHPpKBZZBznzuMEnI9hV2b+ytF8P3WnK0Oq3tvbOkVvcyKZrhF+YxhlOcAnGPaulkgaxhA+zzJvb5mKYKtjPI/pWXc22j2Ai1WTTtKjuy+2G7kTapkc8/KMlj3JxmmpuovZy1X4fda33bnNiIqMFVpNqzfTX773X/gTt02OfhXXrCe0FjYTafZ3Fi8sWl2lqot9Pm25L3DnhmIDEZOeR6YOv4T1C417wudWuCI1v2WNY1QAokfytzjIUkdMmsvwal/N4n1d7fSLa18Plme9v7aSRkuJcfKoLkgnJ+6o4zz0rU8SaxBd+G5tP0yZrC5No0sMAj8lo41bBcjsM89uDnFU4yXuq1l2Wq12/rpY5acrPWOra1buredrq776vf0Pc7KRpbSBz0KD6dK5P4qmKx8Jy6zJHI8umHzlSNiN+Rt59eoqf4aX9xfeDtNW9uUub2KELNMjbg5x1yODVrx9J5Xg/UwI/Md4xGqD+IkivKcXSrcvZmFK/tkpLr/Wp41rPjGex0vT1tdNgk16/mEEVsT8wfPQgdgW/E1tXatbWKl7lg7SrC1ytuZV80naxwP4c8AmuU8PWFxq1rZavqcX9gaxbtJAlw8fzRDn94obhSAT8x6ZyO1dxoGq6fIILfS5pJtK04geb1SV/Uv3xj6ZNepJK3NBaeX+f6feezUxEKMvZ0+3Xdd+/wDT6EN54a8YXXiiya0OmxadFCPKhvpGZmYDl2C9z1A6VpeIPDl7Lpt1ba3D9psp1AnjAMiZyMEHOeDg+tegR3MGoCC4iliMsZGcOM4PrVbUdfsLYSRB1urgDBhi559GPQVw+3qz91r8Dy541ScHbVabvv62+5I8C8RaPaX2rwaNOrWWjaTDHcvqcTmFIzg/IkeMdTlu+Qa0IdZ0KQaWfEEkeootyUtNTS3kiZZSOqdCWPHAyOldm2q2WjtNHMj3uoXTYSOOLiMMeSXPAX39q4W4mvrrxX4R0G3A1LV5tTN/cSzSbookSQMzr2VVUYGOvPqK6p1Hyc01ttr/AMBtevXserh5ycZRivctq2nv5PrrpbbXqdbLoHivUjeHQrSO1s3bMR1iRkU44DbQDJ0ycnBJro/D/wAM9Ks54r/XtmrauuxnmaLagdeflHUjP970rvHIaVmA4JJ92pCBjjPHp1FebUryqLl6f113PLePrP4XbS2n3dNPwFbOMZ5AxycAelKd2DnGcdu1RkjcCGJycA5py+42j19ayOO9xegAAxkc5NYur+GNG1WXzb3T4jcjpNHmN/8AvoYJraLA56njuKRsBlHGTwRQm07opTlB3izzA/B+xj8TjW4Nf1M3OCo89I3YAjGN4CkgDjnNQ3HhvxvpWspJavp2t6OSQ0Kk29xGMe/DD6E/hXqrDONuSw/D8KrvdQRkbp0ALYHOST6fWulYqrrrf1Sf9fI1VZu0ZK6XTb8rHnE2o6upKLot9AwAZ1uYSwPsGAI61i6LdeNNWmNvP4UfSlbLLLGw+YZwNxIG0fzr2SS5jjVWMqkEgAJzgmsTWNEuLzWrPULbV72CG0R82ERAhnc5AZ+5x6VSxTirKKXyv+pK9le7jf1k7fct/T7+5ylj4Hvr2ZRq9+ltCv7x47YF5H5+6XPAH05rudL0ew0yz+yWVqqQE7iDyzH1Y9SfersDS+TEZRiQrhhngtjk08nJwM8c/WsZ1Z1PiZVTESkuRaLshxy3U7sc5yfypuCMjOD270McjofrQwGAqgj61kjCW4DnHFIOAcdxzmlBJkPQ++en4UijI5PBzyaA7A6gDPTHXuKYvyjrhfSnsPmIXGAeue/rSBsqMYODwc5oKS1AYb+HrxkjkfWkAJPykEg/5FBPIAJJ74Hc0E5AJ9celAHL65qDW1u6I0cKlSzzyuQEUdcKASxxXiuvQeJ/Fl5ZWnhzSL2z0okzJJON81yM482UHCRr6Iea9F1PxVYRT3uo3DrHbWYx+9Unk9OMck+lavh/X9S1jTorny1j8/lECFWx2yDXbShKmlVttbq991t5dDWEp0k6aWj0vpbZX/O23VbHF6loOtaHZWWmadDb6lEqmW6ku9qqZD2CqAuPzruPDnhdGWO41bEkpAPkqcIvtxjIB7YA9ql8URTX3h6+tWRorry8xyAZBI57VJ8OdUXVfDFtJ5vmTQ/upWAx8y8d+3FU6tSpTnJ7p726O9vktiKlV06NKMFZS5ot/wB5WkvL3tXppozo4be3jh8mO3hWP+6Ixj8RVO/8P6beo3mWcKSOuDJEoRsfUCtFCCuTn29MVIB0PpnA9K4NndbhCtUjrGT+88x1DT28PXP2cXSqrnEEsjbd3+znuaxdf8Pvd5u9JFtDq8REi3MijOO65xznpk1r/Hv7La6Lpt/IQb6G4AtlKNJl/ZAfmI46nFcxZeL7WArpl9dSpqtzCA0iWrFUlYccdMjOcV3YZTrQ9rSb54trz2T/AOHX+Z76xE5Qj7RLknHXTTSVmnbps153tsMudf1vS7ZJPFumwWscp2Riyk3v7vJzgLg/ie3FTIo1+4t9C8RtbESnMVlb3zyhl6hpQgAH+6TVvyDb6CDc/bdaEMZLOYgGnbPGFHGB+NV/h9qVvBrQvI9QtbPTJ2xNYzQFJVlOBgsfXHbrXfTanzJRV1s1ddNNNbNu/Sz20OWs61DDKtzW7p+9b0k323TbdtVs0dtc+AIdT0dNOvhO1uhyoEpjCkfdwF9O1RXXgmSzsZlt4FWU2/2Zr6Gcrc7P949/evRoZopkEsUgeMjhlYEGqWu3sdjYSSSMMkYwT0ryvrFZO13v+JxUsZKtJWjFp+XS97el+mx4VrH2/S9Qs9Kh1uUi+cRxpdWCTIiDgRlsjcxPJPertvpV3pt5JLpmorNqCECGzMKx20ZP91R0yerc1DeeJV1LxN9h0XSrfVL62cSPcPcokVsTxhc5LNjsKn+3av8A8JbpFiujgSurT3sq5YQoM43SYCgcZx1JNelzVOWPM0m79teuvXp16npwpYak5OG0bNx6X62s10a216aktgNL1nWL5pbMTaxZSot1cGECM3AH8LHl8HjJ9K5vRriyg8Sas+js6SPIFutYvJCW85m/1MC4+8Rnp174FdtqGpGy86aR2e3iR3dVTp67R3PQVh6YumeOtjPaanCbArNDGYzbQM5xySANzccms6DjCXO4+7bW3n1t12ub4mM3RUHO6e11dK2ybS03s9rpsq+MLyPQtQtb2HRrS71C4jW0N5fIZgkRPQKTtznqcfnmodQsp/F2oLJdRXtppFu4xdTSGHzSOCYoUG4jjjkD6VsXb+IbvV5pE0+Szsok/dpMkU+4r3UAgqzdgeOa6DRTJ9l8zWvMh1GVf+QfFKsrRAngyyL8q8fwitadV0YqSs5d09Vf07fd3IrKhy2pprS1rXTt66bFe2hkgyytcC0cBUjlG+ZvQ4yQgPXkmub1ix8XeIk1mFbfSbLTJoTBCZJfmckjnI+bJHXgAe9dheN5lrPZR3csU0yMqmAbHjB7g/3h1z71z9hp1vpccAfUDJsk+V7+43M8h4yCcAnsAKxUr37vTa5dKm6lLmdo21TbfTulbR+vyMe50ObRbjTG0+0n1TWVtlhea6vmW1sVUcnceWYsegB46Y4rZubC6TSPOudU1S11CGEy3SaVMHeQ4OI41dd+Tng/KMnvirviaW2tdGuxqOqtpiSBYxdRShZQ7HgIMZJOMcDpmuc8C6ZpRluvENlLqtzcu7Wiy6rJsLmNRux9ePmPQdutbKtOom5t36f1e9r7+p5dSjGjanCS5dmtbfNWcVpezfYseFLK70mzZdTmm0yxuGQxw3V6Lm6lmP8AfbhV9Ao+YnnNWbDV7a8vPst7bXTXqLLE8JgLR24OcvJLgKp2+hOM9c1nX3jPRzdH+1VuLdI22xTvEGjlYZ/1I67Rz8/H61e0/WtL8ZWrWkN5HqNjGFEttK77FOcruBxkkj9K0kpyTnVhddWv6fzu7m0cPTSUaNXlfa3L03V1Zr0svPU1LaKOGwS002yt3s7O2zaWdrJhRnO0ZPC7jyXO41QtIL2RFfxFotlHdzW7wyQpJuUK/AUuc5yBg4qTU7CS/axe1u5tOe2dpEWIjZIcAbXU9gBwPeop7e2t7QXviTU9SN9BZPbNdZEcMAdiTIka8bxnaDz0zXMuRrT7ra/n/XY7akK1JcrV9OjaXm9F/n6or2Fxq/hPV77W4by71ceVHDHotnB8qjoojA4VFAPOPrXSav4nuNeKWFybK1dEE8litztkZiQFV3x8i7uDgZz0rihLp9x4Yh07RfEs1vdqzT2d6sm+e5RFYMpDYzkjH1FULfTvF+peHb46k+jedLFDN9qMqA7UYMRJtydwGWJPQ8dTWvJFStVvps2nt+K+Wj6JnjT9g6vPT5b2W0lvZa2fL9935pbnd3Tyapp8trq6W11DcZjkiWBo4mxwVXPLDOMMeTjPFU9PsTbXDWu9zZHKx2ojVI7ZV4GFHG3J78kkmud1vxBF4Q8SxyavPqV1oWps7QSTnf8AZSMYCAHOw56Hke9bN3rH9lLca/qEZawfy5bKIKySRRkbXkm9SxPyr2AHrUOEm3yddOm/byf3HbhpUKdODnHmluldu76PVL8rr0LBkttGtbTTNMjlfUo8KqXU4MsiEnc3PMg644H6VB4b1S91Oxkh1Oa3luI5pSsdkvlJDEMbVLY5Yndzz2q5qazzww6jFZxcKEtyyD7QgZS2FJ5HB6Z707wZPLbXH2fTNPW5u5XKTTsp8iBgoIBI4O3qQO9RKb5dXr59/Xc7lTpqDrQjeUdrX0Vtnd2038jD0zVH8Va//Yvh6SW6lUFpnnQoLWMEbmYkc9QABnJr1XwX4NsfDM1xfGVr3V5wVlvHUKVjJB8tF/hXgZA6mtHw3ocOi2jgO1xe3DmW6unPzSuT+ijoAOgrWBUDPQg4Iz0rgrVVUdoqyPNxmZ1ay9nF+716X/r8fwAleSAM+x/nSnqATwR+PrQxAAZcBsYwKBgYwcN9etYnlrzDqvOAQeB2pRwCDk5/zmmkhgqdxyB0pXGScYPegWqFGW6HKn2ppOTgjGR165pcEbR3JzyM4pCSAflGT070CewpOBgOyOemO1VvslsyNH5UZz1LLyM9T9etWAxAIXPGMgUFvr1/OgFJrVaFGy021stxgDAk8sxzj6elXQ3AJGBnmhRk4IJxzS8scqeR1Ge1O9xylKUrydwyPlB5P1pCpOdxOB1Peg4O3j39fagn+8eQM/NSBK7swU5YbWyw4IHGKRx6cg8Yz1oQjd8owAe/FKdxT5Rz0z1xQPzEIJYdcY/CkJ5XJBwfTOKTJVMdV6/WkJAUN0/GgWmpJxgEHg/55pnJOSOvU4xim4KvgnAx1705hhiQdwzwfSjYa7Cpk5GTtB646D1ppABIHOeoNOGA/XocA+uajJIOWXqOT2oHseGaNoV+fDptfF6FZXn89hJOGI9ye3X613Oj6jbW/kxwPGAigBQei9M15hCz2mn2d1cTy3ayTeTumO53k6ktzwPzrC167n8NR32rNtmur1xAiAkIh65P8sV6tRJ1Wp7Pqtr6R281+R7cMJGrhYtS3bdtbJSd5Wv23SdtFY+hb/xDpdjEgvryGFpAfLV3Cl+OSPauQ8AeITe+JbqCwghj0ltx8xCBmT6fSvNNP0e11/RLvVLwytf/AGTCbn3JCi/wpnoSeppfh5rmn2ckcVtaTQXFvgPKHD72PpnGBWuHwkb1YJe8lrtbVuz/AA89TyKqpRwUpc+kpK2+kkk7O29722ta9z6azl+g29efSqmp31xbNbxWUEcs0rHJkbCqoHP1NU9C1UX8OChWRRgn14qhb64upeO7vSI43X+zYVd3bHzF/T6e9eYqMlNq22rOelUi4uUun57LbzMvWPAE/irX7XVPE2p3EMdsMQ2Vk2xQvpv7E9yBmuis/Bnh6zZTBpcAYcB3yzfiTXQLnDbuxxxxUhG1FY8joKz9rNJRvp/mdcsTWeqdtEtNNF+fXc5u88JW0sqz2lzPbSIAVw2VA6Yx6V53470bxEkxhubCzuNFkP72eE+XKB35APb/APXXtC8Ht7e3FNlVZYtrjcpGCD3p0686clKLvbv/AFdfI1WNk0o1dV0s2mvRr9bryPmXSfEWv/2hLa+FpksLSNvKjt9Sb7sY43Ljk8DJznrU3izxFDqukjTLvxRZXe2T/TJY4yFKDqiAZJJ9Rmuy+IngS1l1WH7LItsCjlSifMpYYPPpg/hUHg7wbp+lWAgtrW1N2OWuZI9z/gT0/CvWhjYVqSdSN7b7Xv62ba+d/U654CjRmsRR0UtrKz1uns4pNdGl8r6vjNP1FLG1WZNWsdFgmiKWWmaXYhpo4zwJJGb52fHcnk9+1a8Hh6/ZdEgsYdZk0lZvtNy93dlZSeSAynGRgfrxWnrmmAa1ZRadDZ295M58268r94B0yrckMO1amn6Hqz2kmn3+qnUbSRHE805ImaM8bVx0+ua0eItBTg7Pz62v2S/EweHo1FyNXVtbpXV1ut/Tdeljlba7u7rxRcXl/pcEVkkweZZ9ZEgt1UfKPLUgc5zs6Z65pyx6uL+71vVI7lrkF5dj6q1xb2QxkGSNcZIXGEX1rpz4e8PLHaJDoGnmS4ljt0MqbsBehY9T0/GpdL0m5sZNWS71BZHupHKCC1SJYBt6gA/M3I5PpUPFcsfd0aTXrt5/8AyWEhN+1cVZtbXXfa7l+V+1mcnF42W90O2iOtWA169fbGYrR/Ki3Hps4yQvJycAkZrQ1DX7nQbWSW8tvtWkxqirLaRj7TdTY+Zio+QRjB5zwMDk0/xVoml6boMuoLaR3d5HbfZGuL5TLJLu+VRwQFUsecDOOKt2TtZaVptmWC6jHCsStboI4E5HCrknAzxmpk/aJumktdt+/krfJhQlTp1VCbdu66O66ty5le696P6D/Ek9hdeFDLrr3Npp96kbPbSHy5m3HIXHBB4zXJWvi1Wu9LjfSrS10hJMRvqEmPLC/KjRqfvPxyRnqK6S88N6YdcGqa7E+p3czDyVlcmOFU6ELnBY981DoyN4pSTWtRhsX0WRdun2rW4aaMBsZd/+Ak7RxyPSnCVOKvbTrd/glrr5v70epGclT5Je9JLdJbba/DfW10vkmiPx3pV7Fq2j6zplrDLeiQQSNFF504DcBkDfKuASc4qveJcRWVlDqEljfappwkSXUC+zT9P38fNnAmmIx9M8476t1rNwPF0FhsD2bx7RmQowfGcnHUY7VFrcY1XxBpOkfbbi0WMNdLHBDH5e1COBuBwcnO7FEJVKcYqbutWu6XbvZa6efXYVenFtStaVlu3Z3vba9r3t8ls9TnfEws/EWkXdvaTStZWI+zXMltYqZpJcjb5IOP3Y+bOMZzXSeB4ptM09raTTbGxtIJQkdvCB5uMfemP/AD0OckZ4+lc1L44skt9R0nSrC4gs7RZIvPkm3TO4cIWJ9fmzknNatpa32iy2en6WLOHSXAuXDbnmmlbAaR2PU9BVzwzhdSVr7X18+mzf/AvZIqFVV5KELytur2SX4Xt2d9r2vdu3HJfWMOdfm/tDz9Q8mye0tS8jAjo6gfKBjGanvJdZTWLq3h0K0OkxEkSPK0kk21eQqg4HPHNa8MjWyEQbkDnkByAAeDx3rnPFnh0LPqniFbu6Mcdg8VzarMYxMAoCAEZ2YIB4HNckK3vJVFe+m36aI66uHlBNYeTUd0uZq2vRrX73bsR2Om6brrWl/d6Rd2E6qwa0I2IyHIIJA4UjggYPNXdc0a8g0mPTfBaWunM0iIylQI0jcnew3Z6Dnuam0G1F94QsYr53uleJZZvPbcZGJzgkYyBwB9OasSXNzZ2NjBe3Rlvb24ZUuEiACc8ArkcAEAfStZSk58tOVrPRdPle/wBz+RyVZKNPmrxTT0b3fleyV/Xch8PabH9litdXDTyWsrAS6haxtM+Cfn3HIAPGD14Fa9ommw2q2VnaRzaf55ldJw0rSSMc5BbJOT0zwKj1i6t7KBTKJW3yBDtAJcgY5NXvDenXeoai9xMbXYm1owQxKhhg/jt4FYzk3epJWv8Aj/XmcaoUpUnOEnePys/K1reisi5B4Um1jUYb/U7lvJXB8gDPTPyjngZ4J9q622srW2sYrW0hWG2jPyxxKFCn1+tWxGEVVACoAAFXgAcYFAXBBwDuGa4ZTc3qefOvOSUb6LoIRg444449KGBLDPGfShRxxxk5pVyE4I4ODkVBkNyQxOeT3J6U9fUkAZ4OMUwHK/LxjinshYjJ4PBoC4mCcnvn7v8AjS8kjdkc9OlICGwMdelPQcN9T+NILDBjcOBkDk54peSqL3PrSKylsMDnOOKTjKk5wORTQraaAPvdQPXHWlKkg5K9cjA/Q0jHBOScH+tJHkMAp5bOSaAXYXdkjC8DoPSm4PI+83qe1OH3sD8M00Mxk8vcee9CFoIBvGCOevpTmYbsMFPGc0h4bd6Z7fhTVyQCmAOevegd7IdyoBJG0Zx70i8sG2njgY4pFGVDAAA8/wCRTgCWZfwoAbxyWH1pFQZ5ww45B5pQuXCn73OKAOuAMA8cdDRcaQHhVJyuR1zRjPXGB0IpqNu46heOaFOUZn5cE7T0xRqNCheTgDI6kd6U8/eA44z2x3pCM8kDIpFfeW3DnPrQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pancreatic ductal adenocarcinoma invading perineurally at the retroperitoneal resection margin (right) Hematoxylin and Eosin-stained section.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel S Longnecker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30838=[""].join("\n");
var outline_f30_7_30838=null;
var title_f30_7_30839="Continent colon pouch";
var content_f30_7_30839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Continent colon pouch for pelvic exenteration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30839=[""].join("\n");
var outline_f30_7_30839=null;
var title_f30_7_30840="Early repolarization 12 lead ECG";
var content_f30_7_30840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Early repolarization 12 lead ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early repolarization manifest as inferior J-point slurring and lateral J-point notching, each &gt;1 mm in two contiguous leads.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30840=[""].join("\n");
var outline_f30_7_30840=null;
var title_f30_7_30841="Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient";
var content_f30_7_30841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/7/30841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/7/30841/contributors\">",
"     Lisa Strate, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/7/30841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/7/30841/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/7/30841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/7/30841/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/7/30841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower gastrointestinal (GI) bleeding refers to blood loss of recent onset originating from a site distal to the ligament of Treitz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/1\">",
"     1",
"    </a>",
"    ]. The causes of lower GI bleeding may be grouped into several categories: anatomic (diverticulosis), vascular (angiodysplasia, ischemic, radiation-induced), inflammatory (infectious, inflammatory bowel disease), and neoplastic. In addition, lower GI bleeding can occur after therapeutic interventions such as polypectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7272?source=see_link\">",
"     \"Etiology of lower gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link\">",
"     \"Bleeding after colonic polypectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of lower GI bleeding is variable, but overall mortality is low (about 4 percent in one large series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/2\">",
"     2",
"    </a>",
"    ]. Mortality was more likely in older adults, those with intestinal ischemia, and those with comorbid illnesses.",
"   </p>",
"   <p>",
"    This topic will review the approach to resuscitation and diagnosis in patients with lower GI bleeding, with a focus on bleeding from colonic sources. The etiology of lower GI bleeding, the treatment of specific causes of bleeding, as well as approaches to patients with upper GI bleeding, minimal rectal bleeding, obscure GI bleeding, and occult GI bleeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38679?source=see_link\">",
"     \"Colonic diverticular bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link\">",
"     \"Bleeding after colonic polypectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7272?source=see_link\">",
"     \"Etiology of lower gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8184?source=see_link\">",
"     \"Approach to minimal bright red bleeding per rectum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11336?source=see_link\">",
"     \"Evaluation of occult gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with lower GI bleeding typically complains of hematochezia (passage of maroon or bright red blood or blood clots per rectum). Blood originating from the left colon tends to be bright red in color, whereas bleeding from the right side of the colon usually appears dark or maroon-colored and may be mixed with stool. This is different from the clinical presentation of upper GI bleeding, which includes hematemesis (vomiting of blood- or coffee ground-like material)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    melena (black, tarry stools). However, rapid transit of blood from the right side of the colon or massive upper GI bleeding can appear red, and bleeding from the cecum rarely presents with melena. Thus, although helpful, the distinctions based upon stool color are not absolute, and it is important to exclude upper GI bleeding in patients with massive hematochezia, particularly if it is associated with orthostatic hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Patients suspected of having an upper GI bleed should undergo an upper endoscopy once appropriately resuscitated. Nasogastric lavage may be carried out if there is doubt as to whether a bleed originates from the upper GI tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A nasogastric tube lavage that yields blood- or coffee ground-like material confirms upper GI bleeding; however, lavage may not be positive if bleeding has ceased or arises beyond a closed pylorus. The presence of bilious fluid suggests that the pylorus is open and, if lavage is negative, that there is no active upper GI bleeding proximal to the ligament of Treitz. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Visible rectal bleeding occurring in adults warrants an evaluation in all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. The timing of the evaluation depends upon the patient's risk for having complications related to the bleed. Several studies have identified clinical features that predict the risk of complications in patients with presumed lower GI bleeding and can be used to help categorize patients as either low- or high-risk. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. High-risk features include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability (hypotension, tachycardia, orthostasis, syncope)",
"     </li>",
"     <li>",
"      Persistent bleeding",
"     </li>",
"     <li>",
"      Significant comorbid illnesses",
"     </li>",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Bleeding that occurs in a patient who is hospitalized for another process",
"     </li>",
"     <li>",
"      A prior history of bleeding from diverticulosis or angiodysplasia",
"     </li>",
"     <li>",
"      Current",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use",
"     </li>",
"     <li>",
"      A non-tender abdomen",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      An elevated blood urea nitrogen level",
"     </li>",
"     <li>",
"      An abnormal white blood cell count",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The number of high-risk features correlates with the likelihood of poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients without high-risk findings require less aggressive care and in some cases may be evaluated in the outpatient setting (eg, young, otherwise healthy patient with minor, self-limited rectal bleeding suspected to be from an anal source). The extent of evaluation (flexible sigmoidoscopy versus colonoscopy) in these patients depends, at least in part, upon the patient's age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8184?source=see_link\">",
"     \"Approach to minimal bright red bleeding per rectum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with high-risk features, particularly those with hemodynamic instability, ongoing active bleeding, and significant comorbid illnesses should be managed in the intensive care unit with aggressive resuscitation and early interventions. A gastroenterologist, a general surgeon, and possibly an interventional radiologist should be involved early in the hospital course of high-risk individuals. Two large caliber (18 gauge or larger) peripheral catheters or a central venous line should be inserted for intravenous access. Patients with heart failure or valvular disease may benefit from pulmonary catheter monitoring to minimize the risk of fluid overload. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Review of pertinent laboratory data is an essential step during resuscitation to assess the need for blood product transfusion. The decision to initiate blood transfusions must be individualized, and specific thresholds for transfusion have not been delineated. Young patients without comorbid illness may not require transfusion until the hemoglobin falls below 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (70",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/10\">",
"     10",
"    </a>",
"    ]. On the other hand, older patients and those who have severe comorbid illnesses such as coronary disease require packed red blood cell transfusions to maintain a higher hemoglobin level (eg, 10",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    [100",
"    <span class=\"nowrap\">",
"     g/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, patients with active bleeding and hypovolemia may require a blood transfusion despite apparently normal hemoglobin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with active bleeding and a coagulopathy (prolonged prothrombin time with INR &gt;1.5) or low platelet count",
"    <span class=\"nowrap\">",
"     (&lt;50,000/microL)",
"    </span>",
"    should be transfused with fresh frozen plasma (FFP) and platelets, respectively. Provided the patient is hemodynamically stable, urgent endoscopy can usually proceed simultaneously with transfusion and should not be postponed until the coagulopathy is corrected. However, in patients with an INR &ge;3, we attempt to correct the INR to &lt;3 prior to starting an endoscopy, with additional FFP being given during the endoscopy if the INR is still &gt;1.5. This approach is based on data from patients with upper GI bleeding that suggest endoscopy is safe in patients who are mildly to moderately anticoagulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, because packed red blood cells do not contain coagulation factors, transfusion of a unit of FFP should be considered after every four units of packed red blood cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72880188\">",
"    <span class=\"h2\">",
"     Management of anticoagulants and antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, anticoagulants and antiplatelet agents should be held in patients with lower GI bleeding. However, the risk of reversing anticoagulation should be weighed against the risk of continued bleeding without reversa,l and thus the decision to discontinue medications or administer reversal agents needs to be individualized. In some cases (eg, stopping",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in a patient who is taking it solely for primary prevention of cardiovascular disease), the decision to stop these agents may be straightforward. However, in more complicated cases, consultation with the provider who prescribed the medication may be needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\", section on 'Urgent procedures in anticoagulated patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=see_link&amp;anchor=H5#H5\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'High-risk conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\", section on 'Urgent procedures in patients on antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When to resume these medications once hemostasis has been achieved will also depend on the patient's risks for thrombosis and recurrent bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\", section on 'Resumption of anticoagulants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with hematochezia have a lower gastrointestinal site of bleeding, although up to 13 percent have upper gastrointestinal bleeding proximal to the ligament of Treitz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/6\">",
"     6",
"    </a>",
"    ]. As noted above, nasogastric tube lavage should be considered in patients with hematochezia to exclude an upper gastrointestinal hemorrhage, which would be suggested by the presence of coffee-ground material or bright red blood in the lavage fluid. The need for a nasogastric tube should consider the clinical setting and the rate of bleeding. In addition to excluding upper GI bleeding, a nasogastric tube can facilitate rapid colon preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link&amp;anchor=H5079470#H5079470\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Nasogastric lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper endoscopy should be considered if the nasogastric tube lavage does not yield bilious fluid since a closed pylorus can mask bleeding within the duodenum. This is particularly true in patients with hematochezia who are hemodynamically compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the bleeding is suspected to be coming from a lower GI source, colonoscopy is the initial examination of choice for diagnosis and treatment&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/1\">",
"     1",
"    </a>",
"    ]. Other diagnostic procedures that may be useful include radionuclide imaging, computed tomographic (CT) angiography (multi-detector CT), and mesenteric angiography. These radiographic procedures require active bleeding at the time of examination in order to identify a bleeding source and are therefore reserved for the subset of patients with severe, ongoing bleeding. As discussed below, each procedure has advantages and disadvantages (",
"    <a class=\"graphic graphic_table graphicRef74147 \" href=\"mobipreview.htm?6/27/6588\">",
"     table 1",
"    </a>",
"    ). Recommendations regarding the evaluation of patients with lower GI bleeding are based largely upon clinical experience and the characteristics of the individual tests; no large controlled clinical trials have demonstrated a clear advantage of a particular strategy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    studies have",
"    <strong>",
"     no role",
"    </strong>",
"    in the evaluation of acute lower GI bleeding. Superficial or flat mucosal lesions such as angiodysplasia or acute colitis are not visualized, lesions within the rectosigmoid are difficult to evaluate radiographically, and the presence of barium can make subsequent endoscopy, angiography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical intervention difficult.",
"   </p>",
"   <p>",
"    Rarely, patients with exsanguinating lower GI bleeding will need immediate surgery. The morbidity and mortality associated with colectomy in the absence of preoperative localization of a bleeding site is higher than in patients who have a bleeding site identified prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Thus, all efforts should be made to identify the bleeding source prior to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of colonoscopy compared with other tests for lower GI bleeding include its potential to precisely localize the site of the bleeding regardless of the etiology or rate of bleeding, the ability to collect pathologic specimens, and the potential for therapeutic intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/3,5,19\">",
"     3,5,19",
"    </a>",
"    ]. Disadvantages of colonoscopy include the need for bowel preparation, poor visualization in an unprepared or poorly prepared colon, and the risks of sedation in an acutely bleeding patient. Complications are reported in fewer than 2 percent of colonoscopies performed for lower GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38679?source=see_link\">",
"     \"Colonic diverticular bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=see_link&amp;anchor=H26#H26\">",
"     \"Angiodysplasia of the gastrointestinal tract\", section on 'Endoscopic treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link\">",
"     \"Bleeding after colonic polypectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic therapy can be used to treat many causes of lower GI bleeding, including diverticula, angiodysplasia, hemorrhoids, postpolypectomy bleeding, and radiation telangiectasia or proctitis. (",
"    <a class=\"graphic graphic_picture graphicRef71112 \" href=\"mobipreview.htm?10/42/10915\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/16,21-29\">",
"     16,21-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38679?source=see_link\">",
"     \"Colonic diverticular bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=see_link&amp;anchor=H26#H26\">",
"     \"Angiodysplasia of the gastrointestinal tract\", section on 'Endoscopic treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link\">",
"     \"Bleeding after colonic polypectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies have suggested that urgent colonoscopy (less than 12 hours from admission) with endoscopic treatment can reduce the risk of rebleeding and surgery in patients with severe diverticular hemorrhage compared with patients treated conservatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/16\">",
"     16",
"    </a>",
"    ]. On the other hand, a randomized controlled trial of patients with a variety of causes of lower GI bleeding found that a strategy of urgent colonoscopy compared with",
"    <span class=\"nowrap\">",
"     expectant/elective",
"    </span>",
"    colonoscopy alone or with radiographic interventions improved detection of the source of bleeding but did not significantly reduce mortality, hospital stay, transfusion requirements, or need for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/6,30\">",
"     6,30",
"    </a>",
"    ]. A third trial found no difference in outcomes between urgent and delayed colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the lack of statistically significant findings in these two trials may have been the result of small sample sizes.",
"   </p>",
"   <p>",
"    Observational studies have found an association between early colonoscopy and reduced length of hospital stay largely due to the efficient triage of low-risk patients, although endoscopic therapy was also more likely to be performed during early exams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In addition, few stigmata of recent hemorrhage are reported during elective exams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians perform colonoscopy on an unprepared bowel since blood is cathartic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/33\">",
"     33",
"    </a>",
"    ]. However, studies of colonoscopy without preparation for lower GI bleeding generally report low cecal intubation rates, and blood or stool in the colon lumen can obscure the bleeding source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. Cleansing the colon of stool and blood with four to eight liters of polyethylene glycol (GoLYTELY, CoLyte) over two to three hours as tolerated by the patient is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/3,34\">",
"     3,34",
"    </a>",
"    ]. Studies using rapidly administered, large volume bowel preparations report high rates of successful endoscopic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/16\">",
"     16",
"    </a>",
"    ]. Caution should be given to patients at risk of aspiration or fluid overload. Patients unable to take the preparation orally may require a nasogastric tube. Some authors recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (10 mg) at the start of the colonoscopy bowel preparation to facilitate intestinal transit and minimize the risk of nausea and vomiting, though this is not our practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/16\">",
"     16",
"    </a>",
"    ]. There is no evidence that rapid bowel preparation reactivates or increases the rate of bleeding. Radiographic studies should be obtained prior to colonic preparation if perforation or obstruction is suspected.",
"   </p>",
"   <p>",
"    A definitive or potential bleeding source is visualized in 45 to 90 percent of patients undergoing colonoscopy for lower GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/35\">",
"     35",
"    </a>",
"    ]. Visualization of a potential bleeding site that is not actively bleeding does not exclude the presence of a more proximal source. The identification of more than one potential bleeding site is common (eg, diverticulosis and hemorrhoids). Furthermore, a bleeding site is not always identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Radionuclide imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide scanning detects bleeding that is occurring at a rate of 0.1 to 0.5",
"    <span class=\"nowrap\">",
"     mL/minute,",
"    </span>",
"    and it is the most sensitive radiographic test for GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/38\">",
"     38",
"    </a>",
"    ]. Two types of nuclear scans have been used: technetium (99mTc) sulfur colloid and 99mTc pertechnetate-labeled autologous red blood cells. Both techniques are noninvasive and sensitive for GI bleeding. An advantage of all radiographic tests for GI bleeding is the ability to diagnose bleeding throughout the GI tract, including small bowel sources.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technetium sulfur colloid is rapidly cleared from the intravascular space. Scans are obtained shortly after intravenous injection, looking for evidence of extravasation. However, the short half-life of the colloid within the circulation means that patients must be actively bleeding during the few minutes that the label is present in the vascular space, and repeat scanning for intermittent bleeding is not possible without reinjection.",
"     </li>",
"     <li>",
"      After injection of 99mTc pertechnetate-labeled red cells, abdominal images are obtained frequently during the first 30 to 90 minutes, and then, if necessary, every few hours for up to 24 hours (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79370 \" href=\"mobipreview.htm?27/0/27648\">",
"       image 1",
"      </a>",
"      ). An advantage of this technique is that patients with intermittent bleeding can be scanned several times over a 24-hour period. For this reason, labeled red cells are most commonly used in practice and are most helpful in patients with obscure, intermittent bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major disadvantage of radionuclide imaging is that it requires active bleeding to detect a source and can only localize bleeding to a general area of the abdomen. Furthermore, accuracy rates have varied substantially across reports ranging from 24 to 91 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Poor localization occurs because blood can move in either a peristaltic or antiperistaltic direction. In addition, localization to an area of the abdomen is not equivalent to identifying a specific site. As an example, bleeding in a redundant sigmoid colon may appear as extravasated blood in the right lower quadrant, suggesting right colon bleeding. These difficulties were illustrated in a study of 203 patients undergoing 99mTc-labeled red cell scintigraphy for lower GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/43\">",
"     43",
"    </a>",
"    ]. The scan was positive and suggested a site of bleeding in 52 cases (26 percent). However, the scan was incorrect in 13 of these 52 patients (25 percent), and 8 patients had unwarranted surgical procedures.",
"   </p>",
"   <p>",
"    Thus, colonoscopy is recommended as the initial test for most patients with presumed lower GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. In patients with severe bleeding who cannot be stabilized for colonoscopy, nuclear imaging may be used to select patients with active bleeding for subsequent angiography. However, the patient may stop bleeding by the time the scan is completed, thereby missing the opportunity to localize a lesion by angiography. There are no randomized studies which compare the relative value of the combination of tests versus angiography alone, and results from case series are mixed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     CT angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have described multidetector helical CT angiography for the localization of active hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/46-51\">",
"     46-51",
"    </a>",
"    ]. Bleeding at a rate of 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    can be detected with CT angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/52\">",
"     52",
"    </a>",
"    ]. Compared with single-detector row helical CT, multidetector CT permits markedly increased resolution and shortens scanning time. This allows for improved identification of extravasated contrast material into the intestinal lumen. A meta-analysis of 22 studies with 672 patients found that CT angiography had a sensitivity of 85 percent and a specificity of 92 percent for detecting active GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/53\">",
"     53",
"    </a>",
"    ]. In a review of 124 cases, the accuracy of CT angiography was 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT angiography is an appealing diagnostic modality because it is widely available, fast, and minimally invasive. In addition, it provides anatomic detail that may be helpful for subsequent interventions such as angiography. However, it lacks therapeutic capability, requires radiation exposure, and utilizes intravenous contrast, which can be associated with nephropathy and allergic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/47\">",
"     47",
"    </a>",
"    ]. Like the other radiographic tests for GI bleeding, a positive scan requires active bleeding. In one study of 44 patients undergoing CT angiography immediately followed by radionuclide scanning for lower GI bleeding, nuclide scanning identified more cases of active bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/54\">",
"     54",
"    </a>",
"    ]. Further studies are needed to clarify the role of CT angiography as an initial test in the evaluation of patients with lower GI bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography requires active blood loss of 1 to 1.5",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    under optimal conditions for a bleeding site to be visualized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/55\">",
"     55",
"    </a>",
"    ]. In the absence of prior localization (eg, radionuclide imaging), the superior mesenteric artery is generally examined first in patients with presumed lower GI bleeding because bleeding sources tend to occur in bowel supplied by this artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52754 \" href=\"mobipreview.htm?38/41/39583\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/56\">",
"     56",
"    </a>",
"    ]. If this test is negative, the inferior mesenteric and celiac vessels are studied. The success rate varies widely from 25 to 70 percent, depending upon the timing relative to the episode of bleeding and local expertise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/3,57-59\">",
"     3,57-59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies suggest that the frequency of negative arteriograms can be reduced by using radionuclide imaging to screen for active bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/44,60\">",
"     44,60",
"    </a>",
"    ]. However, other studies have found no difference in the proportion of positive studies with or without preceding radionuclide imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/45\">",
"     45",
"    </a>",
"    ]. The incidence of negative tests is increased by the delay inherent in performing nuclear scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantages of angiography over other tests for lower GI bleeding are that it does not require bowel preparation and anatomic localization is accurate. It also permits therapeutic intervention. Intra-arterial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    infusion via the angiography catheter is one technique to stop or temporize bleeding. However, complications can be serious, including cardiac arrhythmias and bowel ischemia, and the rebleeding rate is as high as 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link&amp;anchor=H3#H3\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\", section on 'Intra-arterial vasopressin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transcatheter embolization is a more definitive means of controlling hemorrhage and has largely replaced",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    infusion. Superselective embolization of distal vessels using coaxial catheters minimizes the risk of bowel infarction. In patients found to have active bleeding, superselective embolization is feasible in 80 percent, and bleeding is successfully controlled in 97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/20\">",
"     20",
"    </a>",
"    ]. Nonetheless, superselective embolization is associated with a risk of intestinal infarction that can reach 20 percent, as well as other serious complications, including arterial injury and thrombus and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/59,61,62\">",
"     59,61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link&amp;anchor=H4#H4\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\", section on 'Embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therefore, arteriography is reserved for patients in whom endoscopy is not feasible due to severe bleeding with hemodynamic instability, or in those with persistent or recurrent bleeding and a nondiagnostic colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bleeding site not identified",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bleeding site may not be evident in some patients despite lower gastrointestinal evaluation. An upper endoscopy with push enteroscopy should be considered in those with severe bleeding since up to 15 percent of such patients have a bleeding site in the upper digestive tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/6\">",
"     6",
"    </a>",
"    ]. Push enteroscopy (endoscopy using a pediatric colonoscope or a dedicated enteroscope) allows visualization of approximately the proximal 60 cm of the jejunum.",
"   </p>",
"   <p>",
"    Bleeding sites can also arise in more distal segments of the small bowel. There are several methods to evaluate the small intestine, such as capsule endoscopy and deep small bowel enteroscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, bleeding may have stopped, making efforts to identify the site more difficult. Such patients should be observed for 24 to 48 hours. An urgent tagged red blood cell scan can be obtained to localize the region of bleeding if bleeding resumes. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Radionuclide imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A provocative challenge with vasodilators, anticoagulants,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombolytics has been reported to aid in the diagnosis of elusive bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. However, the risk of serious complications including refractory bleeding and death is substantial, and this should only be undertaken in expert centers after careful planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/11/18611?source=see_link\">",
"       \"Patient information: Colonoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=see_link\">",
"       \"Patient information: Bloody stools (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/60/24515?source=see_link\">",
"       \"Patient information: GI bleed (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/10/17569?source=see_link\">",
"       \"Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower gastrointestinal (GI) bleeding refers to blood loss of recent onset originating from a site distal to the ligament of Treitz. It is usually suspected when the patient complains of hematochezia (passage of maroon or bright red blood or blood clots per rectum). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood originating from the left colon typically is bright red. By comparison, bleeding from the right side of the colon usually appears dark or maroon-colored and may be mixed with stool. However, rapid transit of blood from the right side of the colon or massive upper GI bleeding can appear red, and bleeding from the cecum may rarely present with melena. Thus, although helpful, the distinctions based upon stool color are not absolute. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Visible rectal bleeding occurring in adults warrants an evaluation in all cases. Patients should be categorized as either low- or high-risk for complications based upon their clinical presentation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with high-risk features including hemodynamic instability (shock, orthostatic hypotension), persistent bleeding,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant comorbid illnesses should be admitted to an intensive care unit for resuscitation, close observation, and possible therapeutic interventions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe hematochezia, it is important to exclude upper GI bleeding, particularly if the bleeding is associated with orthostatic hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/7/30841/abstract/3-6\">",
"       3-6",
"      </a>",
"      ]. Patients suspected of having an upper GI bleed should undergo an upper endoscopy once appropriately resuscitated. Nasogastric lavage may be carried out if there is doubt as to whether a bleed originates from the upper GI tract. A nasogastric lavage that yields blood- or coffee ground-like material confirms upper GI bleeding. However, false negative aspirates can occur if bleeding has ceased or arises beyond a closed pylorus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link\">",
"       \"Approach to acute upper gastrointestinal bleeding in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with bleeding suspected to be coming from a lower GI source, we suggest colonoscopy as the initial investigation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Mesenteric angiography with or without preceding radionuclide scanning or CT angiography, depending upon institutional expertise, is appropriate in the small subset of patients with massive bleeding that cannot be stabilized for colonoscopy or who have ongoing bleeding but no source identified during colonoscopy (",
"      <a class=\"graphic graphic_table graphicRef74147 \" href=\"mobipreview.htm?6/27/6588\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/1\">",
"      Zuccaro G Jr. Management of the adult patient with acute lower gastrointestinal bleeding. American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol 1998; 93:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/2\">",
"      Strate LL, Ayanian JZ, Kotler G, Syngal S. Risk factors for mortality in lower intestinal bleeding. Clin Gastroenterol Hepatol 2008; 6:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/3\">",
"      Jensen DM, Machicado GA. Diagnosis and treatment of severe hematochezia. The role of urgent colonoscopy after purge. Gastroenterology 1988; 95:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/4\">",
"      Zuckerman GR, Trellis DR, Sherman TM, Clouse RE. An objective measure of stool color for differentiating upper from lower gastrointestinal bleeding. Dig Dis Sci 1995; 40:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/5\">",
"      Wilcox CM, Alexander LN, Cotsonis G. A prospective characterization of upper gastrointestinal hemorrhage presenting with hematochezia. Am J Gastroenterol 1997; 92:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/6\">",
"      Laine L, Shah A. Randomized trial of urgent vs. elective colonoscopy in patients hospitalized with lower GI bleeding. Am J Gastroenterol 2010; 105:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/7\">",
"      Davila RE, Rajan E, Adler DG, et al. ASGE Guideline: the role of endoscopy in the patient with lower-GI bleeding. Gastrointest Endosc 2005; 62:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/8\">",
"      Kollef MH, O'Brien JD, Zuckerman GR, Shannon W. BLEED: a classification tool to predict outcomes in patients with acute upper and lower gastrointestinal hemorrhage. Crit Care Med 1997; 25:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/9\">",
"      Velayos FS, Williamson A, Sousa KH, et al. Early predictors of severe lower gastrointestinal bleeding and adverse outcomes: a prospective study. Clin Gastroenterol Hepatol 2004; 2:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/10\">",
"      Strate LL, Orav EJ, Syngal S. Early predictors of severity in acute lower intestinal tract bleeding. Arch Intern Med 2003; 163:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/11\">",
"      Das A, Ben-Menachem T, Cooper GS, et al. Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model. Lancet 2003; 362:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/12\">",
"      Lewis JD, Brown A, Localio AR, Schwartz JS. Initial evaluation of rectal bleeding in young persons: a cost-effectiveness analysis. Ann Intern Med 2002; 136:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/13\">",
"      Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/14\">",
"      Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007; 102:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/15\">",
"      Maltz GS, Siegel JE, Carson JL. Hematologic management of gastrointestinal bleeding. Gastroenterol Clin North Am 2000; 29:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/16\">",
"      Jensen DM, Machicado GA, Jutabha R, Kovacs TO. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. N Engl J Med 2000; 342:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/17\">",
"      McGuire HH Jr. Bleeding colonic diverticula. A reappraisal of natural history and management. Ann Surg 1994; 220:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/18\">",
"      Gianfrancisco JA, Abcarian H. Pitfalls in the treatment of massive lower gastrointestinal bleeding with \"blind\" subtotal colectomy. Dis Colon Rectum 1982; 25:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/19\">",
"      Van Gossum A, Bourgeois F, Gay F, et al. Operative colonoscopic endoscopy. Acta Gastroenterol Belg 1992; 55:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/20\">",
"      Strate LL, Naumann CR. The role of colonoscopy and radiological procedures in the management of acute lower intestinal bleeding. Clin Gastroenterol Hepatol 2010; 8:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/21\">",
"      Savides TJ, Jensen DM. Colonoscopic hemostasis for recurrent diverticular hemorrhage associated with a visible vessel: a report of three cases. Gastrointest Endosc 1994; 40:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/22\">",
"      Foutch PG, Zimmerman K. Diverticular bleeding and the pigmented protuberance (sentinel clot): clinical implications, histopathological correlation, and results of endoscopic intervention. Am J Gastroenterol 1996; 91:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/23\">",
"      Foutch PG. Angiodysplasia of the gastrointestinal tract. Am J Gastroenterol 1993; 88:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/24\">",
"      Jensen DM, Jutabha R, Machicado GA, et al. Prospective randomized comparative study of bipolar electrocoagulation versus heater probe for treatment of chronically bleeding internal hemorrhoids. Gastrointest Endosc 1997; 46:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/25\">",
"      Trowers EA, Ganga U, Rizk R, et al. Endoscopic hemorrhoidal ligation: preliminary clinical experience. Gastrointest Endosc 1998; 48:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/26\">",
"      Barbatzas C, Spencer GM, Thorpe SM, et al. Nd:YAG laser treatment for bleeding from radiation proctitis. Endoscopy 1996; 28:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/27\">",
"      Maunoury V, Brunetaud JM, Cortot A. Bipolar electrocoagulation treatment for hemorrhagic radiation injury of the lower digestive tract. Gastrointest Endosc 1991; 37:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/28\">",
"      Jensen DM, Machicado GA, Cheng S, et al. A randomized prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia. Gastrointest Endosc 1997; 45:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/29\">",
"      Zuckerman GR, Prakash C. Acute lower intestinal bleeding. Part II: etiology, therapy, and outcomes. Gastrointest Endosc 1999; 49:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/30\">",
"      Green BT, Rockey DC, Portwood G, et al. Urgent colonoscopy for evaluation and management of acute lower gastrointestinal hemorrhage: a randomized controlled trial. Am J Gastroenterol 2005; 100:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/31\">",
"      Strate LL, Syngal S. Timing of colonoscopy: impact on length of hospital stay in patients with acute lower intestinal bleeding. Am J Gastroenterol 2003; 98:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/32\">",
"      Schmulewitz N, Fisher DA, Rockey DC. Early colonoscopy for acute lower GI bleeding predicts shorter hospital stay: a retrospective study of experience in a single center. Gastrointest Endosc 2003; 58:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/33\">",
"      Rossini FP, Ferrari A, Spandre M, et al. Emergency colonoscopy. World J Surg 1989; 13:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/34\">",
"      Machicado GA, Jensen DM. Acute and chronic management of lower gastrointestinal bleeding: cost-effective approaches. Gastroenterologist 1997; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/35\">",
"      Strate LL. Lower GI bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am 2005; 34:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/36\">",
"      Angtuaco TL, Reddy SK, Drapkin S, et al. The utility of urgent colonoscopy in the evaluation of acute lower gastrointestinal tract bleeding: a 2-year experience from a single center. Am J Gastroenterol 2001; 96:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/37\">",
"      Chaudhry V, Hyser MJ, Gracias VH, Gau FC. Colonoscopy: the initial test for acute lower gastrointestinal bleeding. Am Surg 1998; 64:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/38\">",
"      Dusold R, Burke K, Carpentier W, Dyck WP. The accuracy of technetium-99m-labeled red cell scintigraphy in localizing gastrointestinal bleeding. Am J Gastroenterol 1994; 89:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/39\">",
"      Nicholson ML, Neoptolemos JP, Sharp JF, et al. Localization of lower gastrointestinal bleeding using in vivo technetium-99m-labelled red blood cell scintigraphy. Br J Surg 1989; 76:358.",
"     </a>",
"    </li>",
"    <li>",
"     Imbembo AL, Bailey RW. Diverticular disease of the colon. In: Textbook of Surgery, 14th ed, Sabiston DC Jr (Ed), Churchill Livingstone, 1992. p.910.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/41\">",
"      Olds GD, Cooper GS, Chak A, et al. The yield of bleeding scans in acute lower gastrointestinal hemorrhage. J Clin Gastroenterol 2005; 39:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/42\">",
"      Feingold DL, Caliendo FJ, Chinn BT, et al. Does hemodynamic instability predict positive technetium-labeled red blood cell scintigraphy in patients with acute lower gastrointestinal bleeding? A review of 50 patients. Dis Colon Rectum 2005; 48:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/43\">",
"      Hunter JM, Pezim ME. Limited value of technetium 99m-labeled red cell scintigraphy in localization of lower gastrointestinal bleeding. Am J Surg 1990; 159:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/44\">",
"      Gunderman R, Leef J, Ong K, et al. Scintigraphic screening prior to visceral arteriography in acute lower gastrointestinal bleeding. J Nucl Med 1998; 39:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/45\">",
"      Pennoyer WP, Vignati PV, Cohen JL. Mesenteric angiography for lower gastrointestinal hemorrhage: are there predictors for a positive study? Dis Colon Rectum 1997; 40:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/46\">",
"      Scheffel H, Pfammatter T, Wildi S, et al. Acute gastrointestinal bleeding: detection of source and etiology with multi-detector-row CT. Eur Radiol 2007; 17:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/47\">",
"      Yoon W, Jeong YY, Shin SS, et al. Acute massive gastrointestinal bleeding: detection and localization with arterial phase multi-detector row helical CT. Radiology 2006; 239:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/48\">",
"      Ernst O, Bulois P, Saint-Drenant S, et al. Helical CT in acute lower gastrointestinal bleeding. Eur Radiol 2003; 13:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/49\">",
"      Tew K, Davies RP, Jadun CK, Kew J. MDCT of acute lower gastrointestinal bleeding. AJR Am J Roentgenol 2004; 182:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/50\">",
"      Sun H, Jin Z, Li X, et al. Detection and localization of active gastrointestinal bleeding with multidetector row computed tomography angiography: a 5-year prospective study in one medical center. J Clin Gastroenterol 2012; 46:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/51\">",
"      Mart&iacute; M, Artigas JM, Garz&oacute;n G, et al. Acute lower intestinal bleeding: feasibility and diagnostic performance of CT angiography. Radiology 2012; 262:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/52\">",
"      Kuhle WG, Sheiman RG. Detection of active colonic hemorrhage with use of helical CT: findings in a swine model. Radiology 2003; 228:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/53\">",
"      Garc&iacute;a-Bl&aacute;zquez V, Vicente-B&aacute;rtulos A, Olavarria-Delgado A, et al. Accuracy of CT angiography in the diagnosis of acute gastrointestinal bleeding: systematic review and meta-analysis. Eur Radiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/54\">",
"      Zink SI, Ohki SK, Stein B, et al. Noninvasive evaluation of active lower gastrointestinal bleeding: comparison between contrast-enhanced MDCT and 99mTc-labeled RBC scintigraphy. AJR Am J Roentgenol 2008; 191:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/55\">",
"      Zuckerman DA, Bocchini TP, Birnbaum EH. Massive hemorrhage in the lower gastrointestinal tract in adults: diagnostic imaging and intervention. AJR Am J Roentgenol 1993; 161:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/56\">",
"      Reinus JF, Brandt LJ. Vascular ectasias and diverticulosis. Common causes of lower intestinal bleeding. Gastroenterol Clin North Am 1994; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/57\">",
"      Browder W, Cerise EJ, Litwin MS. Impact of emergency angiography in massive lower gastrointestinal bleeding. Ann Surg 1986; 204:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/58\">",
"      Ud&eacute;n P, Jiborn H, Jonsson K. Influence of selective mesenteric arteriography on the outcome of emergency surgery for massive, lower gastrointestinal hemorrhage. A 15-year experience. Dis Colon Rectum 1986; 29:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/59\">",
"      Cohn SM, Moller BA, Zieg PM, et al. Angiography for preoperative evaluation in patients with lower gastrointestinal bleeding: are the benefits worth the risks? Arch Surg 1998; 133:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/60\">",
"      Steer ML, Silen W. Diagnostic procedures in gastrointestinal hemorrhage. N Engl J Med 1983; 309:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/61\">",
"      Colacchio TA, Forde KA, Patsos TJ, Nunez D. Impact of modern diagnostic methods on the management of active rectal bleeding. Ten year experience. Am J Surg 1982; 143:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/62\">",
"      Guy GE, Shetty PC, Sharma RP, et al. Acute lower gastrointestinal hemorrhage: treatment by superselective embolization with polyvinyl alcohol particles. AJR Am J Roentgenol 1992; 159:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/63\">",
"      Bloomfeld RS, Smith TP, Schneider AM, Rockey DC. Provocative angiography in patients with gastrointestinal hemorrhage of obscure origin. Am J Gastroenterol 2000; 95:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/64\">",
"      Kim CY, Suhocki PV, Miller MJ Jr, et al. Provocative mesenteric angiography for lower gastrointestinal hemorrhage: results from a single-institution study. J Vasc Interv Radiol 2010; 21:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30841/abstract/65\">",
"      Malden ES, Hicks ME, Royal HD, et al. Recurrent gastrointestinal bleeding: use of thrombolysis with anticoagulation in diagnosis. Radiology 1998; 207:147.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2547 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30841=[""].join("\n");
var outline_f30_7_30841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72880188\">",
"      Management of anticoagulants and antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Radionuclide imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - CT angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bleeding site not identified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2547|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/0/27648\" title=\"diagnostic image 1\">",
"      Technet RBC scan divertic bleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/41/39583\" title=\"diagnostic image 2\">",
"      Angiodysplasia colon angio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2547|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/42/10915\" title=\"picture 1\">",
"      Rx cecal ulcer Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2547|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/27/6588\" title=\"table 1\">",
"      Localization diverticular bleed",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8184?source=related_link\">",
"      Approach to minimal bright red bleeding per rectum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=related_link\">",
"      Bleeding after colonic polypectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38679?source=related_link\">",
"      Colonic diverticular bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7272?source=related_link\">",
"      Etiology of lower gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31352?source=related_link\">",
"      Evaluation of obscure gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/10/17569?source=related_link\">",
"      Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/60/24515?source=related_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_7_30842="Cancer pain management with opioids: Optimizing analgesia";
var content_f30_7_30842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer pain management with opioids: Optimizing analgesia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/7/30842/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/7/30842/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/7/30842/contributors\">",
"     Zankhana Mehta, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/7/30842/contributors\">",
"     Ebtesam Ahmed, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/7/30842/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/7/30842/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/7/30842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/7/30842/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/7/30842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids are widely used for treatment of pain in patients with cancer because of their safety, multiple routes of administration, ease of titration, reliability, and effectiveness for all types of pain (ie, somatic, visceral, neuropathic). Although neuropathic pain may be more difficult to treat, a favorable response to opioid-based analgesia is often possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H8#H8\">",
"     \"Assessment of cancer pain\", section on 'Inferred pathophysiology (types of cancer pain)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioids are also potentially abusable drugs. The public health consequences of opioid abuse drive the imperative that all physicians assume responsibility for risk management when these drugs are prescribed for legitimate medical purposes. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'Risk assessment and management for patients receiving opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover the use of opioids for cancer-related pain, with an emphasis on optimizing analgesia and minimizing side effects. Assessment of cancer pain, a review of specific cancer pain syndromes, general principles of cancer pain management, an overview of risk management in patients treated with opioids, prevention and management of opioid side effects, the clinical use of non-opioid analgesics (including NSAIDs and adjuvant analgesics) and non-pharmacologic methods of cancer pain management are covered elsewhere. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OPIOID DRUGS USED IN CANCER PAIN MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids act by binding to specific receptors, the best characterized of which are the mu, kappa, and delta receptors. These receptors are present in tissues throughout the body, including both the peripheral and central nervous systems.",
"   </p>",
"   <p>",
"    Based upon their effects on the mu receptor, opioids are conventionally divided into pure agonists, agonist-antagonists (of which there are two subtypes: partial agonists and mixed agonist-antagonists), and pure antagonists (",
"    <a class=\"graphic graphic_table graphicRef69457 \" href=\"mobipreview.htm?7/55/8061\">",
"     table 1",
"    </a>",
"    ). Mu receptor antagonists have no intrinsic analgesic properties; they are used to prevent or reverse opioid effects (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Bowel issues'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    With few exceptions, the management of chronic cancer pain usually involves the long-term administration of pure mu receptor agonists (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    ). However, several of the agonist-antagonist drugs are commercially available in the United States and other countries, and at least one, the partial agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    , is used for treatment of cancer-related pain in some settings. Several other centrally-acting analgesics, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"     tapentadol",
"    </a>",
"    , have some mu agonist effects mixed with other prominent mechanisms and also are used for cancer pain in some circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Partial agonists: Buprenorphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    , a partial agonist, has been licensed in Europe and is commonly prescribed for chronic pain. Although experience with this drug in the management of cancer pain is limited, anecdotal reports, a few small prospective uncontrolled studies, and at least one randomized trial support its effectiveness and safety in patients with severe cancer-related pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. A 2009 consensus statement from an international panel with expertise in palliative care and pain treatment endorsed the use of transdermal buprenorphine where available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is less experience with transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    in the United States, where a patch formulation is available (Butrans&reg; 5, 10, or 20",
"    <span class=\"nowrap\">",
"     microgram/hour,",
"    </span>",
"    all intended for seven day use) for treatment of chronic pain. The transdermal patch carries a warning against exceeding 20",
"    <span class=\"nowrap\">",
"     microgram/hour",
"    </span>",
"    due to the risk of QT prolongation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mixed mechanism drugs: Tramadol and tapentadol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     Tramadol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"     tapentadol",
"    </a>",
"    are centrally acting analgesics whose mode of action is based both on the mu receptor binding and monoamine (serotonin and norepinephrine) reuptake blockade. Tramadol is widely used in some countries for moderate to severe cancer pain as an alternative to other opioids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], but it is not used as commonly in the United States. Evidence is lacking to demonstrate superiority of tramadol over other opioids in terms of either efficacy or tolerability in patients with cancer-related pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence to support specific advantages or disadvantages to the combination of a mixed mechanism analgesic and a pure mu analgesic.&nbsp;Most specialists would not support fixed dosing of the two drugs in combination, but based on anecdotal experience, most would be comfortable if a short-acting mixed mechanism drug was added on as &ldquo;as needed&rdquo; basis to a long-acting pure mu agonist for breakthrough pain, or conversely, if an &ldquo;as needed&rdquo; short-acting pure mu agonist was added to a long-acting mixed mechanism drug such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"     tapentadol",
"    </a>",
"    for the same reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mixed agonist-antagonist drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs of the mixed agonist-antagonist group (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    , dezocine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/48/29446?source=see_link\">",
"     pentazocine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    ) are generally not preferred for cancer pain management. This is because of a ceiling effect for analgesia, and the capacity to induce abstinence when administered to patients already receiving other opioids of the mu agonist class.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pure mu agonists conventionally used for moderate or severe pain in patients with limited to no opioid exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the large group of pure mu agonist drugs (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    ) are many (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    and related agents) that are conventionally considered to be first-line agents for the treatment of moderate to severe pain in patients with limited opioid exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/9\">",
"     9",
"    </a>",
"    ]. The World Health Organization (WHO) analgesic ladder for treatment of cancer pain (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/12\">",
"     12",
"    </a>",
"    ], first published in the 1980s, referred to these as \"weak\" or \"mild\" opioids, although this designation is inappropriate and no longer used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'General principles of pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Codeine and related agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     Codeine",
"    </a>",
"    was selected as the prototype \"weak opioid\" for the second step of the WHO analgesic ladder (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/12\">",
"     12",
"    </a>",
"    ]. It is available in several dosage forms that are appropriate for moderate pain in the patient with limited to no opioid exposure. Dose escalation to relatively high doses for severe pain that worsens over time is not preferred, however, because of the size of the dosage units available, and the perception that higher doses carry a relatively severe side effect liability. There is also a concern about variability in response related to genetic factors (see below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     Codeine",
"    </a>",
"    is also available in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . However, the maximal daily dose of acetaminophen (4 g per day and lower in those without known liver disease or risk factors for liver disease) effectively limits the amount of codeine that can be administered with this combination product. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\", section on 'Acetaminophen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, hydrocodone and dihydrocodeine are available only in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (Vicodin, Lorcet) or NSAIDs (both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ). As with acetaminophen and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , the amount of the nonopioid constituent limits use of these agents to relatively opioid-naive patients with moderate pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622751239\">",
"    <span class=\"h4\">",
"     Genetic variation in metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The broad acceptance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    as a WHO analgesic ladder (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    ) step 2 drug has also come under scrutiny as a result of new information about genetic variation in metabolism. The analgesic efficacy of codeine requires conversion to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    via the CYP2D6 isoenzyme of the P450 hepatic enzyme system. CYP2D6 is highly polymorphic, with over 90 known allelic variants.",
"   </p>",
"   <p>",
"    Five to 10 percent of patients inherit a slow metabolizer phenotype and they derive only limited or no therapeutic benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    because it will not be converted to its active moiety. Conversely, patients who are ultra-rapid metabolizers based on CYP2D6 genotype may have higher than expected",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    levels (an initial \"overdose\"), with more side effects and a shorter than expected duration of pain control. Similar effects have been described in patients receiving hydrocodone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    , but without the presumed clinical relevance perceived with codeine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This variation in population genetics and the inability to predict analgesic effects prior to administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/15\">",
"     15",
"    </a>",
"    ] suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    should not be among the preferred drugs for cancer pain management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of pharmacogenomics\", section on 'CYP isoenzymes and drug metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other pure mu agonist drugs also may be used for moderate or severe pain in those with limited prior opioid exposure, as long as the initial doses are adjusted appropriately.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    , or any of the single-entity, pure mu agonist drugs, can be prescribed at doses low enough to be safe for the management of moderate to severe pain in the opioid-naive population; this approach is endorsed in guidelines for cancer pain management from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    and other organizations including the",
"    <a class=\"external\" href=\"file://www.eapcnet.eu/Themes/Clinicalcare/EAPCOpioidGuidelines2012.aspx\">",
"     European Association for Palliative Care",
"    </a>",
"    . This strategy effectively eliminates the second \"rung\" of the analgesic ladder approach (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    ) and reflects attempts to update the original WHO guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Meperidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     Meperidine",
"    </a>",
"    is not preferred for use in the cancer pain population. It is metabolized into a compound (normeperidine) that is relatively toxic, and associated with tremulousness, delirium and seizures. Accumulation of the metabolite is most likely to occur during repeated administration, and dose escalation, and in the setting of impaired elimination caused by renal insufficiency. It is safer to select an alternative mu agonist for the management of chronic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pure mu agonists for severe pain in patients with prior opioid exposure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Morphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    is the prototype opioid drug for severe cancer pain on the third step of the WHO analgesic ladder (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/12\">",
"     12",
"    </a>",
"    ]. It is usually considered to be a standard for comparison (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    ). In the original WHO guidelines, this preference for morphine was not based upon any existing comparative data. Since then, randomized trials and systematic reviews have failed to demonstrate the superiority of morphine over any other mu agonist (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ) in terms of efficacy or tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/9,17-21\">",
"     9,17-21",
"    </a>",
"    ]. Furthermore, there is very large intraindividual variation in the response to the different mu agonist drugs and no way to predict whether a patient will have a more favorable balance between analgesia and side effects when given morphine or one of the other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    should not be considered the \"drug of choice,\" but rather, just one of many drugs that could be selected for chronic cancer pain. The decision to select one or another is often based upon the experience of the clinician, prior experience of the patient, cost, dosing implications of the formulation, and other factors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    has a short half life (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    ), but it is available in multiple formulations, including tablet, oral liquid, suppository, solution for intravenous (IV) and subcutaneous (SC) use, and modified-release drugs that provide continuous analgesia with once or twice daily dosing. The short half-life formulations are useful for breakthrough pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H5#H5\">",
"     \"Assessment of cancer pain\", section on 'Temporal assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the formulation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    is primarily metabolized in the liver and its metabolites are renally excreted. Two active metabolites have been extensively studied, morphine-3-glucuronide (M3G) and morphine-6-gluconoride (M6G) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/22\">",
"     22",
"    </a>",
"    ]. Preclinical data and limited human studies suggest that M6G contributes to analgesic activity and M3G may be the cause of some of the side effects that occur during morphine therapy, although this is not yet proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metabolite concentration may be idiosyncratically high as a result of unknown but presumed genetic factors, or more commonly, metabolite concentration may increase relative to the parent compound (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) as a result of renal disease that reduces excretion of both glucuronides. If this occurs, use of the drug may be associated with unanticipated potency or side effects. Clinically, this means that morphine should be administered cautiously in the setting of renal insufficiency, and if fluctuation in kidney function can be anticipated, morphine may not be the preferred opioid given the risk of changes in effects and side effects as metabolite accumulation occurs. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Use in renal failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Oxycodone, hydromorphone, and oxymorphone",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    all have short half-lives and all are available in multiple formulations. In the United States, all three of these drugs are available in long-acting, modified-release formulations.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     Oxycodone",
"    </a>",
"    binds to both mu and kappa receptors, which may suggest some theoretical advantage. Clinical studies have not substantiated systematic differences in efficacy or tolerability compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    or other mu agonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple dosage forms are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , including oral liquid, immediate release tablet, extended release tablet, suppository, and solution for IV or SC use. The extended release form of hydromorphone (Exalgo&reg;) is available in 8, 12, and 16 mg strengths, and is dosed once daily. Caution must be used to avoid medication errors when prescribing this product, as 8 mg tablets are also available as immediate-release hydromorphone tablets.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     Hydromorphone",
"    </a>",
"    is highly soluble in water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/27\">",
"     27",
"    </a>",
"    ] and a commercially available concentrated solution (10 mg per mL) facilitates SC or IV administration of relatively high doses. Some clinicians prefer to use hydromorphone in patients with renal insufficiency because its active, renally-cleared metabolites appear in relatively low concentration (compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) and may be unlikely to cause unanticipated effects. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Use in renal failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The analgesic efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    is comparable to other opioids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/28\">",
"     28",
"    </a>",
"    ]. It has a relatively low propensity to release histamine, a characteristic also shared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    . At least in theory, this may reduce the risk of pruritus or urticaria, although there is no evidence that this difference is clinically relevant.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/22/29029?source=see_link\">",
"     Levorphanol",
"    </a>",
"    is distinguished by its relatively long half-life (about 12 to 16 hours). Experience in the use of this drug is relatively limited in the US, but it should be viewed as another option for the treatment of cancer pain, particularly when other mu agonists have not been well tolerated or are unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fentanyl",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is a highly lipophilic opioid that may be used parenterally or in formulations developed for transdermal or oral transmucosal delivery. The transdermal formulation is used for chronic pain. Both the non-oral route and the relatively infrequent dosing (every two to three days for transdermal fentanyl) are considered advantages by some patients. Although data from clinical trials about the potential for a relatively reduced risk of constipation from transdermal fentanyl re conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/29-32\">",
"     29-32",
"    </a>",
"    ], two meta-analyses have found a significant advantage for transdermal fentanyl over sustained release oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    in terms of this side effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Fentanyl may be preferred over morphine in patients with renal insufficiency due to lack of active metabolites.",
"   </p>",
"   <p>",
"    Exposing the patch to heat (eg, an increase in body temperature, use of a heating pad or warming blanket during surgery) may cause an unintentional increase in systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    absorption, which may increase the risk of respiratory depression. In addition, fentanyl patches contain metal, which can pose a risk for local skin burn during magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/35\">",
"     35",
"    </a>",
"    ]. Physicians should advise patients to remove the patch before an MRI procedure and replace it after completion of the scan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=see_link&amp;anchor=H35#H35\">",
"     \"Principles of magnetic resonance imaging\", section on 'Other foreign materials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid onset transmucosal preparations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    are discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Management of breakthrough pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Levorphanol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/22/29029?source=see_link\">",
"     Levorphanol",
"    </a>",
"    is distinguished by its relatively long half-life (about 12 to 16 hours). Experience in the use of this drug is relatively limited in the US, but it should be viewed as another option for the treatment of cancer pain, particularly when other mu agonists have not been well tolerated or are unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    is a mu agonist opioid, but it has a unique pharmacology that presumably underlies both its surprising effectiveness in some settings and its potential for unanticipated toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Although at least one controlled trial has shown that it was equally effective to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    for cancer pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/38\">",
"     38",
"    </a>",
"    ], methadone is challenging to use. Guidelines for safe administration must be followed to reduce the risk of unintentional overdose. To ensure safety, clinicians should have an understanding of these guidelines or seek assistance from a consultant before prescribing this drug. The pertinent issues are summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      has a variable half-life, which averages about 24 hours but ranges from 12 hours to almost one week [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/36\">",
"       36",
"      </a>",
"      ]. Since five to six half-lives are required before steady state plasma concentrations are approached, the time required before a methadone regimen can be considered stable varies from several days to several weeks. During the period when plasma levels are rising toward steady state levels, the patient must be considered at risk for unintentional overdose from accumulation in plasma.",
"      <br/>",
"      <br/>",
"      Due to highly variable and prolonged terminal half-life, methadone has the highest risk of among opioids of accumulation and overdosage during initial titration to effect, and during dose adjustment in chronic use.",
"     </li>",
"     <li>",
"      Perhaps more challenging,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      is marketed in most of the world as a racemate containing a 1:1 mixture of the d- and the l-isomer. The d-isomer is a relatively potent N-methyl-D-aspartate (NMDA) inhibitor and not an opioid. NMDA antagonism is associated with nonopioid analgesia and with reversal of opioid tolerance. These effects may explain the observation that methadone can be far more potent than would be expected from the equianalgesic dose table (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"       table 2",
"      </a>",
"      ), particularly when administered to patients with substantial prior opioid exposure. Concern about this unexpected potency must be addressed by selecting a cautious initial dose when switching from another drug to methadone (see below).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      also can prolong the QTc interval [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/39,40\">",
"       39,40",
"      </a>",
"      ], a phenomenon that predisposes to a life-threatening cardiac arrhythmia, torsades du pointe. Although the clinical importance of this effect continues to be controversial, it is prudent to check an ECG prior to therapy in those patients who may be predisposed to QTc prolongation (eg, those taking other drugs with this effect [(",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"       table 3",
"      </a>",
"      )] and those with existing significant heart disease), and repeatedly with dose escalation, starting when the total daily dose reaches 100 mg. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      is metabolized in part by CYP3A4 isoenzymes; drugs that function as inhibitors or inducers of this enzyme (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"       table 4",
"      </a>",
"      ) may alter drug levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PRACTICAL CONSIDERATIONS IN OPIOID USE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prescribing restrictions and risk management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications such as opioids with the potential for abuse and addiction are regulated, with restrictions on whether and how they can be prescribed. In the US, these drugs are designated \"controlled substances\" under a federal law known as the Controlled Substances Act (",
"    <a class=\"graphic graphic_table graphicRef66064 \" href=\"mobipreview.htm?4/37/4701\">",
"     table 5",
"    </a>",
"    ). Issues in risk management when these drugs are prescribed are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'Risk assessment and management for patients receiving opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Selecting the opioid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventionally, patients who are opioid-naive and have moderate to severe pain have been offered one of the opioid-nonopioid combination drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    plus hydrocodone or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    , or perhaps",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    or a newer mixed mechanism analgesic,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"     tapentadol",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    is used, the dose of the opioid usually is 5 mg per tablet; a lower dose (2.5 mg per tablet) should be considered in the elderly or very frail. If acetaminophen-hydrocodone is used, the usual dose of the opioid is 5 to 7.5 mg per tablet. The initial prescription usually is one to two tablets every three hours as needed. As noted previously, due to genetic variation in metabolism and difficulty predicting the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , this drug is not preferred.",
"   </p>",
"   <p>",
"    An alternative to this strategy for the patient who is relatively opioid-naive and who has moderate to severe pain is the selection of a single entity pure mu agonist, with treatment initiated at a low dose. Options include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (5 to 10 mg every three to six hours),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    (2.5 to 5 mg every three to six hours),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    (2 to 4 mg every three to six hours), or transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (12",
"    <span class=\"nowrap\">",
"     microg/hour,",
"    </span>",
"    every 72 hours). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Codeine and related agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If a patient is given a short-acting drug and needs several doses per day (or if a bedtime dose does not permit uninterrupted sleep through the night), a switch to a long-acting formulation is commonly undertaken in an effort to improve convenience and adherence. There is no evidence that any one of the commonly used, long-acting formulations that are available in the US, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , is more likely to be effective than any other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/41\">",
"     41",
"    </a>",
"    ]. Selection usually is determined by the patient's prior experience with opioids, the clinician's experience, cost and availability, and formulation.",
"   </p>",
"   <p>",
"    As noted, there is some evidence that transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    is less constipating than oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and the former drug may be preferred if constipation has been a challenging problem. If an oral formulation is given, some patients prefer once daily dosing, eg, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    or morphine, rather than twice daily dosing.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    is far less costly and can be used effectively as a long-acting drug for cancer pain (usually requiring dosing every six hours for this purpose), the challenges inherent in the safe prescribing of this drug suggests that it should be considered a first-line treatment option only by clinicians experienced in its use. Otherwise, methadone is a second-line agent, to be tried only in the event that trials of one or more of the other modified release agents fail to provide an adequate balance between analgesia and side effects. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Methadone'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H29772191\">",
"     'Switching to methadone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Use in renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted on the above sections, certain opioids should be",
"    <strong>",
"     used cautiously",
"    </strong>",
"    in patients with renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       Meperidine",
"      </a>",
"      (Demerol) is particularly dangerous, since its active metabolite, normeperidine, accumulates with renal dysfunction or prolonged use at high doses. Normeperidine has a long half-life and causes central nervous system (CNS) excitability. For this reason, meperidine is not preferred for cancer pain management.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      is metabolized in part to a potent opioid metabolite, morphine-6-glucuronide, and a metabolite, morphine-3-glucuronide, which is associated with toxicity. These metabolites are renally-excreted and can accumulate and lead to unanticipated changes in potency or side effects in patients with renal failure. Morphine should be administered carefully in the setting of stable renal insufficiency; if kidney function is changing, its use should be reconsidered.",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      can accumulate in patients with renal failure, extending their effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     Hydromorphone",
"    </a>",
"    has active metabolites that are produced in relatively low concentration (compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) and may be unlikely to cause unanticipated effects.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    lack active metabolites and could be considered in the setting of renal insufficiency on this basis. However, the challenges of safe methadone prescribing speak against the use of this drug and most clinicians prefer to use either fentanyl or hydromorphone in patients with renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733130714\">",
"    <span class=\"h2\">",
"     Use in liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most opioids are at least partially metabolized by the liver, complicating their use in patients with liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, lower initial starting doses for most opioids are warranted in patients with liver failure, and clinicians should be cautious prescribing opioids at &ldquo;regular&rdquo; dosing intervals until patients have demonstrated an ability to tolerate the dosing interval. As the liver disease progresses, prolonged dosing intervals may be needed.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       Codeine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      should be avoided entirely in patients with liver failure. Codeine is a prodrug that is converted to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      via the CYP2D6 isoenzyme of the P450 hepatic enzyme system; pain control may be compromised by diminished metabolism. In hepatic disease, meperidine clearance is reduced, and the half life is prolonged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Management of breakthrough pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breakthrough pain is a transitory severe acute pain that occurs on a background of chronic pain that is adequately controlled by an opioid regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Given its high prevalence in patients with cancer pain, and its negative clinical consequences, a treatment approach known as \"rescue\" dosing has become a widely accepted approach.",
"   </p>",
"   <p>",
"    Typically, a short-acting supplemental opioid is offered on an as needed basis for breakthrough pain in conjunction with a fixed scheduled long-acting drug. Depending on the dose required and other factors, the rescue drug may be a single entity oral formulation, such as immediate release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    , or one of the combination products. A typical dose chosen for rescue is 5 to 15 percent of the basal daily requirement of opioid (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Practical considerations in opioid use'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    For the typical oral rescue drugs like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , the dose should be titrated as the dose of the fixed scheduled regimen changes, so that the rescue dose remains roughly proportional to the baseline dose.",
"   </p>",
"   <p>",
"    Breakthrough pain also may be targeted with one of the newer rapid onset, transmucosal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    formulations, which are specifically indicated for cancer-related breakthrough pain. Six formulations are now available in the US: an oral transmucosal fentanyl lozenge (Actiq), an immediate-release transmucosal tablet formulation (Abstral), an effervescent fentanyl buccal tablet (Fentora), a buccal fentanyl soluble film (Onsolis), a nasal spray (Lazanda), and a sublingual spray (Subsys). In the United States, all of these products, including generics, have a mandatory shared risk evaluation and mitigation strategy (REMS), the purpose of which is to reduce the risk of abuse and unintentional overdose.&nbsp;To prescribe any of these drugs, physicians must complete online education.&nbsp;Furthermore, each patient treated requires registration of the patient, physician, and pharmacist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of these drugs have established efficacy of transmucosal application, with an onset of effect that is faster than that expected from oral formulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. Comparative effectiveness against one of the typical short-acting oral formulations has been determined only for the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    nasal spray [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/49\">",
"     49",
"    </a>",
"    ], and the more rapid onset of effect appears to be highly favorable, at least for some patients. Few studies have directly compared these transmucosal formulations with one another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/53\">",
"     53",
"    </a>",
"    ]. When these products are used, the initial rescue dose is fixed and not based upon the basal daily opioid dose. Rescue doses can be subsequently titrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Selecting the route of administration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral route is usually preferred for chronic treatment of cancer pain because of convenience and flexibility. Many cancer patients require alternative routes of analgesic administration at some time during the course of their illness.",
"   </p>",
"   <p>",
"    In most patients, orally-administered, immediate-release formulations have a peak analgesic effect at 1 to 1.5 hours, while the analgesic peak with modified-release formulations is in about three to five hours. Some of the immediate release opioids, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    , are also available in liquid formulations, which may be useful for patients with odynophagia or dysphagia or who can only receive medications through feeding tubes.",
"   </p>",
"   <p>",
"    Oral modified-release medications should never be crushed because of the potential for \"dose dumping\" and acute toxicity. Several of the modified release opioids can \"dose dump\" if coadministered with alcohol, which can dissolve the matrix in which the drug is embedded. It is best to inform patients that alcohol consumption should be avoided during the hours around administration of each dose.",
"   </p>",
"   <p>",
"    Use of the oral route may not be feasible in patients with oral mucositis, dysphagia, bowel obstruction, or severe nausea. Some of the modified release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    formulations (eg, Avinza&reg;, Kadian&reg;) are capsules that can be opened and sprinkled on food without changing the delivery characteristics; this can permit the administration of a modified-release drug through a feeding tube, if necessary, but the pellets can clog all but the largest feeding tubes. Liquid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    may be a better choice for those patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Transdermal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    is widely used for chronic pain. Each transdermal patch provides 48 to 72 hours of relatively stable drug delivery for most patients. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Fentanyl'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    may be preferred over an orally administered opioid in the setting of poor gastrointestinal tract absorption or dysphagia, or if constipation is an issue. Transdermal fentanyl may also be preferred by patients who are distressed by the number of tablets required to manage medical disorders and for those whose adherence to treatment would be improved by use of the transdermal route.",
"   </p>",
"   <p>",
"    Transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    may not be effective in patients lacking adequate adipose tissue over which the patch can be placed. In such patients, without an adequate subcutaneous drug reservoir, fentanyl serum levels never become therapeutic because the liver metabolizes the small amount of drug presented to it. Patients with low albumin levels who have frequent infections are at risk for toxicity from transdermal fentanyl because of sudden increases in the free fraction of fentanyl along with increased absorption from the reservoir when the patient&rsquo;s temperature exceeds 102 degrees F.",
"   </p>",
"   <p>",
"    Transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    is available in some countries and has had some anecdotal use in the management of the opioid-na&iuml;ve patient with cancer pain. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Partial agonists: Buprenorphine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Rectal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients are treated with rectal administration of an opioid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/54\">",
"     54",
"    </a>",
"    ]. In the United States, short-acting rectal formulations are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (5, 10, 20, 30 mg rectal suppositories),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    (3 mg) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    (5 mg). In addition, there is limited anecdotal experience in the rectal use of a long-acting modified-release formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potency of rectally administered opioids is believed to approximate oral dosing, but absorption is variable and relative potency may be higher or lower than expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. For this reason, a switch from oral to rectal dosing is usually accompanied by a reduction in the equivalent dose. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Equianalgesic opioid dose conversion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Subcutaneous and intravenous administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with a progressive illness like cancer, it is commonplace for a pain regimen that was initially administered via an oral or transdermal route to be switched, at least temporarily, to continuous intravenous (IV) or subcutaneous (SC) infusion. The intramuscular route is not generally used because it is painful and provides no pharmacological advantage.",
"   </p>",
"   <p>",
"    Continuous SC infusion can be easily accomplished using a \"butterfly\" catheter inserted under the skin of the chest wall or abdomen; the needle can remain in place for a week or more, and any drug with a injectable formulation can be administered in this way [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/58\">",
"     58",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    is not preferred via the SC route as it can act as an irritant to the skin.",
"   </p>",
"   <p>",
"    In order to maintain the comfort of an infusion site, the SC infusion rate should not exceed 5 mL per hour. Higher volumes can be delivered, however, if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    is added to the infusion. In order to limit the total volume of injectate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    may be chosen over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    because of its greater water solubility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/59\">",
"     59",
"    </a>",
"    ]; it is commercially available in a relatively concentrated 10",
"    <span class=\"nowrap\">",
"     mg/ml",
"    </span>",
"    solution for injection.",
"   </p>",
"   <p>",
"    Patients receiving continuous IV or SC infusion may benefit from access to intermittent administration of a short-acting drug for breakthrough pain. The IV route has the most rapid onset of action. When administered as an IV bolus, some drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , have a peak onset almost immediately, whereas other drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , may require 15 to 30 minutes because of the time required to penetrate the blood-brain barrier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622751254\">",
"    <span class=\"h4\">",
"     Patient-controlled analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pump with a patient-controlled analgesia (PCA) option can be used to administer continuous infusion by either the IV or SC route, and thereby facilitate the option of \"rescue doses\". PCA devices are programmed for the size of the dose, the minimum time between doses (lockout interval), and the cumulative dose allowed in one or four hours (several times higher than the anticipated need).",
"   </p>",
"   <p>",
"    Although safe and efficacious PCA settings for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    are widely accepted when this modality is used for acute postoperative pain, the settings are usually quite different when PCA is selected for cancer pain. Patients typically have a prior opioid regimen that is switched to an appropriate dose of a continuous infusion. The supplemental rescue dose administered via the PCA pump is selected to be roughly in the range of 5 to 15 percent of the total daily dose. In contrast to acute pain, the treatment of which often involves access to PCA delivered doses every six to seven minutes, the so-called lockout period when PCA is used to deliver rescue doses during chronic infusion may be longer, such as 10 to 20 minutes, although there is substantial inter-institution variability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Intrathecal and intraspinal administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Properly selected patients can benefit from more sophisticated pain management approaches, such as intraspinal opioid administration (epidural or intrathecal, collectively called \"neuraxial\" analgesia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/60\">",
"     60",
"    </a>",
"    ]. At least one randomized trial comparing conventional analgesic therapy with neuraxial analgesia via an implanted programmable pump in cancer patients with pain found that the intrathecal route yielded better pain control and fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients whose pain has not responded to routine systemic therapy should be considered for referral to a specialist in pain management for evaluation of this and other neuraxial techniques, among other interventional strategies for pain management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Dose titration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following selection of a starting dose, adjustment is almost always required to optimize an opioid regimen and sustain its benefits over time. Dose individualization is the key to optimizing the outcomes of opioid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/62-66\">",
"     62-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous or frequently recurrent pain is most effectively managed with a fixed schedule, \"around-the-clock\", opioid regimen, which is usually combined with \"as needed\" rescue doses for breakthrough pain. Dose titration to achieve adequate pain relief from a fixed scheduled regimen is attainable in most cases.",
"   </p>",
"   <p>",
"    Conventionally, dose titration is accomplished in one of two ways. The fixed scheduled dose can be increased by 30 to 100 percent of the total dose taken in the prior 24 hour period (with the percent increase informed by the severity of the pain, the degree of medical frailty or comorbidities that may increase opioid risk, and the existing formulations). Alternatively, the fixed scheduled dose can be increased by a daily amount that is determined by averaging the total amount of supplemental rescue medication taken during the prior few days (adjusted for the estimated equianalgesic potency, if needed, (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    )). These step-wise methods of dose escalation ensure safety as the dose is increased. Caution should be exercised in adding &gt;50 percent of the total dose taken in prior days when the supplemental rescue medication is used for incident pain only or procedure-related pain such as occurs during dressing changes. Such patients will continue to require rescue doses and may become excessively somnolent in between pain exacerbations.",
"   </p>",
"   <p>",
"    As a general rule, the dose of an opioid can be increased until a favorable balance between analgesia and side effects is obtained, or the patient develops intolerable and unmanageable side effects. It is accepted best practice to continue dose escalation without regard to a maximum dose unless events occur that indicate the need for an alternative strategy. However, higher doses (eg, those above 200 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    per day, or its equivalent) are not commonly needed. If titration above this point is required, the process should be accompanied by careful reassessment to ensure that the drug still provides benefits and that the regimen is not compromised by subtle toxicities or burdens associated with cost or number of tablets.",
"   </p>",
"   <p>",
"    Ideally, the interval between dose escalations should be long enough to allow a new steady state (which requires five to six half-lives, irrespective of the route or drug) to be approached following each dose adjustment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two to three days for the modified-release oral formulations",
"     </li>",
"     <li>",
"      Three to six days for the transdermal patch",
"     </li>",
"     <li>",
"      Although five days is usually sufficient to judge the full effect of a change in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      dose, the variability of this drug's half-life means that occasional patients will require much longer periods (up to several weeks) to ensure that effects have become stable (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Methadone'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with severe pain, more rapid dose escalation is needed. However, when doses are escalated at intervals shorter than those necessary to approach steady state (five to six half-lives), there is a possibility of \"overshooting\". In this phenomenon, the patient undergoing rapid dose titration reports benefit, but continuation of the successful dose eventually results in toxicity as drug levels continue to rise toward steady state.",
"   </p>",
"   <p>",
"    When rapid dose titration is needed to address poorly controlled pain, the risk of overshooting should be assessed. The risks are greater when the drug has a relatively long half-life (the greatest concern is with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ) or the patient is medically frail. In some cases, hospitalization should be considered for the express purpose of monitoring aggressive escalation of the dose. Hospitalization during a period of particularly intense pain, or \"pain crisis\", is a medically appropriate option for selected patents.",
"   </p>",
"   <p>",
"    As the dose of the fixed schedule opioid regimen is increased, the dose of the \"rescue\" drug also must be increased. In most cases, the dose of this short-acting medication should remain in the range of 5 to 15 percent of the total daily dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/47\">",
"     47",
"    </a>",
"    ]. The exception to this is found when using the rapid-onset transmucosal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    formulations, which may have effects at doses that are not proportional to the fixed schedule dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/67\">",
"     67",
"    </a>",
"    ]. In the case of these drugs, the starting dose should be low and dose titration should ascend with the commercially available dose units, stopping at a level associated with benefit. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Management of breakthrough pain'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As higher opioid doses are reached, there may be a temptation to apply excessive caution during further titration. An understanding of the pharmacology of these drugs should provide the reassurance necessary to avoid undertreatment, as illustrated by the following illustrative case.",
"   </p>",
"   <p>",
"    A patient with slowly progressive breast cancer, who has undergone several periods of opioid dose adjustment because of worsening pain, is taking long-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    240 mg twice daily plus \"rescue\" doses consisting of five tablets of short-acting oxycodone 5 mg (25 mg per dose); on each day, approximately four rescue doses are needed. She has no side effects except for constipation, which has been controlled with laxatives. When her pain worsens again, she is assessed, and in the absence of unmanageable side effects, the decision is made to further escalate the dose. Her total daily dose of oxycodone has been 480 mg (long-acting) plus 100 mg (rescue) or 580 mg. There are two approaches to dose increase:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One approach to increasing the dose is to add 30 to 50 percent to the total daily dose (30 percent of 580 = 174). The largest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      tablet is 80 mg, and an increase of 30 percent can be easily accomplished by adding one 80 mg tablet to each of the fixed doses: a fixed regimen of 320 mg twice daily. The rescue dose can be changed to 35 mg per dose at the same time.",
"     </li>",
"     <li>",
"      The alternative approach, adding the total daily rescue dose, or 100 mg per day in this case, to the fixed scheduled dose yields a more conservative outcome but still one in the range to be useful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both strategies are appropriate and safe; any smaller increment is unlikely to be beneficial.",
"   </p>",
"   <p>",
"    This case illustrates a typical pattern observed during long-term treatment of cancer pain. The opioid dose is usually maintained for a prolonged time, unless there is progression in the pain-producing pathology. Recurrent pain or the new occurrence of side effects necessitates a new assessment, and often, another period of dose titration. Although the use of relatively high doses requires careful reevaluation, the absolute dose of the opioid is inconsequential as long as the balance between analgesia and side effects remains acceptable for the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Using opioid rotation to manage poorly responsive pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient who develops treatment-limiting side effects during opioid dose titration is said to be poorly responsive to the specific regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/68\">",
"     68",
"    </a>",
"    ]. Clinicians must be attuned to this possibility, recognize it promptly, and be prepared to offer an alternative strategy for pain management.",
"   </p>",
"   <p>",
"    A new plan of care may involve any of a large number of options (",
"    <a class=\"graphic graphic_table graphicRef75273 \" href=\"mobipreview.htm?7/21/7515\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/69\">",
"     69",
"    </a>",
"    ], each of which must be evaluated in terms of benefit and burden, within the context of the larger goals of care. Strategies for prevention and management of common opioid side effects are covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A common approach to the management of poorly responsive pain is known as \"opioid rotation\", which is defined as a switch from one opioid to another in an effort to provide better outcomes . The rationale for this strategy is based on pharmacologic and clinical observations that suggest that a change in drug is more likely than not to improve the balance between pain relief and side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Equianalgesic opioid dose conversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each opioid drug has a different potency, defined as the dose necessary to produce a given effect. When switching from one opioid to another, the starting dose of the new drug must be informed by the difference in their relative potencies. The starting dose of the replacing drug must be close enough to its predicted equianalgesic dose to prevent the development of withdrawal (if the dose of the new drug is too low), or unintentional overdose (if it is too high). Equianalgesic dose table (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    ) has been developed as a means for comparing potencies between opioids.",
"   </p>",
"   <p>",
"    Consulting tables such as these to calculate the equianalgesic dose between an existing regimen and a new one is only the first step, however. Although the relative potency estimates represent the best science after more than 40 years of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/72\">",
"     72",
"    </a>",
"    ], application of the ratios in the equianalgesic dose table to the clinical setting must be done cautiously because of the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individual patients may not have the characteristics of those who were included in the relative potency studies.",
"     </li>",
"     <li>",
"      There is very large individual variation in drug metabolism and pharmacodynamics, indicating that even patients with similar characteristics may have very different responses to different drugs.",
"     </li>",
"     <li>",
"      Tolerance to adverse effects during long-term treatment does not occur to different drugs in the same way. This \"incomplete cross-tolerance\" means that a new drug can have unexpectedly strong effects.",
"     </li>",
"     <li>",
"      Because of variations in drug absorption, a dose reduction may be needed when switching from one route of administration to another (eg, from oral to rectal dosing), even for the same drug (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Rectal'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To ensure that opioid rotation is done safely, clinical guidelines have been developed that incorporate reductions in the calculated equianalgesic dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/73\">",
"     73",
"    </a>",
"    ]. These reductions have been conceptualized as ranges, one automatic and one based on specific patient characteristics, and clinical judgment must be used to apply them (",
"    <a class=\"graphic graphic_table graphicRef59062 \" href=\"mobipreview.htm?30/36/31308\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29772191\">",
"    <span class=\"h4\">",
"     Switching to methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal way to switch from an alternative opioid to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    is debated. After reducing the calculated equianalgesic dose, typically by 75 to 90 percent (",
"    <a class=\"graphic graphic_table graphicRef59062 \" href=\"mobipreview.htm?30/36/31308\">",
"     table 7",
"    </a>",
"    ), methadone can be initiated using a number of strategies. There are two dominant strategies: the &ldquo;stop and go&rdquo; approach, where the current opioid is immediately replaced by methadone, and the three-day switch, where the dose of the current opioid is reduced step-wise by one-third each day, and substituted with one-third of the equianalgesic dose of methadone, over three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/75-80\">",
"     75-80",
"    </a>",
"    ]. Switching over a three-day period is probably a preferable strategy as it may avoid methadone accumulation and toxicity, particularly in patients on high doses of opioids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/7/30842/abstract/22,24,81\">",
"     22,24,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/6/11363?source=see_link\">",
"       \"Patient information: Narcotic pain medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opioids are widely used for treatment of cancer pain because of their safety, multiple routes of administration, ease of titration, reliability, and effectiveness for all types of pain (ie, somatic, visceral, and neuropathic). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The analgesic effect of the drugs typically used to manage cancer pain is a consequence of agonist action at the mu receptor. Based upon their effects on the mu receptor, opioids are conventionally divided into pure agonists, agonist-antagonists, and pure antagonists. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With few exceptions, the management of chronic cancer pain usually involves the long-term administration of pure mu receptor agonists (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"       table 2",
"      </a>",
"      ). However, drugs other than the pure mu agonists (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      , a partial agonist, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"       tapentadol",
"      </a>",
"      , mixed mechanism centrally acting analgesics) can be used for treatment of cancer-related pain in some circumstances. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Partial agonists: Buprenorphine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Mixed mechanism drugs: Tramadol and tapentadol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mixed agonist-antagonist drugs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9543?source=see_link\">",
"       butorphanol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/48/29446?source=see_link\">",
"       pentazocine",
"      </a>",
"      ) are generally not used for cancer pain management. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mixed agonist-antagonist drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Choice of initial opioid agonist",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The oral and transdermal routes are preferred for chronic treatment of cancer pain. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Selecting the route of administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short-acting pure mu receptor agonists such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"       oxymorphone",
"      </a>",
"      are the preferred agents for moderate to severe cancer pain in the patient who is opioid-naive. There is no evidence to support superior efficacy or tolerability of any agent over another. Because of genetic variation in metabolism of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      and an inability to predict drug effects, we suggest not using codeine in this setting (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Codeine and related agents'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We also suggest not using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      because of toxicity concerns (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Meperidine'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For the opioid-naive patient, a combination product containing short-acting hydrocodone or short-acting oxycodone plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      is commonly selected. Another option is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      in a transdermal formulation, or a mixed mechanism drug such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"       tapentadol",
"      </a>",
"      . Some clinicians use a single entity pure mu agonist like morphine or hydromorphone or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , as long as the dose is very low.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"       Hydromorphone",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ) may be preferred for patients with renal insufficiency. A concentrated solution of hydromorphone is useful for subcutaneous or intravenous administration if relatively high doses are needed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Oxycodone, hydromorphone, and oxymorphone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Use in renal failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Titration and switch to a long-acting formulation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following selection of a starting opioid dose, adjustment is almost always required. Continuous or frequently recurrent pain is most effectively managed with a fixed schedule, \"around-the-clock\", opioid regimen. Although the absolute dose of the opioid is inconsequential as long as the balance between analgesia and side effects remains acceptable for the patient, the need to titrate to relatively high doses should be accompanied by careful reassessment of the pain and drug effects. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Dose titration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a patient is given a short-acting opioid and is needing several doses per day (or if a bedtime dose does not permit uninterrupted sleep through the night), a switch to a long-acting modified -release formulation can improve convenience and adherence.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      has the longest history of use for the treatment of cancer pain and is usually considered the standard for comparison across opioid drug classes (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"       table 2",
"      </a>",
"      ). Any of the single entity drugs can be selected (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"       table 2",
"      </a>",
"      ), and there is no evidence to suggest superior efficacy or tolerability for any one agent over another. However:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      over an orally administered opioid in the setting of poor gastrointestinal tract absorption or dysphagia, and for patients in whom constipation has been or is expected to be difficult to manage (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Selecting the opioid'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Selecting the route of administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with renal insufficiency, we suggest long-acting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Use in renal failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the challenges inherent in the safe prescribing of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      , this drug is best considered second-line, to be tried only in the event that trials of one or more of the other modified release agents fail to provide an adequate balance between analgesia and side effects; if the clinician is not clear about the procedures that should be followed to ensure the safe use of methadone (starting dose, monitoring, timing of dose escalation, etc), it is best to seek the help of a consultant before starting this therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Methadone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Management of breakthrough pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have breakthrough pain should be offered a short-acting supplemental opioid on an as needed basis in conjunction with a fixed scheduled long-acting drug. The rescue drug may be a single entity oral formulation, such as immediate release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"       oxymorphone",
"      </a>",
"      , or one of the combination products (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      plus oxycodone). A typical dose chosen for rescue is 5 to 15 percent of the basal daily requirement of opioid. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Management of breakthrough pain'",
"      </a>",
"      above.)&nbsp;",
"     </li>",
"     <li>",
"      Breakthrough pain may also be targeted with one of the newer rapid onset, transmucosal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      formulations, which are specifically indicated for cancer-related breakthrough pain. In such cases, the initial rescue dose should be one of the two lowest commercially available doses, and not based upon the basal daily opioid requirement. Regardless of the formulation, the rescue dose should be titrated to yield optimal benefit for breakthrough pain.",
"     </li>",
"     <li>",
"      For patients with severe pain, rapid titration of the opioid dose may be achieved using intravenous dosing at short intervals. A technique for accomplishing this involves the use of a patient-controlled analgesia (PCA) pump to administer a continuous infusion of opioid by either the IV or SC route, plus intermittent bolus \"rescue doses\". The IV route has the fastest onset of action. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Subcutaneous and intravenous administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Management of poorly responsive pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several options are available for patients who develop treatment-limiting side effects during opioid dose titration (",
"      <a class=\"graphic graphic_table graphicRef75273 \" href=\"mobipreview.htm?7/21/7515\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      One approach, opioid rotation, may improve the balance between pain relief and side effects. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Using opioid rotation to manage poorly responsive pain'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      When switching between opioids, equianalgesic dose tables (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"       table 2",
"      </a>",
"      ) have been developed as a means for comparing potencies between opioids. However, application of the ratios in the equianalgesic dose table to the clinical setting is limited by incomplete cross-tolerance and other factors. Clinical guidelines have been developed that incorporate reductions in the calculated equianalgesic dose based upon specific patient characteristics; clinical judgment must be used to apply them (",
"      <a class=\"graphic graphic_table graphicRef59062 \" href=\"mobipreview.htm?30/36/31308\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Equianalgesic opioid dose conversion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/1\">",
"      Mercadante S, Porzio G, Ferrera P, et al. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther 2009; 31:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/2\">",
"      Apolone G, Corli O, Negri E, et al. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group. Clin J Pain 2009; 25:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/3\">",
"      Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage 2008; 36:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/4\">",
"      Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci 2007; 12:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/5\">",
"      Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006; 20 Suppl 1:s25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/6\">",
"      Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009; 25:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/7\">",
"      Prommer EE. Tramadol: does it have a role in cancer pain management? J Opioid Manag 2005; 1:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/8\">",
"      Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J Pain 2008; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/9\">",
"      Quigley C. Opioids in people with cancer-related pain. Clin Evid (Online) 2008; 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/10\">",
"      Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994; 5:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/11\">",
"      Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep 2009; 61:978.",
"     </a>",
"    </li>",
"    <li>",
"     WHO analgesic pain ladder available online. www.who.int/cancer/palliative/painladder/en/ (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/13\">",
"      Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/14\">",
"      de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 2003; 23:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/15\">",
"      L&ouml;tsch J, Rohrbacher M, Schmidt H, et al. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 2009; 144:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/16\">",
"      Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005; 13:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/17\">",
"      Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2007; :CD003971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/18\">",
"      Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev 2007; :CD003868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/19\">",
"      Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002; :CD003447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/20\">",
"      Mercadante S, Tirelli W, David F, et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain 2010; 26:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/21\">",
"      Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med 2011; 25:471.",
"     </a>",
"    </li>",
"    <li>",
"     Sj&ouml;gren P. Clinical implications of morphine metabolites. In: Topics in Palliative Care Vol 1, Portenoy RK, Bruera EB (Eds), Oxford University Press, New York 1997. p.163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/23\">",
"      Penson RT, Joel SP, Gloyne A, et al. Morphine analgesia in cancer pain: role of the glucuronides. J Opioid Manag 2005; 1:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/24\">",
"      Quigley C, Joel S, Patel N, et al. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 2003; 17:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/25\">",
"      Penson RT, Joel SP, Bakhshi K, et al. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2000; 68:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/26\">",
"      Sj&oslash;gren P, Thunedborg LP, Christrup L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 1998; 42:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/27\">",
"      Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage 2003; 25:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/28\">",
"      Mayyas F, Fayers P, Kaasa S, Dale O. A systematic review of oxymorphone in the management of chronic pain. J Pain Symptom Manage 2010; 39:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/29\">",
"      Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009; 13:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/30\">",
"      Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/31\">",
"      van Seventer R, Smit JM, Schipper RM, et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003; 19:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/32\">",
"      Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997; 35:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/33\">",
"      Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 2009; 25:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/34\">",
"      Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008; 11:492.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Public Health Advisory. Risk of burns during MRI scans from transdermal drug patches with metallic backings. file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm111313.htm (Accessed on January 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/36\">",
"      Bryson J, Tamber A, Seccareccia D, Zimmermann C. Methadone for treatment of cancer pain. Curr Oncol Rep 2006; 8:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/37\">",
"      Leppert W. The role of methadone in cancer pain treatment--a review. Int J Clin Pract 2009; 63:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/38\">",
"      Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/39\">",
"      Cruciani RA. Methadone: to ECG or not to ECG...That is still the question. J Pain Symptom Manage 2008; 36:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/40\">",
"      Reddy S, Hui D, El Osta B, et al. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 2010; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/41\">",
"      Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003; 26:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/42\">",
"      Chan GL, Matzke GR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 1987; 21:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/43\">",
"      Launay-Vacher V, Karie S, Fau JB, et al. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain 2005; 6:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/44\">",
"      Oliverio C, Malone N, Rosielle DA. Opoid use in liver failure #260. J Palliat Med 2012; 15:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/45\">",
"      Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/46\">",
"      Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004; 18:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/47\">",
"      Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/48\">",
"      Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010; 21:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/49\">",
"      Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol 2011; 9:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/50\">",
"      Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2012; 28:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/51\">",
"      Jandhyala R, Fullarton JR, Bennett MI. Efficacy of Rapid-Onset Oral Fentanyl Formulations vs. Oral Morphine for Cancer-Related Breakthrough Pain: A Meta-Analysis of Comparative Trials. J Pain Symptom Manage 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/52\">",
"      Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010; 151:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/53\">",
"      Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/54\">",
"      Bruera E, Fainsinger R, Spachynski K, et al. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 1995; 13:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/55\">",
"      Walsh D, Tropiano PS. Long-term rectal administration of high-dose sustained-release morphine tablets. Support Care Cancer 2002; 10:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/56\">",
"      Wilkinson TJ, Robinson BA, Begg EJ, et al. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemother Pharmacol 1992; 31:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/57\">",
"      Moolenaar F, Meijler WJ, Frijlink HW, et al. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain. Eur J Clin Pharmacol 2000; 56:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/58\">",
"      Wilcock A, Jacob JK, Charlesworth S, et al. Drugs given by a syringe driver: a prospective multicentre survey of palliative care services in the UK. Palliat Med 2006; 20:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/59\">",
"      McNeill JA, Sherwood GD, Starck PL. The hidden error of mismanaged pain: a systems approach. J Pain Symptom Manage 2004; 28:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/60\">",
"      Sloan PA. Neuraxial pain relief for intractable cancer pain. Curr Pain Headache Rep 2007; 11:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/61\">",
"      Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20:4040.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     Fine P, Portenoy RK. Opioid analgesia. New York: McGraw Hill, 2004. file://www.stoppain.org/pcd/content/forpros/opioidbook.asp (Accessed on April 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/64\">",
"      Jost L, Roila F, ESMO Guidelines Working Group. Management of cancer pain: ESMO clinical recommendations. Ann Oncol 2008; 19 Suppl 2:ii119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/65\">",
"      Krakowski I, Theobald S, Balp L, et al. Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002). Br J Cancer 2003; 89 Suppl 1:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/66\">",
"      Cormie PJ, Nairn M, Welsh J, Guideline Development Group. Control of pain in adults with cancer: summary of SIGN guidelines. BMJ 2008; 337:a2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/67\">",
"      William L, Macleod R. Management of breakthrough pain in patients with cancer. Drugs 2008; 68:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/68\">",
"      Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001; 21:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/69\">",
"      Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001; 21:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/70\">",
"      Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004; :CD004847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/71\">",
"      Reddy A, Yennurajalingam S, Pulivarthi K, et al. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist 2013; 18:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/72\">",
"      Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009; 38:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/73\">",
"      Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing \"best practices\" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009; 38:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/74\">",
"      Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002; 20:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/75\">",
"      Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998; 82:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/76\">",
"      Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998; 9:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/77\">",
"      Ben&iacute;tez-Rosario MA, Salinas-Mart&iacute;n A, Aguirre-Jaime A, et al. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage 2009; 37:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/78\">",
"      Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999; 17:3307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/79\">",
"      Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/80\">",
"      Parsons HA, de la Cruz M, El Osta B, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010; 116:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/7/30842/abstract/81\">",
"      Moksnes K, Dale O, Rosland JH, et al. How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial. Eur J Cancer 2011; 47:2463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2814 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-210.101.131.231-DF96EE1385-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30842=[""].join("\n");
var outline_f30_7_30842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OPIOID DRUGS USED IN CANCER PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Partial agonists: Buprenorphine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mixed mechanism drugs: Tramadol and tapentadol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mixed agonist-antagonist drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pure mu agonists conventionally used for moderate or severe pain in patients with limited to no opioid exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Codeine and related agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H622751239\">",
"      Genetic variation in metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Meperidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pure mu agonists for severe pain in patients with prior opioid exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Morphine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Oxycodone, hydromorphone, and oxymorphone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fentanyl",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Levorphanol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Methadone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PRACTICAL CONSIDERATIONS IN OPIOID USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prescribing restrictions and risk management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Selecting the opioid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Use in renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H733130714\">",
"      Use in liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Management of breakthrough pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Selecting the route of administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Oral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Transdermal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Rectal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Subcutaneous and intravenous administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H622751254\">",
"      Patient-controlled analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Intrathecal and intraspinal administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Dose titration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Using opioid rotation to manage poorly responsive pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Equianalgesic opioid dose conversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29772191\">",
"      Switching to methadone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Choice of initial opioid agonist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Titration and switch to a long-acting formulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Management of breakthrough pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Management of poorly responsive pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2814|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/45/724\" title=\"figure 1\">",
"      WHO analgesic ladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2814|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/55/8061\" title=\"table 1\">",
"      Class opioids pain mgmt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/31/11760\" title=\"table 2\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/48/2830\" title=\"table 3\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 4\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/37/4701\" title=\"table 5\">",
"      US scheds controlled drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/21/7515\" title=\"table 6\">",
"      Opts poor resp opioid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/36/31308\" title=\"table 7\">",
"      Guidelines opioid rotation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/6/11363?source=related_link\">",
"      Patient information: Narcotic pain medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_7_30843="Acid reflux medicines PI";
var content_f30_7_30843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medicines used to treat acid reflux",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medicine type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medicine name examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Antacids",
"       </td>",
"       <td>",
"        Calcium carbonate (sample brand name: Tums&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aluminum hydroxide, magnesium hydroxide, and simethicone (sample brand name: Maalox&reg;)*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Histamine blockers",
"       </td>",
"       <td>",
"        Ranitidine (brand name: Zantac&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Famotidine (brand name: Pepcid&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine (brand name: Tagamet&reg;)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Proton pump inhibitors",
"       </td>",
"       <td>",
"        Omeprazole (brand name: Prilosec&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esomeprazole (brand name: Nexium&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pantoprazole (brand name: Protonix&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lansoprazole (brand name: Prevacid&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexlansoprazole (brand name: Dexilant&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rabeprazole (brand name: AcipHex&reg;)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The Food and Drug Administration warns that Maalox&reg; Total Relief should not be used as an antacid. Maalox&reg; Total Relief contains an ingredient that can cause stomach bleeding.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30843=[""].join("\n");
var outline_f30_7_30843=null;
var title_f30_7_30844="Pseudorenal panel abnormalities paraproteinemia";
var content_f30_7_30844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pseudorenal panel abnormalities described with paraproteinemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Chemical",
"       </td>",
"       <td class=\"subtitle1\">",
"        Paraprotein type described",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium",
"       </td>",
"       <td>",
"        IgG, IgM, IgA",
"       </td>",
"       <td>",
"        Hyponatremia",
"       </td>",
"       <td>",
"        Water exclusion effect*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloride",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        Hypochloridemia",
"       </td>",
"       <td>",
"        Water exclusion effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        IgG, IgM",
"       </td>",
"       <td>",
"        Hypobicarbonatemia",
"       </td>",
"       <td>",
"        Interaction between paraprotein and assay reagent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood urea nitrogen",
"       </td>",
"       <td>",
"        IgM",
"       </td>",
"       <td>",
"        Low urea levels",
"       </td>",
"       <td>",
"        Paraprotein coats electrodes and interferes with ionic conductance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creatinine",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        Low creatinine levels",
"       </td>",
"       <td>",
"        Precipitation",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creatinine",
"       </td>",
"       <td>",
"        IgM",
"       </td>",
"       <td>",
"        High creatinine levels",
"       </td>",
"       <td>",
"        Interaction between paraprotein and assay reagent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"       <td>",
"        IgA, IgM",
"       </td>",
"       <td>",
"        Hypercalcemia",
"       </td>",
"       <td>",
"        Precipitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphate",
"       </td>",
"       <td>",
"        IgG, IgM, IgA",
"       </td>",
"       <td>",
"        Hyperphosphatemia",
"       </td>",
"       <td>",
"        Precipitation in acid pH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphate",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        Hypophosphatemia",
"       </td>",
"       <td>",
"        Precipitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin",
"       </td>",
"       <td>",
"        IgM",
"       </td>",
"       <td>",
"        Hypoalbuminemia",
"       </td>",
"       <td>",
"        Slowing of reaction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Increased colloid phase decreases the aqueous phase per volume of sample resulting in plasma having lower levels of electrolytes per volume of sample.",
"     <br/>",
"     <sup>",
"      &bull;",
"     </sup>",
"     Immunoglobulins can precipitate or flocculate because of chemical interaction with the test reagents or to their inherent chemical structure.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Krish P, Jhaveri KD. Hyperbicarbonatemia in a patient with Waldenstrom&rsquo;s macroglobulinemia. Kidney Int 2012; 81:603. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30844=[""].join("\n");
var outline_f30_7_30844=null;
var title_f30_7_30845="Contents: Rheumatology calculators";
var content_f30_7_30845=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Rheumatology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Rheumatology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/36/27205\">",
"           Calculator: Rheumatoid arthritis Clinical Disease Activity Index (CDAI)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/36/13894\">",
"           Calculator: Rheumatoid arthritis Disease Activity Score (DAS-28)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/51/39733\">",
"           Calculator: Rheumatoid arthritis Simplified Disease Activity Index (SDAI)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/19/42288\">",
"           Calculator: Corticosteroid Medication Dosing Conversions (glucocorticoid effect)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-9DF00875EA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f30_7_30845=[""].join("\n");
var outline_f30_7_30845=null;
var title_f30_7_30846="Pos pressure urethroscopy";
var content_f30_7_30846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Positive pressure urethroscopy of a large urethral diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In figure A, the black arrow identifies the urethral lumen and the white arrow points to the large ostia of the diverticulum which is distended by fluid instillation. In figure B, the white arrow points to the ostia as exudate is expressed from the diverticulum using a vaginal examining finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert E Gutman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30846=[""].join("\n");
var outline_f30_7_30846=null;
var title_f30_7_30847="PG functions and inhibition";
var content_f30_7_30847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Prostanoid synthesis and inhibition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 418px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depiction of prostanoid synthesis and actions and potential levels of inhibition: 1. Aspirin and other nonsteroidal antiinflammatory drugs; 2. Alternative fatty acid substrates; 3. Glucocorticoids and selective PGHS-2 (COX-2) inhibitors; 4. Prostanoid receptor antagonists; 5. Nitric oxide synthase inhibitors, antihistamines; 6. Monoclonal antibodies to adhesion molecules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_7_30847=[""].join("\n");
var outline_f30_7_30847=null;
